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Abstract 
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial joints 
leading to cartilage destruction and bone erosion. One of the hallmarks of RA is the 
presence of circulating autoantibodies and the expansion of autoreactive B cells. Within 
RA joints, ectopic B cell follicles remain functional and support Immunoglobulin (Ig) 
somatic hypermutation, class-switching and in situ autoantibody production even in the 
absence of recirculating cells, as evidenced by the RA-SCID model, suggesting that 
autocrine mechanisms support ongoing B cell activation within the RA joints.  
 
In this PhD thesis, I investigate the mechanisms regulating RA synovial fibroblasts (SFs) 
production of B cell survival/proliferation factors BAFF/APRIL, with particular focus on 
toll-like receptors (TLR) signaling and how these factors in turn regulate B cell activation.  
 
First, I demonstrate that TLR3 stimulation on RASFs led to strong induction of 
BAFF/APRIL mRNA expression. Resting and TLR3-stimulated RASFs released higher 
protein levels of BAFF/APRIL as compared to RA dermal fibroblasts (RADF) controls. 
TLR3 stimulation of RASFs, but not RADF in co-culture with IgD+ B cells strongly 
enhanced activation induced cytidine deaminase (AID) expression, Iγ-Cμ and Iα-Cμ 
circular transcripts (CTs) as well as class-switching to IgG/IgA. Notably, TLR3-induced 
effects were completely abrogated by the combined blockade of BAFFR/BCMA.   
 
Following this, I report a negative feedback mechanism centered on secretory leukocyte 
protease inhibitor (SLPI) which, is induced in RASFs in response to TLR3 stimulation 
and modulates RASFs-dependent B cell responses, in part, via inhibition of BAFF 
production in RASFs but also by direct down-regulation of B cell activation, expression 
of AID and class-switching to IgG/IgA. 
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Overall, I highlight a novel and fundamental role for the TLR3-B cell survival factor axis 
in regulating B cell activation in the RA synovium, which may have profound relevance 
in response/resistance to biological therapies targeting B cells in RA. 
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CHAPTER 1 
Introduction 
 
1.1 Rheumatoid arthritis: general aspects 
 
1.1.1 The immune system and autoimmunity 
 The survival of human body depends on a continuous fight between the defensive 
mechanisms of the immune system and various threats arising from the microbial world. 
Included in the immune system is of a variety of effector cells and accompanying 
molecules that can be divided into two separate branches: innate and adaptive.  Having 
the ability to fight against a wide range of pathogens, the innate branch rapidly responds 
and clears most of the harmful substances. On the other hand, the adaptive immune 
system is more sophisticated, mounting a highly specific response combined with the 
formation of an immunological memory. An important characteristic of this fight 
involves the ability of host’s immune system to distinguish unfriendly pathogenic 
microbial agents from the host’s endogenous tissue. Occasionally, the self-recognition 
control system fails, which may lead to false recognition of the host and a loss of immune 
tolerance to self components, allowing an immune response that may eventually lead to 
autoimmunity. Autoimmunity associated diseases can be characterised by a combination 
of two arms: organ specific, such as Hashimoto’s thyroiditis, or a more systemic 
distribution, such as systemic lupus erythematosus (SLE). Rheumatoid arthritis (RA) has 
features of both organic specific (synovial joints) and systemic autoimmunity the latter 
being characterised by the involvement of several organs such as the skin, kidney, lung 
and the cardiovascular system (Figure 1.1). 
 - 20 -  
 
 - 21 -  
Figure 1.1 Rheumatoid arthritis and examples of systemic autoimmune disease.  
 
The immune system protects organisms from infection with layered defenses of 
increasing specificity. Firstly, physical barriers prevent the entry of pathogens into the 
organism (grey circular ring). If a pathogen breaches these barriers, they activate the 
innate immune system that provides an immediate, but non-specific/broad-specific 
response (blue arrows). If pathogens successfully evade the innate response, a second 
layer of protection, termed the adaptive immune system, will be activated which has a 
specific and long-lasting response (purple arrow). However, over-activation of immune 
response, in which the immune system fails to properly distinguish between self and non-
self, results in autoimmune disorders (lower left green box). Autoimmune disease could 
be classified as organ specific or non-organ specific depending on whether the response 
is primarily against antigen localised to particular organs or against widespread antigen, 
respectively. (Modified image adapted from Prime to the immune response by Tak Mak 
and Mary Saunders 2011 Academic Press Chapter 1 “Introduction of the immune 
response” and Immunology by David Mal, Jonathan Brostoff, David B Roth and Ivan 
Rott Chapter 20 “Autoimmunity and autoimmune disease”).  
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1.1.2 History and classification of criteria 
RA was first described by Landré-Beauvais in 1800 with the term ‘primary aesthenic 
gout’ to describe this type of inflammatory arthritis. Later in 1848, a british 
rheumatologist, Sir Alfred Garrod, discovered excess uric acid in the blood of gouty 
patients and this allowed him to distinguish gout from what he described in 1859 as 
“rheumatoid arthritis”.  However, at this stage, RA and osteoarthritis (OA), a 
degenerative joint disease that is often associated with a mild inflammatory reaction, 
were considered part of the same disease spectrum until the distinction made by his son 
in 1907 [1]. Originally, RA had no specific medical definition while the discovery of 
rheumatoid factor (RF) in 1940 [2, 3] allowed for the classification of arthritis as 
seropositive and, thus, RA was first described as an autoimmune disease. Later in 1987, 
the American College of Rheumatology (ACR) issued a set of criteria used for 
differentiating RA from other inflammatory arthritis diseases [4] with a specificity of 
~90% (Table 1.1) Those classification criteria were modified further in 2010 by the ACR 
and the European League Against Rheumatism (EULAR) and now can for identify 
patients with a relatively short duration of symptoms, who may benefit from early 
establishment of disease-modifying anti-rheumatic drugs (DMARD) (Table 1.2) [5]. This 
new set of criteria are a score-based algorithm, by which a collective score from four 
different observations results in a total score of out of 10, where by ≥6 will classify a 
patient as having RA.  
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Criteria Definition 
1. Morning stiffness stiffness of joints lasting at least 1 hr 
2. Arthritis of 3 or more joint areas Soft tissue joint swelling observed by a physician 
3. Arthritis of hand joints Arthritis in at least one area of hand/wrist 
4. Symmetric arthritis Simultaneous involvement of the same joint areas 
on both sides of the body 
5. Rheumatoid nodules Subcutaneous non tender nodules in 
juxtaarticular regions 
6. Serum rheumatic factor presence of autoantibodies which bind Fc 
portion of IgG 
7. Radiographic changes RA typical changes with erosions or 
decalcifications in hand or wrist 
 
Table 1.1. 1987 Criteria for the classification of Rheumatoid Arthritis.  
4 of the 7 criteria have to be fulfilled to be classified as suffering from RA. Points 1 
through 4 have to be present for at least 6 weeks. Point 2 and 3 exclude distal 
interphalangeal joints (DIP). Source adapted from the ACR, 2007, 
www.rheumatology.org).[5] 
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Classification criteria for RA 
Patients should have at least 1 joint with definite clinical synovitis (swelling) and with the synovitis not 
better explained by another disease 
A  Joint involvement Score 
1 large joint* 0 
2-10 large joints 1 
1-3 small joints # 2 
4-10 small joints 3 
≥ 10 joints (at least 1 small joint) 5 
B Serology (at least 1 test result is needed for classification)  
 Negative RF and negative ACPA 0 
 Low-positive RF or low-positive ACPA 2 
 High-positive RF or high-positive ACPA 3 
C Acute-phase reactant  
 Normal CRP and normal ESR 0 
 Abnormal CRP or abnormal ESR 1 
D Duration of symptoms  
 < 6 weeks 0 
 ≥ 6 weeks 1 
Large joint refers to shoulders, elbows, hips, knees and ankles. # Small joint refers to proximal 
interphalangeal (PIP), thumb IP, metacarpophalangeal (MCP) joints of the hands, 2-5
th
 metatarsophalangeal 
(MTP) and wrists. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein, RF, rheumatoid factor; 
ACPA, anti-citrullinated protein antibodies. 
 
Table 1.2. The 2010 American College of Rheumatology/European League Against 
Rheumatism classification criteria for rheumatoid arthritis.  
 
Score-based algorithm: add score of categories A–D; a score of ≥ 6/10 is needed for 
classification of a patient as having definite RA. Source adapted from Arthritis Rheum 
2010 [5] 
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1.1.3 Definition and clinical features 
RA is a chronic, systemic, autoimmune inflammatory disease resulting in joint deformity, 
chronic ill-health, losses of mobility and function. If untreated, it can also cause 
premature mortality due to increased risk of infections in multiple organs as well as 
cardiovascular diseases. RA can affect individuals of all ages but is most commonly 
present between the ages of 35 and 45, with maximal onset in women around the 
menopause. As a very variable disease, RA affects each person in a unique and different 
way.   
 
The most characteristic feature of RA is a sustained and persistent inflammatory synovitis 
(swelling), primarily of the peripheral joints in a symmetric distribution. The commonly 
affected joints involved are the metacarpophalangeal (MCP), proximal interphalangeal 
(PIP) and metatarsophalangeal (MTP) joints. The finger DIP, the 1
st
 carpometacarpal 
(CMC) joint of the hand and the 1
st
 MTP joint are generally spared since these joints are 
typically involved in OA. Although RA develops its pathology within the synovium, 
many nonarticular organs become involved, particularly in patients with severe joint 
disease. Fatigue, fever, weight loss, and malaise are the general symptoms that can be 
associated with variable manifestations of extra-articular involvement (Table 1.3). 
 
Affected tissue or organ Extra-articular manifestations 
Cardiovascular Pericarditis, endocarditis, myocarditis, myocardial infarction 
Nervous system Entrapment neuropathies, progressive multifocal 
leukoencephalopathy 
Skin Subcutaneous nodules 
Pulmonary Pulmonary nodules; interstitial lung disease 
Eyes Scleritis, episcleritis, retinal vasculitis 
Other Vasculitis, diabetes, gastrointestinal bleeding, cancer (e.g., 
lymphoma), hematologic abnormalities (e.g. Felty's 
syndrome) 
Table 1.3. List of extra-articular disease of RA. 
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Although numerous studies have been carried out aiming to dissect RA disease, the 
poorly defined natural history of this disease as well as the fluctuating clinical course and 
unpredictable prognosis adds to the difficulty in monitoring RA disease. Moreover, RA is 
an epidemiologically relevant cause of disability.  
1.1.4 Epidemiology 
RA is the most common inflammatory arthritis and its prevalence ranges between 0.5% 
and 1.0% of the adult population. However, the occurrence of RA is not the same 
throughout the world. Northern European RA prevalence varies between Norway 
(0.44%), Sweden (0.51%) and the UK (minimum 0.81%), [6-8] and in Europe overall, 
RA prevalence decreases from north to south. Conversely, native American-Indian 
populations have the highest recorded occurrence of RA, with prevalence of 5.3% noted 
for the Pima Indians [9] and 6.8% for the Chippewa Indians [10]. A much lower 
prevalence has been reported in Southeast Asia [11], including China and Japan [12, 13], 
which have a very low occurrences of 0.2–0.3%. Importantly, even though no single case 
has been found in rural Nigeria [14] and rural South Africa ,[15] prevalence rate rises to 
nearly 1% in black populations in urban areas, indicating that geographic area of 
residence may be a strong determinant for disease pathogenesis [16]. On the other hand, 
it is still unclear whether differences in epidemiological data between countries are solely 
dependent on environmental factors or if other factors such as genetic origins. As an 
example, the investigation of a Caribbean population of African origin living in 
Manchester, UK, showed a low frequency [17], reflecting that the protection to this group 
was in fact genetically determined. Similarly, a study on a Chinese population living in 
an urban area in Hong Kong showed the same consistent low occurrence [18]. 
Furthermore, the incidence of RA is about 3 times higher in women than in men (Table 
1.4), possibly due to hormones factor as RA generally develops in women when their 
hormonal factors are at the highest levels, for instance: after pregnancy or near 
menopausea. This differential ratio between women and men falls with increasing age. 
Interestingly, studies conducted at various time points within the same geographic 
regions suggest a fall in the incidence of RA in women as explained by a protective effect 
of oral contraceptive pill [8]. 
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Country Female (%) Male (%) 
Greece 0.45% 0.19% 
Northern Italy 0.51% 0.13% 
France 0.51% 0.09% 
United Kingdom 1.16% 0.44% 
United States 1.4% 0.74% 
Table 1.4. Prevalence of RA by gender in various countries. Source from [19] 
 
1.1.5 Etiology 
1.1.5.1 Genetics 
It is long recognised that the susceptibility to develop RA is in part heritable. This is 
supported by evidence that the concordance rate in monozygotic twin is 12-15%, 
compared to 3.5% in the fraternal (dizygotic) twin [20, 21]. Although the occurrence of 
familial clustering of the disease is relatively low, the prevalence of the disease between 
first-degree relatives is considerably higher than the general population [22]. Below, I 
discuss the main genetic risk factors believed to influence the development and/or course 
of RA, including human leukocyte antigen (HLA) and non-HLA susceptibility genes. 
1.1.5.1.1 HLA susceptibility genes 
The firmest link between a genetic susceptibility factor and RA is the association of the 
disease with HLA region, which account up to 40-50% of the genetic influence [22, 23]. 
In human, the class II cluster in HLA region for histocompatibility complex (MHC) class 
II includes HLA-DP, -DQ, and -DR. It has been reported that RA is associated with the 
HLA-DR alleles which have similarity on a highly conserved amino acid sequence 
(QRRAA, RRRAA or QKRAA), extend from position 70 to 74 within the third 
hypervariable region of the DRβ chains (one of the components of HLA-DR heterodimer), 
termed the “shared epitope” (SE). This hypothesis provides a strong rationale for 
adaptive immunity in having a pathogenic role in RA via selectively binding of 
arthritogenic peptides in SE-HLA-DR molecules, which facilitate the presentation to 
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auto-reactive T cells. Other prevailing explanations include molecular mimicry with 
foreign antigens (Ags) [24], T cell repertoire selection [25], and/or SE directly acting as 
immune-stimulatory ligands unrelated to groove peptides [26].  
 
Most RA patients express particular HLA-DR-alleles, such as HLA-DR4 (DRB1*0401, 
0404, 0405, 0408) and HLA-DR14 (DRB*1402), which are more prevalent in RA with 
the strongest association with the DR4, and HLA-DR10(DRB*1001), in addition to some 
HLA-DR1β chain  (DRB1*0101, and 0102) [27]. The HLA SE alleles are a risk factor 
for antibodies against cyclic citrucllinated peptide (ACPA, as discuss later) and have 
reported to be a predictor for severity of established RA [28]. However, only 70% of 
patients with RA display susceptible HLA-DR, suggesting that these alleles are neither 
necessary nor sufficient for RA expression. Moreover, although the HLA-DR locus has 
been demonstrated as important in many cohorts [29], the association with DR4 or 
QKRAA is not as prominent or is not associated with RA in Greeks, Pakistanis, Chileans, 
and African-Americans [30, 31]. Importantly, the exact nature of the epitope and its role 
in the diseases are still under debate. For example, the presence of aspartic acid in 
position 70 alone has been reported to be protective [32], whereas individual with the 
sequence outside residues 70-74 indeed have much higher incidence and prevalence of 
RA [33-35]. 
1.1.5.1.2 Non-HLA susceptibility genes 
Protein tyrosine phosphatase non-receptor type 22 (PTPN22), which encodes lymphoid 
tyrosine phosphatase (Lyp), is a tyrosine phosphatase involved in intracellular T cell 
signaling [36]. The minor allele of a single nucleotide polymorphism (SNP) in PTPN22 
has been found in nearly 15% of patients with seropositive RA [37] and may increase the 
rate of progression of RA [38]. This SNP directly changes the amino acid sequence of the 
encoded protein resulting in enhanced regulation of T-cell receptor signaling during 
thymic selection, allowing autoantigen-specific T cells to escape clonal deletion, thereby 
predisposing to autoimmunity. PTPN22 polymorphisms have been identified in European 
populations but are rarely found in Asian populations. In contast SNPs in the gene 
encoding for peptidyl arginase deiminase (PADI), an enzyme responsible for the post-
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translational modification of arginine to citrulline, have been found more consistently in 
RA patients from Asian than in European populations [39, 40]. In a Japanese study, a 
strong association was observed between eight SNPs in the PADI4 genes and 
susceptibility to RA, as suggested by an extended haplotype in the PADI4 gene that can 
enhance the stability of PADI4 mRNA and therefore increase the cellular levels of 
PADI4 protein and citrullinated peptides [41]. Despite this, no consistent association 
between PADI4 gene and circulating anti-CCP antibodies has so far been demonstrated 
[42, 43].  
 
A growing list of genetic risk factors for RA has recently been developed using advanced 
genotyping techniques (GWAS) and increased knowledge of the human genome. Newly 
recognised RA susceptibility genes include an allele of the Fcγ receptor, a polymorphism 
marker in the β2-adrenergic receptor; a low-indicible allele of the cytochrome P450 
subtype 1A2 [44], nuclear factor kB (NF-kB)–dependent signaling (e.g. TRAF1-C5, 
TNFAIP3) and genes involved in T-cell activation (e.g. STAT4, CTLA-4) [45, 46], as 
well as certain polymorphism in cytokine, cytokine-receptor loci, inflammatory 
mediators and chemokines. However, all newly discovered genetic risk factors are 
insufficient alone for full expression of the disease and do not explain the major part of 
heritability of RA as they are also fairly common in healthy individuals. Although the 
contribution of each gene is relatively small compared with class II MHC, a combination 
might provide an appropriate genetic background to influence the course of RA.  
1.1.6 Environment 
1.1.6.1 Environmental factors inducing protein citrullination: Smoking and 
periodontal disease 
Among environmental factors, smoking has by far the strongest association with RA. 
Cigarette smoking not only increases susceptibility to RA, but is also a risk factor for 
greater disease severity. Compared to those who had never smoked, patients with a 
smoking history are more likely to be seropositive, have nodules or radiographically 
apparent erosions [47, 48]. Multivariate analysis revealed that the duration of use, but not 
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the number of cigarettes smoked per day, was significantly associated with increased risk 
[49]. Accordingly, smoking cessation may help prevent RA development. Other potential 
factors include silica dust, mineral oils, and other airbone exposures. Indeed, in a 
Swedish study, it was suggested that inhaled components of cigarette smoke, rather than 
nicotine, may be more important than nicotine itself in etiology [50].  
 
More importantly, in ACPA-positive individuals the combination of the presence of 
shared epitopes and smoking increases the relative risk of developing RA by 21 folds 
[51]. It was proposed that long-term smokers have augmented PADI activity in 
macrophages, which increased the deposition of citrullated proteins in their lungs [52]. 
The association between RA and periodontal disease has long been postulated [53]. RA 
patients have significantly higher prevalence of chronic periodontitis compared to normal 
individuals. However, the potential biological explanation for such association has long 
been obscure. Recently, evidence that the bacterium responsible for periodontal disease, 
porphyromonas gingivalis, expresses abundant level of PADI and is able to induce 
protein citrullination [54], has led to the hypothesis that chronic periodontitis may be a 
fundamental factor for inducing breach of immunological tolerance to citrullinate 
proteins, leading to humoral autoimmunity in the pre-clinical stage of RA. In keeping 
with this scenario, a recent study identified a high prevalence of antibodies against 
citrullinated alpha-enolase in RA patients, which associate with both the SE and smoking 
[55] and may also cross-react with bacterial enolase, particularly in RA patients with 
porphyromonas gingivalis infection [56]. 
1.1.6.2 Infectious agents 
In addition to porphyromonas gingivalis, several microorganisms have been implicated in 
the development of RA in a genetically susceptible host. Among the bacteria that have 
been suspected are mycoplasma species [57, 58], and mycobacterium tuberculosis [59]. 
Among viruses, possible candidates include Epstein-Barr virus (EBV) and parvovirus 
B19 [60, 61]. 
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EBV is one of the best studies for evaluating the possible association of viruses with RA. 
Sera of RA patients contain high titres of antibodies to latent and replicative EBV Ags. 
Interestingly, EBV glycoprotein gp110 contains the same QKRAA sequence of the SE on 
the HLA-DRB1*0401 allele [24]. Thus, in certain EBV-affected individuals, the mimicry 
molecules may drive autoimmunity. In addition, EBV is a polyclonal activator for B cells 
[62] and can stimulate the proliferation of autoantibody producing B cells [63]. EBV 
DNA has also been detected in higher amounts in the blood, synovial fluid and saliva of 
patients with RA as compared to healthy individual [61]. There are conflicting data on 
the remaining organisms, for example parvovirus B19, which has been found in RA 
synovial tissue and fluid, and has been reported to be capable in transforming normal 
synoviocytes into an invasive phenotype [64]. Contrary to this though, acute parvovirus 
B19 arthritis patients show no development of chronic arthritis [65] and there are data 
demonstrating the presence of its DNA also in the synovial tissue of healthy individuals 
[66].  
1.1.7 Current pharmacological therapies of arthritis 
If RA is left untreated or insufficiently treated, joint destruction, subluxation and 
permanent disability are the likely outcomes.  RA patients appear to have at least 2-fold 
increase in mortality, and this increased risk of mortality is primarily attributed to an 
increased incidence of cardiovascular disease [67]. Nowadays, there is no known cure for 
RA but many treatments are able to stop the progression of this chronic illness. Therefore, 
the goals of treatment are to relieve symptoms of joint pain and swelling, to prevent joint 
damage and to decrease morbidity and mortality [68]. Treatment of RA has been 
radically transformed over the last few decades. The first anti-inflammatory agent used 
for treating RA was acetylsalicylic acid which was introduced later as Aspirin [69]. 
Subsequently, other substances were developed with similar drug activity and were 
grouped in a category called non-steroidal anti-inflammatory drugs (NSAIDs). These 
substances do not inhibit the progress of RA, instead they decrease inflammation and 
provide fast relieve of pain and stiffness by inhibition of constitutional cyclooxygenases 
(COX)-1 and induced COX-2, which are enzymes implicated in prostaglandin synthesis.  
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Another category of drugs is corticosterioids, which have both anti-inflammatory and 
immunosuppressive activity. Glucocorticoids are used for suppression of more severe 
symptoms, which act on the inflammatory process by interfering with the cytokine 
network, inflammatory enzymes, adhesion molecules, permeability factors, cellular 
function and survival [70, 71]. Treatment with glucocorticoids is proved to be very 
effective in suppressing the inflammation of RA [72] and has also been reported to 
reduce the progression of joint destruction in RA [73, 74]. Prolonged treatment with 
glucocorticoids, however, exerts many serious side effects which are sometimes more 
severe than RA itself. These include diabetes, hypertension, excess weight gain and 
osteoporosis [75]. In clinical practice glucocorticoids have traditionally been 
recommended for short periods during acute phase of disease, in particular, in 
combination with disease modifying anti-rheumatic drugs (DMARDs) or in the period 
before DMARDs. Unlike NSAID and corticosterioids, DMARDs are “slow acting” drugs, 
which are applied for a long period of time. Several “conventional” DMARDs that are 
currently available for the treatment of RA include cytotoxic drugs such as methotrexate 
(MTX), leflunomide, cyclosporine, azathioprine, sulphasalazine as well as the anti-
malarial drug hydroxychloroquine (HCQ). These drugs are moderately to well tolerated 
[76] and to certain extent are effective in suppressing the rheumatoid process [77]. 
DMARD monotherapys are all shown to have beneficial effects on RA activity, but its 
effect is more pronounced when used either in combination therapy with other DMARDs 
or in conjunction with biologic agents [78, 79]. 
 
In recent years, medications directly targeting specific pathways of the immune system, 
such as cell surface markers or proinflammatory cytokines that lead to joint inflammation 
and other abnormalities seen in RA, have been developed and described as biologic 
DMARDs. These new biologic agents are genetically engineered drugs and because of 
their expense and side effects, it is recommended that most people with mild to moderate 
RA be treated with conventional DMARDS before the use of biologic agent unless they 
are failing to response to the use of combined conventional DMARD therapy.  
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The first of these biological therapies was the tumor necrosis factor (TNF) blocking agent, 
Infliximab [80]. Many different anti-TNF antibodies are now used in clinical practice 
which includes infliximab, adulimumab, etanercept, and the newer golimumab and 
certolizumab. These medications are effective when used alone, but are often given in 
conjunction with other DMARD to increase benefit on clinical response, prevent 
radiographic progression and to reduce the negative effects [81]. Despite the achievement 
of anti-TNF treatments, up to 40% of patients with RA may not have a clinical response 
to anti-TNF therapy [82]. Therefore new biologics have emerged. The evidence for the 
role of B cells in the immunopathogenesis of RA is increasing rapidly. The migration of 
B cells into inflamed synovium therein: (1) participating in synovial follicular 
microstructure; (2) performing their classic role in the presentation of antigen to CD4
+
 T 
cell; (3) producing auto-antibodies raise its contributing role in the etiology of RA. The 
clinical impact of B cell targeted therapies includes depleting B cells (an anti-CD20 agent, 
Rituximab; and an anti-CD22 antibody, Epratuzumab) or targeting B cells survival 
factors (anti-B cell stimulator protein agent, Belimumab/LymphoStat-B®, a human mAb 
that specifically recognises and inhibits the biological activity of B cell survival factor of 
the TNF family, BAFF; Atacicept, a fully human recombinant fusion protein that blocks 
the activity of BAFF and of a proliferation-inducing ligand, APRIL [83]. 
 
Recently, the therapeutic intervention of RA has become more focused on the very 
beginning of the disease [84]. It has been demonstrated that patients treated in this early 
period have higher clinical response rates to the mediation than those receiving delayed 
therapies [85] and they experienced less radiographic damage over time [86]. The 
intensive treatment in the very brief period when arthritis begins and the development of 
radiological progression is referring to the so-called “window of opportunity”. This 
concept asserts that the use of current therapy may not only shorten the effective 
induction of low disease activity, but also effectively change the clinical course of the 
disease.  
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1.2 Synovitis of RA 
1.2.1 Normal synovium 
Joints that support free mobility of the bone are termed diarthroses. Diathrodial joints are 
surrounded by a fibrous membrane capsule that encloses a fluid-containing cavity. It is 
composed of two distinct layers: an outer layer consisting of a thick, dense connective 
tissue called the fibrous layer (stratum fibrosum), and an internal one termed the synovial 
membrane or synovium (Figure 1.2), which helps in mediating nutrient exchange 
between blood and joint. In the normal state, synovium is divided into two anatomical 
and functional compartments: the external layer (subintima) and the inner layer (intimal).  
 
Figure 1.2. Diagram of diathrodial joint. Modified image adapted from Anatomy of the 
Human Body, Henry Gray, 1918.    
 
The inimal lining is the most superficial cell layer in contact with the joint cavity. The 
lining is normally one or two cells thick and composed of type A and type B 
synoviocytes, representing about one-third and two-thirds of the normal synovial lining 
cell, respectively (Figure 1.3 and Table 1.5). Synoviocytes are distinguished from other 
fibroblasts due to their location on the internal connective tissue surface. The synovial 
lining lacks epithelial cells (EC), tight junctions or desmosomes. Instead, it develops 
sporadic, discrete and discontinuous regions of contact with wide interceullular spaces. 
This is in contrast to other serosal surfaces, whose integrity is maintained by densely 
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compacted cells that form extensive interactions. Furthermore, the synovial lining lacks a 
classic basement membrane that underlies most other body lining surfaces. Rather, it is 
composed of densely packed cells within a meshwork of dense extraceullar matrix 
interspersed with collagen fibrils and other matrix protein. Overall, the synovial lining 
creates a cellular basement membrane between the synovial fluid compartment and a 
richly vascularised synovial sublining region [87]. The healthy sublining layer is 
normally paucicellular and mostly composed of fibroblasts and macrophages and it 
contains blood vessels, lymphatics, and nerves. Occasionally, lymphocytes, mast cells 
and adipocytes are also found in the sublining layer.  
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Figure 1.3. Diagram showing the location and structure of two types of synoviocytes.  
 
Type A cells (A) are located at the superficial layer of the synovial lining and type B cells 
(B) characterised by a cytoplasm rich in large pale nuclei and cytoplasmic processes, are 
present at various depths. Frequently found in the deeper layer of the synovial lining. 
Modified image adapted from Iwanaga et al Arch Histol Cytol 2000;63(1):17-31 [87] 
 
 
Marker Macrophages-like synoviocytes Fibroblast-like synoviocytes 
Common CD16/CD Immunoglobulin G Fc 
receptor 
Type IV and 
V collagens  
Structural protein 64 
CD45  Leukocyte common antigen Vimentin  Intermediate filament 
CD14  LPS/LBP receptor Thy-1 CD90 
MHC class 
II  
Major histocompatibility 
complex Class II 
MHC class 
II  
Major histocompatibility complex 
class II 
CD11b/ 
CD18  
Integrin adhesion molecule 
and complement receptor 
‘Mac-1’ 
ICAM-1  Intercellular adhesion molecule-1 
CD68  Lysosomal glycoprotein   
Relative 
specific 
  UDPGD  Uridine diphosphoglucose- 
dehydrogenase 
VCAM-1  Vascular cell adhesion molecule-
1, CD106 
DAF  Decay accelerating- factor, CD55 
Very specific   Cadherin-11  Calcium-dependent adhesion 
molecule-11 
Table 1.5. Selected markers expressed by macrophage-like and fibroblast-like 
synoviocytes.  
 
Table adapted from Bartok & Firestein Immunological Reviews 2010 Vol. 233: 233–255  
[88] 
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1.2.1.1 Type A synoviocytes 
Type A synoviocytes are macrophage-like synovial cells localised in the more superficial 
regions of the intimal lining. Their belonging to tissue macrophages is evidenced by the 
fact that they are immunoreactive to several monoclonal antibodies against macrophages 
or macrophage-derived substances [87]. For instance, they express CD11b, CD68, CD14, 
CD163 and abundant MHC class II such as HLA-DR and the Fc receptor. Like other 
tissue macrophages, type A cells are derived from bone marrow and are terminally 
differentiated cells that have little capacity to proliferate. They likely migrate to the 
synovium and become resident cells, although it is still under debate whether the 
differentiation takes place in situ or prior to arrival [89]. Physiologically, type A cells 
maintain homeostasis of the joint cavity by phagocytosing wastes and cell debris in the 
synovial fluid and intimal matrix. Other characteristics of these cells include antigen 
presentation to T cells, the ability to produce prostaglandin as well as in acting as a 
primary source of several cytokines in the joint, such as interleukin-1 (IL-1), IL-12, IL-15 
and tumor necrosis factor-α (TNF-α). 
1.2.1.2 Type B synoviocytes 
Type B synoviocytes or fibroblast-like synoviocytes show two phenotypes: intimal and 
subintimal. Currently, it is unknown whether intimal and subintimal fibroblasts arise 
from independent lineages, and because of the difficulty in determining the source of 
these fibroblast cells, a general term `synovial fibroblast' (SF) has been applied [87].  
 
One of the major functions of SF in the normal joint is the production of hyaluronan, an 
important constituent of synovial fluid and extracellular matrix (ECM). Uridine 
diphosphoglucose dehydrogenase, a rate-limiting enzyme for synthesis of hyaluronan is 
therefore preferentially expressed by SF [90]. SF also secretes the synovial fluid 
constituent lubricin, which is critical for joint lubrication [91]. Other specialised products 
may include vimentin (an intermediate filament that is widely expressed in mesenchymal 
cells and macrophages) [92], phospholipids [93] and unusual carbohydrate entities [94]. 
Also, molecules associated with basal laminae, including fibronectin, type IV collagen, 
laminin, chondroitin-6-sulphate-bearing proteoglycans, tenascin-C (an extracellular 
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matrix glycoprotein associated with tissue injury and repair), type VI collagen microfibril 
and fibrillin-1-containing microfibril, are expressed by SF for continuing maintenance of 
the synovial ECM. Further, SF are also actively involved in collagen synthesis, reflected 
by the presence of prolyl-4-hydroxylase, procollagen I and III in the cytoplasm of SF [89, 
95]. 
 
In addition to specialised matrix synthesis, SF expressed a number of cell-surface related 
molecules. For instance, they constitutively show prominent expression of adhesion 
molecule vascular adhesion molecule 1 (VCAM-I)/CD106 and decay accelerating factor 
(DAF). Integrin species (α5β1 and αvβ; intergrin receptors), intercellular adhesion 
molecules (ICAM-1)/CD54, CD55 (complement decay accelerating factor), CD44 and 
CD90/Thy-1 are also reported to be expressed by SF [96]. Recently, cadherin-11, an 
integral membrane adhesion molecule, is reported to be abundantly expressed on SF and 
serves as a major mediator for homotypic aggregation of SF in vitro and in vivo  [97].  Its 
importance in the synovial architecture was confirmed in cadherin-11 deficient mice, in 
which the synovial intimal lining was virtually nonexistent [97, 98]. Normal SF also 
synthesises degradative enzymes, such as serine protease, matrix metalloproteases 
(MMPs) and the membrane type-MMPs (MT-MMP). The distinct features of 
synoviocytes implicate them not only in the healthy purpose of the joint but also in the 
abnormal activities that occur during inflammatory disease such as RA. The mechanism 
by which this appears to occur will be discussed in depth below. 
1.2.2 The rheumatoid synovium 
Inflammation in the joint first involves the synovial membrane, which is the central site 
to the pathophysiology of RA. The early changes in rheumatoid synovium tissue are 
manifested in hyperplasia of synovial lining cells, accompanying injury of 
microvasculature with vascular congestion, microvascular damage/occlusion and 
transformation of synovial endothelial cells into high endothelial venules. This 
inflammatory stage is often associated with edema, vascular proliferation, necrosis and 
fibrosis of synovial stroma as well as exudation of fibrin characterised by fibrin deposits 
on the surface of the synovial lining (surface fibrin deposits) and/or within the synovial 
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stroma itself (stromal fibrin deposits). Angiogenesis is also an early and critical event in 
the pathogenesis of RA, which promotes ingress of leukocytes and pannus formation [99]. 
 
Thickening of the synovium is the hallmark of RA. Within a short period of time the cell 
lining expands to 10-20 cells thick. The sublining region undergoes striking alternation in 
both the composition and number of cells, with prominent ingression of T cells and 
macrophages, along with B cells, plasma cells (PC) and dendritic cells (DC). The role of 
some of these cells in pathology and joint destruction will be discussed later in this 
chapter. Besides these cells, polymorphonuclear cells are sometimes present, particularly 
during acute phase in RA. Natural killer cells, mast cells and neutrophils have also been 
identified, with the latter appearing in very large numbers. Neutrophils are mainly found 
in the synovial fluid but they can also be observed close to the synovial-cartilage junction 
[100].  
 
The synovial lining is often folded into numerous villi that cover the cartilage-bone 
interface and isolate it from the synovial fluid. This expansion of synovium is termed 
pannus, which behaves like a locally invasive tumor with cells composed of macrophages, 
osteoclasts and invasive SFs with relatively few lymphocytes. A formation of resorption 
pit (Howship’s lacunae) is responsible for the degradation of bone mineral and collagen 
matrices caused by the activated osteoclasts (Figure 1.4). Subchondral bony erosions are 
the ultimate characteristic of RA. 
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Figure 1.4. In RA synovium, SFs interact with diverse cell types promoting 
inflammation and join destruction. 
 
In a RA joint, the synovium is swollen due to an infiltrate of immune cells. (1) Pannus 
tissue, an extension of the hyperplastic synovial lining consisting of both activated 
fibroblast-like and macrophage-like synoviocytes. (2) SFs actively degrade cartilage by 
producing matrix degrading enzymes (MMPs and cathepsin). (3) SFs promote osteoclast 
differentiation and activation via RANKL, leading to bone destruction. Also, SFs may 
produce osteoblast activity inhibitor (DKK-1). (4) Sublining SF interact with numerous 
cell types: T cell recruitment and retention by SF-secreted chemokines (SDF-1 and 
CD40). Although SFs do not normally express MHC its expression is seen on freshly 
isolated RASFs and can be induced upon T cell cytokine (IFN-γ). RASFs can in turn 
secret cytokines such as IL-15, which are involved in Th17 differentiation; B cells are 
similarly recruited and retained via SF-derived chemokines (SDF-1, CXCL13) and via 
adhesion molecules (VCAM-1). SF-derived IL-6 can in turn promote B cell survival; 
DCs in the synovium present antigen to T cells and activate T cells, thus providing help 
to autoreactive B cells; Macrophages are activated to produce many kinds of 
proinflammatory products partly by immune complexes binding to surface receptors such 
as Fcγ receptors; SFs can produce proangiogenic factors (VEGF) which can directly 
promote inflammatory cell recruitment via endothelial cells. Finally, the cell-cell 
adhesion molecules cadherin-11 links RASFs to other RASFs, which is crucial for 
synovial lining formation. SFs interact with macrophages via soluble factors (TNF-α, IL-
1 and IL-6) or adhesion molecules (ICAM-1 and VCAM-1).  
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In tissue homeostasis and immunoregulation, cells die by apoptosis and are ingested by 
macrophages, which concomitantly avoid an inflammatory reaction, compatible with 
prevention of tissue damage. Upon tissue injury that occurs during hypoxia and acidic 
conditions, cells die of a necrotic process, releasing their contents and inducing a rapid 
inflammatory response, which damages the surrounding tissues in the short term but is 
also a prerequisite for tissue remodeling and repair. Many studies have previously 
suggested that the rheumatoid synovial microenvironment is relatively ischemic, hypoxic 
[101, 102]  and highly genotoxic (deleterious milieu on a cell's genetic material affecting 
its integrity). Due to inflammation and expansion of the synovial membrane during RA 
development there is increased pressure in the synovial cavity, reduced capillary density 
and increased metabolic needs in the arthritic joints, resulting in abundant reactive 
nitrogen and oxygen and cellular stress that normally kills cells [103].  
 
Interestingly, RASFs express death receptors, such as Fas/CD95, which when crosslinked 
by antibodies induce apoptosis [104]. However, RASFs were shown to be relatively 
resistant to FasL, TNF, and tumor necrosis (TNF)-related apoptosis inducing ligand 
(TRAIL)-induced apoptosis [105]. This resistance has been related to the high expression 
of anti-apoptotic molecules such as Fas-associated death domain-like IL1 beta-converting 
enzyme-inhibitory protein (FLIP), sentrin-1, members of the Bcl-2 family (such as Bcl-2 
and Mcl-1), and constitutive activation of Akt (protein kinase B) [88, 106]. In contrast, 
other Bcl-family members such as Bax, Bak, BH3 interacting domain death agonist (Bid) 
and Puma are pro-apoptotic and promote mitochondrial membrane permeability [88]. It 
has been reported that phosphorylation of Akt in RASFs protects against Fas-induced 
apoptosis through inhibition of Bid cleavage [106].  
 
Cells that enter the rheumatoid joints are exposed to a number of pro-inflammatory 
cytokines and immune complexes, typically present in the synovial fluid. Indeed, the 
deposition of immune complexes has been considered to be a major determinant of 
neutrophil-mediated articular tissue injury, which is responsible for the irreversible 
anatomical destruction of the normal tissue architecture with consequent articular 
dysfunction [107].  
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Recently, Dubikov et al reported that the rate of apoptosis in RA synovial cells was 
associated with the presence of Bcl-2 and p53, in which their expression level was 
correlated to disease severity (increased from early to late RA) [108]. It would thus 
appear that the ratio of anti- and pro-apoptotic molecules within the rheumatoid joint 
constitutes a rheostat that sets the threshold for susceptibility to activation-induced cell 
death. 
 
In line with these observations, necrotic cells may also be found in RA joints as a result 
of inflammatory and destructive processes. Whereas necrotic cells can easily be detected 
in the synovial fluid, they are not typically present in large quantities in the synovial 
tissue. However, apoptotic cells in synovial tissue may undergo secondary necrosis [109]. 
It has been described that the RNA released from necrotic, but not apopotic, synovial 
fluid cells may act as an endogenous ligand for toll-like receptor 3 (TLR3) and activates 
RASFs for the stimulation of proinflammatory gene expression [110]. (Details on TLR 
will be discussed later in section 1.4.2). Accordingly, it is generally accepted that the 
presence of necrotic cells, especially neutrophils, is proinflammatory [111]. However, it 
has also been suggested that not all necrotic cells pose a danger. A study of Miles et at 
proposed that necrotic human neutrophils exert anti-inflammatory effects via the release 
of α-defensin, and if a macrophage encounters such a cell its ability to secrete pro-
inflammatory cytokines and nitrogen oxide is inhibited, while its ability to phagocytose 
material is increased [112]. Therefore, neutrophil necrosis may initiate resolution 
response at sites of inflammation.  
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1.2.2.1 T cells in RA  
T cells constitute the most prominent infiltrating lymphocytes within the sublining region, 
where they account for 30-50% of all cell types. The activated CD4
+
 T-helper (Th) 1 cell 
predominates over Th2 in RA disease. For instance, human rheumatoid synovial 
membrane and synovial fluid presents large amounts of interferon γ (IFN-γ), a signature 
Th1 cytokine, but no IL4, a typical Th2 cytokine [113]. Multiple animal models have 
identified a new subset of Th cell characterised by the production of  IL-17A (henceforth 
called IL-17) by Th17 cells in the RA joint pathology [114]. In human studies, IL-17 has 
been shown to induce monocyte- and fibroblast-derived proinflammatory cytokines 
(TNF-α, IL-1β, IL-8), which, mediate of bone and cartilage damage such as MMP and 
receptor activator of nuclear factor kappa B ligand (RANKL) [115] as well as in induce 
osteoclastogenesis [116]. Likewise, CD4
+
 Th17, but not IL17 producing γδ T cells, drive 
arthritic bone destruction in mice and human [117].  The importance of CD4
+
 T cells can 
also be shown in their transfer to severe combined immunodeficient (SCID) mice 
engrafted with human synovium, which leads to synovial inflammation by antigen-
specific T cell response [118-120]. Conversely, a recent study using the proteoglycan 
induced arthritis (PGIA) animal model, demonstrated that T cell homing to secondary 
lymphoid organs (SLOs) is more important than migration to the joint [121, 122]. 
Costimulation of naïve T cells with CD28 after engagement with its ligand B7-1/CD80 is 
important for T cells survival and proliferation. To limit uncontrolled T cell activation, 
stimulated T cells upregulate expression of a second receptor for B7-1, cytotoxic T 
lymphocyte antigen-4 (CTLA-4), which is an inhibitory receptor and has a greater 
affinity for B7-1 relative to CD28, thus acting as modulator for T cell activation. In 
clinical trials, CTLA-4 immunoglobulin fusion protein (Abatacept) yields promising 
result as a monotherapy, in combination with methotrexate, as well as in patients who are 
refractory to anti-TNF therapy [123, 124]. These findings highlight the importance of 
cell-cell interaction mechanisms for mediating T cells activation. 
 
Another CD4
+
 subset, T regulatory cells (Treg), is also included in the new paradigm for 
RA based on their participation in regulating autoimmune inflammatory response in vivo. 
Their role is further strengthened by the observation that RA patients are defective of 
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CD4
+
CD25
+
 Treg cells [125]. However, the contribution of Tregs is still controversial as 
the protective role is dependent on both their number and function. For instance, Treg 
cells in RA joint fluid failed to inhibit the production of IFN-γ and TNF-α by CD4+ cells 
or monocytes. This observation could be explained by an instrinsic inability of RA Tregs 
in suppressing, or by the fact that the large amount of proinflammatory cytokine secreted 
in the RA joint fluid influences the sensitivity of effector T cells to be suppressed [126]. 
Finally, CD8
+ 
T cells, which are primarily associated with cytotoxic responses towards 
virally infected cells, can be abundantly expressed within the RA synovium where they 
may contribute to chronic inflammation via different mechanisms [127, 128]. For the 
purpose of this thesis, it must be noticed that a subset of non-cytotoxic CD8
+
 T cells has 
been shown to maintain ectopic GC in the RA synovium and are able to modulate 
antibody production from synovial tissue engrafted into SCID mice [129]. 
1.2.2.2 B cells in RA  
Compared to T cells, the infiltration of B cells is subtle in the pannus lesion where they 
constitute about 5% of the sublining synovial cells. However, they are a significant and 
constant population in those RA synovium characterised by the presence of lymphoid 
follicles in the sublining region [130]. Together with (auto) antibody production, cytokine 
release and antigen presentation, B cells can also regulate lymphoid tissue architecture 
and ectopic lymphoid neogenesis, which, as mentioned below, is a common feature in the 
RA synovial membrane. The role of the interaction between resident stromal 
microenvironment and B cells in RA pathology will be discussed in later chapter (1.4). 
 
The first evidence for a role of B cells in RA is based on the observation of high levels of 
circulating autoantibodies in RA patients. Rheumatic factor (RF) is an autoantibody with 
specificity against the Fc portion of self-IgG and has been shown to fix and activate 
complement. RF itself has not been recognised as a causative agent in arthritis when 
transferred into healthy individuals [131], but it is a positive predictor of disease severity 
and progression in RA [132]. On the other hand, RF is not very specific for RA as it can 
also be dectected in up to 10% healthy individual as well as in other autoimmune 
conditions including SLE. However, in healthy individuals RF is a low affinity IgM 
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produced by B1 cells as a natural antibody, whereas RF in RA patients undergoes class-
switching as a consequence of B cell-T cell interaction, a phenomenon also observed for 
anti-CCP antibody. Autoantibodies such as anti-Sa and anti-CCP are dependent on the 
citrullinated protein. Citrullination is a form of post-translational modification of protein, 
in which the amino acid arginine is converted into citrulline by peptidylarginine 
deiminases [133, 134]. This process occurs in the inflamed synovium as well as in other 
inflamed tissue. In relation to RA, the target antigens include citrullinated fibrinogen, 
vimentin or α-enolase or type II collagen. A recent study indicated that, autoantibodies 
against citrullinated protein, though not directly pathogenic, were able to increase 
arthritis severity in a murine model [135]. This may suggested that that B cells and/or 
their products are crucial in the exacerbation of RA disease, possibly by amplifying 
inflammation. Besides producing antibodies, B cells can also act as efficient antigen-
presenting cells (APC) to T cells. RF
+
 B cells can take up antigen in a context of IgM-
RF-IgG complex via membrane bound Ig receptor, thereafter, they can target for T cell 
help and activation by several specific foreign antigens. In contrast, nonspecific B cells 
are unlikely to present antigen to T cells even though they have the ability in binding 
antigen-antibody complexes [136]. In line with this, T cell activation in the synovial 
tissue of RA patients is dependent on the presence of B cells. Furthermore, activated 
effector B cells are able to secrete polarised assays of cytokines. 
 
B cells role in RA disorder has been proven by the effectiveness of B cell depletion 
therapies. Rituximab is a B-cell-cytolytic chimeric IgG1 CD20-specific monoclonal 
antibody, which can potently kill B cell subsets from the immature stage (pre-B-cell) up 
to the memory B cell stage. Alternatively, atacicept, a fusion molecule of the soluble 
transmembrane activator and calcium modulator and cyclophilin ligand (CAML) 
interactor (TACI) receptor and IgG, binds to and sequesters two key B-cell factors 
involved in RA: the B cell associated survival factors, BAFF and APRIL the B cell 
associated survival factors, BAFF and APRIL [83]. BAFF and APRIL are involved in B 
cell survival, differentiation and class-switching during different stage of B cell 
development. Recently, atacicept has been shown to decrease levels of IgG, IgM and IgA, 
as well as naive B cells and PC (which are CD20 negative). In Phase II studies in patients 
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with RA, atacicept 150 mg was associated with median IgG decreases (~30%) [137]. The 
critical of B cells role and the contribution of survival factors in RA pathophysiology is 
further discussed in details in section 1.3.   
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1.2.2.3 Histopathology of synovitis, formation of B cell follicles  
Multiple lines of evidence suggest an Ag-dependent immune reaction in a subset of 
patients with RA, who has the ability to create lymphoid microstructures in a 
nonlymphoid organ, such as the synovial membrane. There is mounting evidence 
showing that RA is a heterogeneous entity with three distinct histologically defined 
phenotypes in the synovial membrane: 1) leukocytes infiltrate into the sublining region of 
synovium with a diffuse pattern (about 50%); 2) cells cluster as perivascular cuffs 
forming lymphoid aggregates (about 25%); 3) a high degree of cellular organisation 
where the leukocytes are organised into secondary follicles with a germinal centre (GC) 
phenotype, extensively expressed within follicular dendritic cell (FDC) networks 
accompanied by active proliferating B cells expressing the maturation marker CD20 and 
proliferation antigens such as Ki67 (about 25%) [138]. The latter can arrange and 
organise themselves anatomically and functionally as in secondary lymphoid organs 
(SLO), leading to the de novo formation of B cell follicles and T cells area. This 
phenomenon has been termed lymphoid neogenesis, or tertiary lymphoid organ (TLO) or 
ectopic lymphoid structure (ELS). Manzo et al [139] demonstrated that ELS in the 
rheumatoid synovium consist of a more continuous spectrum, with lymphocytic 
aggregates displaying different stages of lymphoid neogenesis (Figure 1.5). 
 
 
 - 49 -  
 - 50 -  
Figure 1.5. Development pathways of lymphoid organisation in RA synovium.  
 
Distinct pathways of lymphoid neogenesis can be set in place by an Ag-triggered immune 
response occurring in extranodal tissue. Selection of the pathway depends on modulating 
host factors, e.g. aberrant expression of cytokines/chemokines, the attitude of immune 
system dyregulation and the extent for recruitment of cellular components are all required 
for determine certain types of lymphoid microstructures. Organisation of the three types 
of lymphoid infiltrate may suggest RA is a heterogeneous entity or a continuous spectum 
that represents different stages of RA.  Modified image adapted from Weyand et al Am J 
PatholVol: 159:3.  [140]    
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Among the chemokines that regulate the compartmentalisation of T cells and B cells, 
CXCL13 (formerly BLC or BCA-1) and CCL21 (formerly 6Ckine or SLC) seem to be 
especially important, and their expression in rheumatoid synovium correlates with the 
presence of ELS [141]. CCL21 is highly expressed on stromal cells within the T cell zone 
of SLO, endothelial cells of high endothelial venules [142] and lymphatic vessels [143], 
inflamed synovial specimens of RA [141], fibroblasts from RA synovial membrane and 
macrophages from RA synovial fluid [144]. CXCL13 is recognised as one of the most 
important chemoattractors for B cells.  Its corresponding receptor, CXCR5, is mainly 
expressed on B cells [145] and thus CXCL13 has proven to be crucial in the formation of 
ectopic B cell follicles in RA [146]. In RA, high expression of synovial CXCL13 is 
shown to be associated with the presence of synovial lymphoid aggregates that resemble 
GC compared with synovial diffuse infiltration [141].  
 
Takemura et al showed that the architecture of lymphoid structures in rheumatoid 
synovium is also regulated by members of the tumor necrosis factor (TNF) superfamily, 
lymphotoxin (LT)-α and LT-β, and these proteins can form two different trimeric 
molecules; a membrane-bound heterotrimer LTα1β2 (one α chain and two β chains) that 
binds exclusively to LTβ receptor (LTβ-R), or soluble homotrimer LTα3 that binds to 
TNF-R1 and TNF-R2. A third related member of this family is called LIGHT (LT-related 
inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator 
on T cells). LT-α1β2 and LIGHT, but not LT-α3, are present in RA and have proven to 
be predisposed for follicular synovitis [146]. Also, LIGHT may activate non-lymphoid 
cells expressing HVEM or LTβR, such as RASFs, which in turn up-regulate the 
expression of proteinase MMP-9, increase the expression of adhesion surface molecule 
CD54 and increase the release of proinflammatory cytokine IL-6 [147].  
 
The development of ELS in rheumatoid synovial tissue, however, has not been reported 
to confine a specific clinical subset of RA. Thurlings et al demonstrated that lymphoid 
neogenesis is related to increased expression of systemic inflammatory biomarkers, but 
not to IgM-RF or ACPA [148], an observation that contradicts with the findings from 
Klimiuk PA et al [149], and thus, suggesting that the synovial inflammatory responses 
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varies among patient joints and over time. Of significance, rheumatoid synovium has 
been regarded as an auto-antibody producing organ as supported by the view that 
synovial PC are able to produce and secrete RF, ACPA and other auto-antibodies [150, 
151]. Our group recently reported that, although the circulating auto-antibodies in RA are 
not associated with the presence of ELS, the production of auto-antibodies within the 
synovial tissue does correlate with ELS [152]. Accordingly, ELS
+
 synovium engrafted 
into SCID mice was shown to provide elements required for the survival of auto-reactive 
B cells and the subsequent production of circulating auto-antibodies, such as RF and anti-
CCP [152] via local differentiation of autoreactive PC [153].  
1.2.2.4 Innate immune cells in RA: macrophages and DC 
The myeloid lineage gives rise to several cell types participating in the disease, such as 
monocytes/macrophages and CD11c
+
 myeloid DCs. These are only briefly mentioned 
here. 
 
Monocytes/macrophages. Monocytes migrate from the blood into tissue and 
differentiate into resident macrophages. This takes place via sublining blood vessels in 
the normal and RA synovium. However, the amount of monocyte infiltrates, and the 
degree of macrophages accumulates, are markedly increased in RA synovium. The 
clinical relevance of monocytes/macrophages is not only revealed by the direct 
correlation between their number/activation with disease activity and radiographic 
progression of joint damage, but also, by the beneficial effect of therapies such as gold 
salts, [154], methotrexate [155], anti-TNF [156, 157] and monocyte apheresis [158]. 
Furthermore, monocytes/macrophages are a major source of cytokines, such as 
proinflammatory (TNF-α, IL-1) or regulatory cytokines (IL-10), as well as chemokines 
such as IL-8, MCP-1 and MIP-1α. In line with this, the highest levels of secreted IL-8 are 
observed in patients with seropositive RA and treatment with recombinant murine IL-8 
markedly magnified experimental arthritis, indicating a correlation with activated 
macrophages in this disorder. Notably, IL-8 exerts a predominant role in angiogenetic 
processes [159], thus providing a link between macrophage activation and the well-
known neovascularisation as observed in RA synovium. Furthermore, it is indicated that 
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macrophages are responsible for producing reactive oxygen species and degradative 
enzymes that drive distal joint inflammation and destruction, respectively. 
 
Dendritic cells. DCs are the most potent subset of APC with a unique ability to activate 
naive T cells for helper and cytotoxic function. DCs are distributed in diverse locations 
such as mucosal and skin surfaces, where the potential for attack by pathogens is high. 
However, DC populations have also been found in RA joint fluid and synovium. In the 
latter, perivascular DCs are found tightly associated to T and B cell follicles. The 
infiltrate of DCs in the synovial tissue and fluid could take-up, process and present 
antigen locally, contributing to disease perpetuation. The local cytokines in RA synovium 
in turn promote DC accumulation where they undergo phenotypic and functional 
differentiation in situ that could lead to ongoing autoantigen presentation to T cells [160]. 
Moreover, animal models and histological evidence showed that DCs drive the formation 
and maintenance of ectopic lymphoid tissue in inflammatory environments, probably 
including the synovium [161]. Finally, evidence is accumulating suggesting that DC also 
play a role in the complications surrounding RA, including atherosclerosis [162] .  
 
Transfer of exogenous type II collagen-pulsed mature DCs is sufficient to induce arthritis 
in DBA/1 mice. More importantly, a model of pre-clinical arthritis demonstrated a 
regulatory function of plasmacytoid DCs (pDCs) in limiting self-reactivity and 
subsequent articular pathology [163], whereas conventional DCs (cDCs) are shown to 
orchestrate the initial breach of self tolerance [164]. Furthermore, immature human DCs 
may be directly involved in osteoclastogenesis and DC-derived-osteoclasts may promote 
osteolytic lesions as observed in RA [165]. 
1.2.2.5 Synovial fibroblasts in RA, RASFs 
Along with the immune system, the resident cells of joints are also important players in 
RA pathogenesis, including osteoclasts, osteoblasts, chondrocytes and SF. Regarding SF, 
there is evidence to suggest that stromal activation within the synovium may be a first 
step for RA development. Details of RASFs involvement will be discussed in Chapter 1.4. 
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1.2.3 Cytokine networks in RA 
Cytokines bind to receptors on target cells and regulate a vast array of biologic activities 
such as cell proliferation and release of other cytokines. The expression levels of 
cytokines exhibit vast heterogeneity between different RA individuals. Although many 
cytokines do not cause RA per se, they have been identified in the synovium or synovial 
fluid where they orchestrate the rheumatoid process. More importantly, neutralising 
antibodies against cytokines is an established treatment for RA, especially with TNF-α-
directed approaches. As numerous cytokines have been implicated in RA, the role of IL-1 
IL-6, IL-5 and TNF-α superfamily cytokines, and some novel cytokines have been 
selected to discuss in more detail below.  
1.2.3.1 The IL-1 superfamily 
IL-1 family cytokines are ubiquitous group of polypeptides with related origin, receptor 
structure and signaling pathways. They include IL-1α, IL-1β, IL-18, IL-18 binding 
protein (IL-18BP) and IL-1 receptor antagonist (IL-1Ra). All cytokines are synthesised as 
inactive precursors and cleaved by enzyme caspase-1 before or during release from the 
cell. IL-33 is a newly described member of this family due to the requirement of caspase-
1 for processing and release.  
1.2.3.1.2  Interleukin-1 
IL-1α and IL-1β are produced by various cells such as monocytes, macrophages, 
neutrophils and hepatocytes. In human joint, synovial macrophages are the most 
abundant source for IL-1, and nearly half of the cells express IL-1β. The release of IL-1 
in the synovial lining subsequently can activate SFs for proliferation, stimulate the 
biosynthesis of IL-6, IL8, and GM-CSF and induce the expression of adhesion molecule 
such as VCAM-1 and ICAM-1. This cytokine is also believed to mediate most of the 
articular damage in arthritis, because it induces the degradation of proteoglycan 
degradation [166], production of metalloprotease and collagenase [167], and enhances 
bone resorption [168]. Indeed, the level of this cytokine in the synovial fluid correlates 
with joint inflammatory activity [167].  
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Animal models show that injection of IL-1α and IL-1β into rabbit and rat knees results in 
arthritic manifestation similar to RA, which could be blocked by IL-1Ra [169]. In RA, 
the balance between IL-1 and its physiological inhibitor IL-1Ra is shifted in favour of IL-
1. In line with this, IL-1Ra-deficient mice show spontaneous arthritis in an IL-17 
dependent manner [170]. More importantly, even though synovial inflammation is 
developed in TNF-α transgenic mice crossed with IL-1 deficient mice, they had 
significantly reduced bone erosion and osteoclast formation [171]. Despite the 
accumulating evidence in favor of a pivotal role for IL-1 in RA pathology, the use of IL-
1Ra (anakinra) has failed to produce adequate therapeutic value compared to other 
biologics, possibly due to its short half-life and the necessitate for very high 
concentration [172]. 
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1.2.3.1.3 Interleukin-18 
IL-18 was original defined by its ability to bias the immune response towards the Th1 
cells, and was described as IFN-γ inducing factor. In the context of RA, IL-18 has been 
described to be present in serum, synovial fluid and synovium, with significantly higher 
level than in OA patient [173]. [126]. In vitro studies indicate that IL-18 induces the 
production of GM-CSF, nitric oxide, TNF-α, IL-6 and IFN-γ from RA synovial cell 
cultures. IL-18 and its receptor are abundantly found in RASFs and RA synovial 
macrophages, and the release of IL-18 by these cells is markedly increased by TNF-α and 
IL-1β, suggesting a potential role in the RA propagation [174, 175]. 
 
In the CIA model, injection of IL-18 increased the development of an erosive, 
inflammatory arthritis, suggesting that IL-18 can be pro-inflammatory in vivo [173]. In 
contrast, IL-18 deficient mice have reduced frequency and severity of CIA [176], and IL-
18 blocking, either with IL-18 binding protein or anti-IL-18 antibodies, reduced the 
clinical severity of CIA [177]. The same inhibitory effect could be observed in IFN-γ 
knockout mice, demonstrating that other non-Th1-related activities of IL-18 might be 
significant. Interestingly, IL-18 knockout mice develop antigen-induced arthritis (AIA) 
with severity similarly to wildtype controls, suggesting that the contribution of IL-18 in 
the pathogenesis of arthritis may also be dependent on the model examined [178]. 
1.2.3.1.4 Interleukin-33 
IL-33 was recently identified as ligand for the orphan IL-1 family receptor T1/ST2 with 
response polarised to the Th2 phenotype. SFs may be the main source of IL-33 [179]. 
Little or no IL-33 was found in resting RASFs, whereas its expression was markedly 
upregulated upon the presence of proinflammatory cytokines such as TNF-α and IL-1β 
[180]. Its expression has been detected in serum and synovial fluid from RA patients 
[181]. Furthermore, it has been demonstrated that IL-33 enhances CIA, whereas IL-33R 
knockout mice or mice that were administrated with soluble form of ST2 (a natural 
antagonist of IL-33) had attenuated disease severity [180]. More interestingly, Mun and 
colleagues showed that IL-33 can stimulate osteoclast formation and differentiation [182] 
whereas another study described it as an inhibitor of bone resorption [183]. 
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1.2.3.2 Tumor necrosis factor superfamily 
The TNF superfamily is an extensive group of related genes that exert diverse effects by 
stimulating a variety of cells. At least 19 members of the family have been identified, 
with TNF-α considered as the central cytokine in RA since its blockade is one of the most 
effective therapies developed for RA. Several other members (BAFF and APRIL) 
implicated in synovial inflammation will be discussed later in the relevant section (1.3).  
  
TNF-α forms a membrane bound homodimer and is subsequently cleaved by TNFα-
convertase, a member of MMP. TNF-α, similar to IL-1, stimulates collagenase and PGE2 
production by human synovial cells [184], and it stimulates proteoglycan resorption and 
inhibits its synthesis in explant of cartilage [185]. It also has the ability to promote B cells 
proliferation and differentiation [186], enhance cytokine production, adhesion molecule 
expression and proliferation and MMP production from culture synoviocytes [88]. 
 
In RA, TNF-α is expressed at many sites within the synovium, including the 
cartilage/pannus junction [187]. Elevated levels of TNF-α, as well as its soluble receptor 
have been detected in synovial fluid of RA patients [188, 189]. In vivo studies 
demonstrated that overexpression of TNF-α in transgenic mice leads to development of 
arthritis [190]. Interestingly, spontaneous arthritis also establishes in transgenic mice that 
express only the membrane-bound form of TNF-α on T cells [191]. Accordingly, TNF-α 
blockade is an effective anti-inflammatory agent as shown in the CIA mouse model, 
though the effect on cartilage and bone damage is less prominent than that with IL-1 
inhibitors [192]. 
 
Five TNF-blocking agents have been approved in clinical practice since 1998: 1) 
Infliximab (Remicade), a mouse-human chimeric anti-TNF-α IgG1 antibody; 2) 
Etanercept (Enbrel), a soluble dimeric fusion protein of human TNF receptor type II-
IgG1 (TNFR-Fc); 3) Adalimumab (Humira), a fully human anti-TNF-α IgG1 monoclonal 
antibody produced by phage display technology.[193] Newer anti-TNFα, biologics have 
been approved recently, including 4) Certolizumab pegol (Cimzia), a TNFα-specific Fab 
fragment of a humanised monoclonal antibody and 5) Golimumab (Simponi), a human 
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monoclonal antibody. Another important member of the TNF superfamily for RA 
development is receptor activator of NF-kB ligand (RANKL), a type 2 transmembrane 
cytokine that is produced by bone and lymphoid tissue [194]. Its significant role is in the 
differentiation and activation of osteoclasts. The expression of RANKL is enhanced by 
several osteotropic factors/resorption stimuli such as IL-1, parathyroid hormone and 1,25-
dihydroxyvitamine D3  [195, 196]. Subsequently, the binding of RANKL to its receptor 
RANK induces signal for differentiation into osteoclasts via cell-cell contact with the 
precursor cells [195], thereafter, promoting osteoclastic bone resorption activity and 
survival. Osteoprotegerin, on the other hand, acts as a soluble ‘decoy’ receptor for 
RANKL and blunts osteoclastogenesis [196]. In regard to synovium, RANKL is highly 
expressed in synovial tissue of RA patients and is mainly produced by SF and T 
lymphocytes [197]. Cytokines, such as IL-17 [198], as well as TLRs (TLR2, TLR3 and 
TLR4) [199, 200], have been involved in the production of RANKL by RASFs. 
Denosumab, a fully human IgG2 monoclonal antibody that binds RANKL, has been 
approved in 2011 for postmenopausal osteoporosis and limitation for bone loss, and is 
currently in early phase II clinical trials for its potential in RA [201]. 
1.2.3.3 Interleukin-6 
IL-6 is a protein produced by various cell types such as T cells, monocytes and culture 
SFs [202]. Originally defined by its B cell stimulating properties, it promotes 
immunoglobulin synthesis in B cell lines. It also actively participates in the 
differentiation of cytotoxic T cells, regulation of acute phase response from the liver and 
induces proliferation of synovial fibroblast-like cells [203]. 
 
Regarding RA, IL-6 is elevated in both serum and synovial fluid [204] of patients with 
RA. Moreover, serum IL-6 activity correlates with serum level of acute phase reactant, 
such as C-reactive protein, α1-antotrysin, fibrinogen and haptoglobin. It also participates 
in producing RF from B cells [205] as well as in stimulating osteoclast differentiation in 
combination with soluble IL-6 receptor α (sIL-6Rα or gp80) [206]. IL-6 blockade has 
undergone intense investigation for RA, whereby IL-6 knockout mice do not develop 
AIA [207] and blockade of IL-6 receptor attenuates CIA in mice [208]. More importantly, 
 - 59 -  
a humanised monoclonal antibody against the IL-6R, Tocilizumab (Actemra), is currently 
approved for use in RA patients who failed anti-TNFα therapy [209]. 
1.2.3.3 Novel cytokines implicated in RA pathogenesis 
Recently, the list of potential contributors to the pathogenesis of RA has been expanded 
for different cytokines. The most interesting are reported below:  
 
1) IL-17 is produced by CD4
+
CD45RO
+
 memory T cells in the RA synovium [210].  In 
turn, the release of IL-17 triggers the production of other proinflammatory mediators by 
RASFs, such as IL-6, IL-8, GM-CSF and PGE2 [211]. It could also participate in the 
process of osteoclast formation [116], up-regulation of NO synthesis in cultured human 
cartilage [212] and triggering the production of proinflammatory cytokine in human 
peripheral blood macrophages [213].  
 
2) IL-15 was shown to be increased both in the synovial fluid and serum of RA patients 
[214, 215]. RASFs were found to spontaneously secrete large amounts of IL-15 that are 
further upregulated upon TNF-α and IL-1β stimulation. Interestingly, IL-17 production 
was recently reported to be induced by IL-15 [216]. Moreover, both a soluble fragment of 
the IL-15Rα and an antagonistic IL-15 mutant/Fcγ2a fusion protein (binds to the receptor 
but do not undergo signaling), have been reported to have both protective and therapeutic 
actions in the CIA models [217, 218].   
 
3) IL-23 is able to induce IL-17 expression by Th17 cells and IL-23 deficient mice are 
resistant to CIA due to their failure to develop IL-17- producing CD4
+
 cells [219]. In RA, 
a unique subunit of IL-23 has been abundantly detected in the RA, but not OA synovium 
even though the levels of bioactive IL-23 remain low [220].  
 
4) IL-32 is a strong inducer of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, 
and IL-8. Its expression is elevated in the rheumatoid synovium and correlated with the 
severity of joint inflammation. Importantly, RASFs have been described as a major 
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source of IL-32, which is tightly regulated by proinflammatoriy cytokines and TLR, 
especially TLR3 [220]. 
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1.3 Role of B cells in RA pathogenesis 
1.3.1 Physiological Human B lymphocytes and antibody-mediated immunity 
B lymphocytes comprise one of the major arms of the immune system, being responsible 
for humoral (antibody-mediated) immunity, involving antibody production by B 
lymphocyte derivatives, PC. Similar to T lymphocytes, B cells are antigen specific and 
can provide immunological memory, the two hallmarks of the adaptive immune response. 
B cells bear the surface immunoglobulin on their plasma membrane, known as B cell 
receptor (BCR), which is functionally related to the T cell receptor (TCR). The BCR is 
capable of binding and recognising individual antigenic epitopes on soluble molecules.  
By contrast, TCRs do not recognise antigenic determinants on intact or undenatured 
molecules. Both BCRs and TCRs are products of site-specific somatic rearrangement, 
which allow an immense primary diversity of Ag specificities. In addition, B cells are 
capable of modifying their antibodies in a secondary diversification pathway during an 
immune response, resulting in a higher specificity for a certain antigen. Following 
antigenic stimulation, B and T cells divide and develop into specific effector cells 
(activated) or memory cells (primed). Memory cells become activated only during re-
exposure to the same antigen, while effector cells function irrespective of the presence of 
Ag. Effector cells are generally short lived with a half-life of only a few days in 
comparison to the long-lived (months to years) memory population. 
1.3.1.1 Antibody 
As mentioned above, different sIg are continuously produced and inserted into the B cell 
membrane, where they act as specific Ag receptors. Apart from the transmembrane form, 
the antibodies can also be expressed in a secreted form, which is solely produced by the 
end-stage of B cell differentiation, the PC. Antibodies or the so-called immunoglobulins 
are glycoproteins. Their structure is bilaterally symmetrical, comprising two identical 
light and two identical heavy polypeptide chains, forming roughly a Y-shaped molecules 
(Figure 1.6). Each chain can be divided into two distinct regions where one is very varied 
in sequence (variable region) while the other is relatively constant (constant region). The 
 - 62 -  
site at which the antibody binds antigen is located in the variable domain, where the 
variable regions of one heavy chain (VH) and one light chain (VL) pair to generate two 
identical antigen-binding sites which lie at the tips of the arm of the Y. Within the 
variable regions of both heavy and light chains, some polypeptide segments show 
exceptional variability within three hypervariable regions in each chain known as 
complementarity-determining regions (CDR). These segments are responsible for the 
direct interaction with antigen. The remaining parts of the variable regions are called 
framework regions (FWR), which determine the fold and ensure that CDRs are 
maintained close to each other. On the other hand, the carboxy-terminal half of the heavy 
chain (Fragment crystallisable, Fc fragment) determines the effector function of the 
molecule. Therefore, while the V region accounts for the specificity of antigen binding, 
the C regions are responsible for the immunobiological functions of antibodies. 
 
 
Antigen-
binding 
sites
Variable region
Constant region
Light chain
Heavy chain
VL
CL
Hypervariable regions
 
Figure 1.6. Basic structure of an antibody.  
 
Schematic drawing of an antibody illustrates its bilaterally symmetrical Y-shaped 
structure composed of two itdentical heavy and light chain polypeptides. The variable 
region (shown in grey) of the both heavy and light chain form the antigen binding site, 
whereas the constant regions of the antibody (shown in blue) determine the specific 
immune effector response.  
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1.3.1.2 Antibody classes 
There are five antibody classes in humans; IgA, IgD, IgE, IgG and IgM, and the heavy 
chains that define these different isotypes are designated by the lower case Greek letter, α, 
δ, ε, γ, μ. There are four main ways in which antibodies contribute to immunity:  
 
(1) Inhibiting binding of bacterial exotoxins to their receptors on target cells or binding to 
cell attachment sites on viruses, a process used for neutralising pathogen; 
 
(2) Coating the surface of a pathogen that certain antibodies are specific for (opsinisation), 
where the bound antibodies are then recognised by specific Fc receptors (FcR) on the 
surface of phagocytic cells. Alternatively, antibodies bind to complement receptors on 
phagocytes (complement fixation), which enhance the opsonisation and promote direct 
killing of bacteria cells; 
 
(3) Formation of an immune complex (integral binding of an antibody to a soluble 
antigen) triggers the activation of the complement classical pathway and thus contributes 
to the direct lysis of microorganisms by forming a pore in their cell membrane; 
 
(4) Sensitisation for extracellular killing by natural killer (NK) cells via a process called 
antibody-dependent cellular cytotoxicity (ADCC), in which NK cells express the FcR and 
recognise and kill target cells that are coated with antibodies. 
 
IgM  
All mature naïve B cells constitutively express cell-surface IgM (mIgM) as an antigen-
specific receptor, yet IgM comprises less than 10% of the immunoglobulin found in 
plasma, suggesting that most antibodies are produced by B cells that have undergone 
isotype switching. IgM is secreted as a pentamer (sIgM) and is largely confined to the 
intravascular pool. On initiation of a primary immune response, IgM is the first antibody 
class to be produced and is often of low affinity. When bound to antigen with repeating 
identical epitopes, pentamer sIgMs undergo dislocation to form a “staple” structure, 
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which is able to initiate neutralisation and acts as a potent activator of the classical 
complement system. 
 
IgD 
Together with IgM, IgD is expressed on naïve mature B cells (mIgD) that are yet to 
encounter antigen. This antibody class accounts for less than 1% of the serum 
immunoglobulin pool and has no known effector functions. 
 
IgG 
IgG equilibrates between the intravascular and extravascular pools and is the 
predominant immunoglobulin of the secondary immune response. In human, this class of 
antibody is subdivided into four subclasses, IgG1, IgG2, IgG3 and IgG4. IgG1 is the most 
abundant antibody in internal body fluids and accounts for 70-75% of the total serum 
immunoglobulin pool. It is secreted as monomers that have relatively higher affinities for 
antigen compared to IgM antibodies. The four IgG subclasses are highly homologous in 
structure, but each has a unique profile of effector functions. All subclasses, except IgG4, 
are able to activate complement. IgG1 and IgG3 are able to enhance phagocytosis by 
opsinisation. Of note, IgG2 and IgG4 are the only isotypes for placental transfer.  
 
IgA 
IgA is present in serum as a monomer of the basic four-chain structure and can be 
subdivided into two subclasses IgA1 and IgA2. It is the predominant antibody isotype in 
seromucous secretion, such as saliva, colostrum, milk and trachebroncual and 
genitourinary secretions. In secretions, IgA exits in a dimeric form (sIgA) in association 
with a protein chain termed the secretory component. The serum concentration of sIgA is 
relatively low, but can appear to be very high in intestinal secretions. Available effector 
functions are opsonisation, activation of the complement system as well as in protection 
of the respiratory, gastrointestinal and reproductive tracts. 
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IgE 
Serum IgE antibodies are produced in very low amounts (<0.05μg/ml) relative to the 
other immunoglobulin isotypes. However, in response to antigen, IgE triggers the release 
of inflammatory mediators from basophils and mast cells and plays an important role in 
protection against parasitic worms and in allergy. 
1.3.2 Human B cell development and differentiation 
B cells are generated from hematopoietic stem cells (HSC) originated in the yolk sac 
from a precursor called hemangioblasts. During fetal to postnatal life, this pool of cells 
progressively migrates from yolk sac to a primary lymphoid organ, fetal liver, and finally 
to the bone marrow (BM) during the adult’s life where lymphopoiesis occurs. The 
development of functional mature B lymphocytes takes place in two stages which are 
localised in different tissues: (i) the differentiation from HSC through multipotent 
progenitors (MPPs), then through common lymphoid progenitor (CLP) to distinctive B 
cell lineage restricted-cells in BM niches, and (ii) the maturation from immature BM-
derived B cells to mature pre-effector (plasmablast)/effector/memory B cells in the spleen, 
where, mature B cells may stay and recirculate within the site or migrate repeatedly 
through the blood and the lymph to B cell areas of other SLO, like lymph nodes (LN), 
muscosa-associated lymphoid tissue (MALT), which includes Peyer’s patches(PP) and 
the tonsil. Of note, out of 10-20 million immature B cells are generated daily in the BM, 
where only 10% reach the periphery; of these, only 10-30% join the mature B cell pool. 
Quiescent memory B-cells remain recirculating in the PB or they migrate to Ag-draining 
tissues. In the meantime, plasmablasts look for survival niches in the BM or the MALT to 
complete their differentiation to PC (Figure 1.7). 
1.3.2 .1 Early development steps in bone marrow 
BM stromal cells form specific niches and provide microenvironmental conditions for the 
development of B cell subsets via specific cell-cell contact and soluble cytokines. The 
early-pro B cell binds to hyaluronic acid and VCAM-1 on stromal cells via CD44 and 
VLA-4 respectively, and these initial contacts promote the binding of the surface c-kit 
tyrosine kinase on early pro-B cell to stem-cell factor (SCF) on the stromal cell surface. 
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At the late pro-B cell stage, a second growth factor receptor, IL-7R (CD127) appears on 
the surface, which promotes the production of several transcription factors such as Pax5 
and PU.1. These transcriptional factors induce the synthesis of the terminal 
deoxynucleotidyl transferase (TdT) and the recombination activating gene (RAG) 
products, rag-1 and rag-2 [221]. The recombinase proteins are required for DNA 
rearrangement between the D and J gene segment at the Ig heavy chain (IgH) locus, and 
the enzyme TdT catalyses the insertion of N-nucleotides to the joining exons. Later, the 
genetic recombination of germline IgH chain is completed by joining one VH gene 
segment to the preformed DJH complex. Meanwhile, the expression of Pax5 promotes the 
commitment to pre-BI cells where CD19 is first detected [222]. Upon the generation of a 
functional VDJ exon, the heavy chain gene is spliced to the constant Igμ exons, 
generating an Igμ heavy chain in the cytoplasm and in the cell surface, classified as pre-B 
II cells. The μH chains will associate with surrogate light (SL) chains consisting of 
VpreB and λ5 and signaling proteins composed of Igα and Igβ (CD79a and CD79b), 
forming the pre-B cell receptor (pre-BCR). Pre-BCR signaling induces allelic exclusion, 
cellular proliferation and Ig light chain (IgL) gene rearrangement, which increases the 
diversity of the antibody molecules generated. After successful rearrangement of both 
IgH and IgL loci, B cells are able to express IgM, which is transported to the cell surface 
as BCRs. At this stage, cells expressing only IgM, as well as pan B cell markers (e.g. 
CD20 and CD22), can be classified as immature B cells [223]. The final stage of 
development in the BM includes loss of CXCR4 (C-X-C chemokine receptor-4), the 
receptor for CXCL12, resulting in loss of B cell retention in the BM [224]. 
1.3.2.2 Late development steps in peripheral lymphoid organs 
All newly formed immature IgM
+
 B cells that have left the BM but not yet matured into 
naïve IgM
+
IgD
+
 B cells are called transitional (T) B cells, and they can be distinguished 
from mature B cells by a series of cell surface markers, such as CD24/CD38 (these 
markers are downregulated as cells become more mature). Recent studies show that 
human splenic B cells can be subdivided into three short-lived T subsets, T1/T2/T3. Early 
T1 can differentiate into T2, which in turn are thought to serve as the precursor to either 
subsequent transitional pre-marginal zone (T2-preMZ) or mature follicular (FoBI and 
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FoBII) B cells. The T2-preMZ cells likely give rise to MZ B cells. The recently described 
T3 cells represent mature anergic cells that are not able to give rise to mature B cells. 
Since the fraction of immature B cells that survive the transition to the mature naïve stage 
is small, the development stage of transitional cells is widely believed to harbour 
checkpoints for removing autoreactive B cells.  
 
The mechanisms that govern the selection for the long-lived mature B cell compartment 
are poorly understood, but the strength of BCR signaling and self-antigen specificity 
appear to be crucial determinants in this transition [225-227]. Moreover, emerging 
evidence suggests that trophic or environmental signals can influence these outcomes 
significantly, and inappropriate effects may lead to the development of autoimmune 
diseases [228, 229]. BAFF is one of the most important of these trophic factors (see 
below), and BCR and BAFF receptors are functionally linked in the regulation of B cell 
maturation and the subsequent maintenance of mature B cells [230, 231]. 
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Figure 1.7. Schematic representation of B cell differentiation stages in bone marrow 
and peripheral lymphoid organs.  
 
Sucessful completion of eleven important processes is required to meet the subsequent 
checkpoints as are indicated by letters A through K. The development of B cells is 
characterised by changes in surface receptor expression and Ig gene rearrangement which 
allows the identification of different developmental stages. The first stage identified in 
the B cell lineage is the pre-pro-B cell at which rearrangement of the heavy chain is first 
induced, but functional heavy chain is not expressed until the pre-B cell stage. 
Rearranged μ heavy chain is expressed on the surface in combination with λ5 and VpreB 
to yield the pre-BCR, which is associated with Igα and Igβ (CD79a/b) on the cell surface 
and initiated with light chain rearrangement. Surface expression of functional μ heavy 
and light chain complexes (IgM) is a characteristic feature of the immature B cell. 
Immature B cells, which survive from negative selection, are released from the bone 
marrow into the circulation and migrate to the SLO. The initiation of IgD expression on 
B cells indicates their development into transitional B cells that require both BCR and 
BAFF dependent signaling for development into mature naïve B cells. An activated 
mature B cell can subsequently branch into two main developmental possibilities; 
becoming an antibody secreting PC or a memory B cell. Image derived from Berkowska 
et al [232]. 
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1.3.2.3 B cell subsets in peripheral blood/secondary lymphoid organs 
The identification of the selective expression of B cell markers in different B cell 
subpopulations has allowed their differentiation in the peripheral blood and SLO of 
human adults.  Memory B cells were historically identified by the loss of IgD together 
with CD38: memory (IgD
-
 CD38
-
), naïve (IgD
+
CD38
-
) and GC (IgD
-
CD38
+
) B cells 
(Figure 1.8). Most studies now include IgM and/or CD27 expression to improve the 
discriminatory power for different human B cells subsets: naïve (IgM
+
IgD
++
CD19
+
CD38
-
CD27
-
), pre-GC/GC founder (IgM
+
IgD
+
 CD19
+
CD38
+
CD27
-
), switched memory (IgD
-
 
CD19
+
CD38
-
CD27
++
) and late plasmablast (IgD
-
 CD19
+
CD38
++
 CD27
+
). CD27
-
 and 
CD27
+
 B cells were found to have distinct responses to stimulation, for instance CD27
+
 B 
cells produce 5- to 100-fold more Ig in vitro than CD27
-
 B cells [233-235]. Indeed, using 
CD27 as a marker for the identification of memory B cells led to the discovery of a new 
memory B cell population, the IgM pre-switched memory (IgM
+
IgD
low
CD27
+
) [236] that 
contains comparable mutated Ig sequences as IgD
-
CD27
+
 memory cells [237]. This B cell 
subset could be driven to differentiate into antibody secreting cells under appropriate 
stimulation, and it is still uncertain whether such response is dependent on T cell 
participation.  
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Figure 1.8. Scheme of the differentiation stages of mature B cell development in 
human tonsil.  
 
The B cell subsets isolated from tonsil samples of young children were idenitified by 
indicated markers. Image adapted from Jackson et al [233]. 
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1.3.3 The germinal centre reaction 
The immune system requires the production of high affinity antibodies of different 
subclasses to accomplish its many effector functions. The GC is a microenvironment in 
peripheral lymphoid organs where specific steps occur leading to the maturation of high 
affinity humoral responses. A critical role in the GC reaction is played by FDCs which 
are radiation-resistant stromal cells that form a network able to capture and present large 
amounts of antigen in the form of immune complexes in highly ordered units termed 
iccosomes [238, 239]. Upon stimulation of Th cells by the APC migrating in the 
subcapsular sinus, a subset of antigen specific Th cells known as T follicular helper (TFh) 
cells undergo clonal expansion within the T cell zone [240], migrate into the boundary 
between B cell follicles and the T cell zone and later to the B cell follicle via CXCL13 
and its receptor CXCR5 where they contribute to initiating a GC response via cognate B 
cell help and cytokine production (mostly IL-21)  [241, 242]. Under T cell help (through 
cell-to-cell interactions, T-cell-CD40L engagement of CD40 on B cells and 
costimulatory-signal, CD28-CD86) and the regulation of other cytokines, including IL4, 
IL10, and transforming growth factor (TGF)-β [243, 244], activated B cells either 
recirculate to other lymphoid follicles or migrate to extrafollicular sites. In extrafollicular 
areas, activated B cells undergo terminal differentiation into short-lived PC [245]. GCs 
display anatomically distinct dark and light zones as defined on the basis of their 
histological appearance. The dark zone is demarcated by Ki-67
+
 proliferating centroblasts 
that actively mutate their antibody genes via somatic hypermutation (described in details 
in 1.3.4). CXCR4 is required for GC B cell positioning in the dark zone where its ligand, 
CXCL12, is locally produced by stromal cells. Centroblasts subsequently exit the light 
zone as non-dividing centrocytes via the CXCL13-CXCR5 axis. Centrocytes rely on 
antigen-antibody immune complexes on FDCs and CD4
+
 T cells to receive survival 
signals [246] that are dependent on antibody affinity. Inadequate survival signal and T 
cell help leads to GC B cell apoptosis with subsequent uptake by tingible body 
macrophages [247] (Figure 1.9).  
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Figure 1.9. The germinal centre reaction.  
 
Mature B cells are activated when they encounter cognate antigen. When T cell help is 
available, B cell activation takes place in the T cell zone of lymphoid organs, e.g., lymph 
node, termed T cell-dependent response. Afterwards, naïve mature B cells will migrate 
from the T cell rich areas into B cell follicles called centroblasts. The centroblasts 
downregulate their surface Ig expression and undergo rapid proliferation and somatic 
hypermuation in which the latter generates mutations at a high rate in the V region genes, 
thereby antibody variants are generated (1). After having mutated their Ig, centroblasts 
stop dividing and then migrate into the light zone following a chemokine gradient and 
then differentiate into resting centrocytes that are selected for high affinity of their BCR 
for the cognate antigen. FDCs in the light zone retain Ag and present it to all B cells, but 
only centrocytes with high affinity receptors are selected and allowed to survive, whereas 
low affinity or self-reactive BCR-expressing cells undergo apoptosis. The positively 
selected centrocytes interact with T cells thereby receiving CD40-mediated signals and 
resulting in isotype class-switching that replaces the originally expressed 
immunoglobulin heavy-chain constant region genes by those of another class. Finally, 
selected GC B cells develop into either memory B cells or PC and leave the GC (2). 
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Together with SHM, another fundamental process involving somatic DNA modification 
occurs in this unique anatomatic location, termed class switched recombination (CSR). 
Both SHM and CSR require the presence of activation-induced cytidine deaminse AID, 
an enzyme that is only expressed in GC B cells [248] and in B cells undergoing CSR or 
SHM in vitro [249]. AID deficiency leads to impaired CSR and SHM in both mice [248] 
and humans [250]. Moreover, AID has been shown to be the only B-cell-specific protein 
required for CSR and SHM, because ectopic expression of this enzyme alone is sufficient 
to trigger SHM and CSR in mammalian (non-B) cells [251] and even in Escherichia coli 
[252]. Of note, although CSR and SHM can occur together in the GC upon BCR/CD40 
activation, normally SHM is initiated before CSR [253]. However, neither CSR nor SHM 
are prerequisite of the other because not all IgG or IgA carry hypermutated sequences, 
whereas some IgM can display mutations, such as in unswitched memory B cells.  
 
A substantial proportion of B cells which complete affinity maturation become memory 
B cells that are programmed to recognise and respond to Ags on repeat exposure or 
become long-lived PC that are programmed to migrate to the BM (upon surface 
expression of CD44, VLA-4 and CXCR4) where they secret large quantities of specific 
antibodies. Syndecan-1 (CD138) positive PC are end-stage cells as highlighted by the 
expression of a transcriptional repressor called B lymphocyte-induced maturation 
protein-1 (Blimp-1) and X-box-binding protein-1 (XBP-1) which result in the inhibition 
of proliferation and of Pax-5 expression [254].   
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1.3.4 Somatic hypermutation 
In activated B cells, SHM introduces point mutations in the V region of heavy and light 
chain genes, specifically at the hypervariable regions (CDRs) that encode the Ag-binding 
site [255]. The first stage of SHM requires the intervention of AID. AID deaminates 
cytidine (C) residues in the DNA, converting them to uridine (U) residues. The resulting 
U:G mispair can subsequently process in different ways (Figure 1.10): U can: 1) simply 
undergo replication, where DNA polymerases insert an A nucleotide opposite the U, 
ultimately producing C to T (G to A on the other strand) transition mutations (phase 1a), 
2) be deglycosylated by the uracil DNA glycosylase (UNG) (phase 1b, mismatch repir, 
MMR), yielding a nick by UNG and the mismatch repair machinery can produce an 
abasic site that can be bypassed by error-prone DNA polymerases to generate transition 
and transversion mutations, 3) be recognised by the component of mismatch recognition 
and repair machinery (phase 2, base excision repair pathway, BER), where U:G 
mismatch is excised and resynthesised by error-prone polymerase that will create 
additional mutations including mutation at A:T base pairs near the initiating U:G lesion 
[256]. SHM occurs at the centroblast stage of B cell maturation where B cells expressing 
Ig with a high affinity to given Ags are selected to receive signal for survival, while those 
that have lost functional Ig, or acquired only low-affinity Ig after SHM, die by apoptosis. 
Therefore, after repeated cycles of GC, B cells are selectively expanded with high affinity 
antibody, which in turn exit the GC and then programme to secret massive amount of 
specific antibodies.  
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Figure 1.10. Model of somatic hypermutation.   
 
After AID catalysed deamination of cytosine (C) to uracil (U), the DNA may be 
subjected to three different modification pathways as shown, leading to mutation in the 
variable region of an antibody. The mechanism is described in text. MMR: mismatch 
repair; BER: base excision repair, MSH2, MSH6, example of component of mismatch 
repair machinery (MSH). 
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1.3.5 Class switch recombination 
By substituting the H chain C region of IgM with that of IgG, IgA, or IgE, class-
switching enables antibodies to acquire new effector functions that are crucial for the 
neutralisation of invading pathogens. CSR involves an exchange of upstream Ig heavy 
contant region Cμ with downstream targeted Cγ, Cα, Cε genes through a recombination 
process involving a switch (S) region that is located before each C gene segment (except 
Cδ). Each S region is preceded by a short intronic (I) exon and a promoter that initiates 
the expression of germline transcripts (GLTs). It has been generally believed that CSR is 
regulated by two major activatory signals. The first is when IgD
+
 naive B cells are 
exposed to specific activating cytokines, among which IL-4 induces switching to IgG and 
IgE [257, 258], IL-10 to IgG and IgA [259, 260] and TGF-β to IgA [261, 262]. The 
stimulatory signal activates the IH gene promoter located at the 5' end of each S region 
and triggers NFκB-dependent transcriptional activation for initiating GL transcription. 
The resulting GL transcripts are thought to be crucial to elicit CSR as they render the S 
region suitable for AID binding [263, 264] (Figure 1.11). 
 
Accessibility to AID is achieved when a primary transcript is spliced out to form a non-
coding GLT. At this stage, the primary transcript is physically associated with the 
template strand of DNA, inducing chromatin opening and allowing the access for AID. 
The second signal is delivered by either: (1) cellular interactions, such as CD40/CD40L; 
or (2) complex viral/bacterial proteins, such as LPS; or (3) soluble factors, such as B cell 
survival factors, BAFF and APRIL [263-265].  
 
AID initiates CSR by deamination of C residues in both strands of the S DNA region thus 
creating U and multiple DNA lesions which ultimately lead to DNA double strand break 
(DSB). Thereafter, CSR is processed by looping-out deletion of the DNA segment 
between recombined S regions with generation of: (1) an extrachromosomal reciprocal 
switch DNA product, known as switch circle (SC), which contains the IH promoter of the 
targeted S region, (2) the deleted DNA fragment, Cμ and, (3) a chromosomal sequence, 
termed mature transcript, which encodes the class-switched protein. Under the influence 
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of AID and the IH promoter, the SC is transcribed into chimeric I-Cμ product, known as a 
circular transcript (CT). Since CT are rapidly degraded by nucleases (within 48h), CT 
constitutes specific molecular markers of ongoing
 
CSR [263]. 
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Figure 1.11. Model of Class Switch Recombination (CSR) and the generation of 
circular transcript (CT).  
 
The human IgH chain locus and the molecular events involved in switching from Cµ to 
Cε are shown schematically on the left. Ovals indicate switch regions (S), and the 
rectangles before and after S regions are IH exons and constant region exons. Location of 
the IgH chain intronic enhancer (iEµ) and 3' IgH chain enhancers (triangles) are shown. 
The IgE CSR product is shown at the bottom. The V-shaped lines representing splicing; 
arrowheads are the positions and directions of the primers used to amplify SCs, CTs, 
germline transcripts, and mature transcripts. Modified from Cerutti et al J Immunol 
169:11 [264]. Right: Flowchat illustration of CSR pathway.  
 
 - 83 -  
1.3.6 T-cell-independent B cell activation 
B cell responses are classified as T-D or T-I depending on whether T cell help is required 
to induce antibody production. Most Ags elicit a T-D antibody response within the GC 
following their processing and presentation to cognate helper T cells in the context of 
MHC class II molecules. It has been demonstrated that CSR is highly dependent on 
CD40 ligation as secondary isotype production is dramatically impaired in hyper-IgM 
syndrome where CD40L is mutated [266, 267]. In contrast, T-I Ags are typically 
polysaccharides that cannot be presented via MHC molecules and are of two main types 
distinguished by their requirement for BCR recognition. T-I type 1 Ags are mitogenic 
stimuli such as LPS or CpG that activate TLR to induce non-specific or polyclonal B cell 
activation.  T-I type 2 Ags are large molecules with highly repetitive structures, such as 
capsular polysaccharides from bacterial cell walls or repetitive antigenic epitopes from 
viral particles. As these Ags do not function as B cell mitogens, they can only stimulate 
mature B cells and simultaneously crosslink a number of B cell receptors for activation. 
This process mainly occurs in the extrafollicular splenic marginal zone of the spleen and 
intestinal lamina propria which provide prompt protection against invading pathogens by 
actively participating in IgG and IgA production [268]. Although the initiation of CD40-
independent CSR remains obscure, growing evidence indicates that DC, epithelial cells 
or stromal cells play an important role in such response. IgA CSR can be induced by 
release of APRIL by gut ECs and DCs after recognition of intestinal bacteria [244]. 
Accordingly, IgA production is near normal in the absence of CD40, but is dramatically 
impaired in APRIL- or BAFF-deficient mice [269-271]. Both human [259, 272] and 
mouse [265, 269] naïve B cells are reported to be able to undergo T-I Ig class-switching 
and antibody production upon exposure to BAFF or APRIL in the presence of 
appropriate cytokines. Of note, although CD40 deficiency impairs T-D but not T-I IgG 
and IgA responses [273], BAFF deficiency impairs both T-D and T-I IgG and IgA 
synthesis [274]. Similar observations can be obtained by neutralising BAFF and APRIL 
with respective decoy receptors (as discussed below) [275-278]. Alternatively, when 
overexpressing these two cytokines in mice, Ig production is increased and an 
autoimmune-like phenotype is observed, suggesting their crucial roles in the activation of 
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B cells. I shall discuss these two members of the TNF syperfamily, BAFF and APRIL in 
more detail below. 
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1.3.6.1 Classical B cell regulatory factors 
1.3.6.1.1  BAFF ( B cells activating factor of the TNF-family) 
 
BAFF was discovered by several groups utilising genomic data to uncover novel TNF 
family members. It is also known as BLyS (B lymphocyte stimulator), TALL-1 (TNF- 
and ApoL-related leucocyte-expressed ligand 1), THANK (TNF homologue that activates 
apoptosis, NF-B, and JNK) and zTNF4. BAFF is a type II transmembrane protein of the 
TNF ligand superfamily (TNFSF13b) and it is closely related to APRIL (a proliferation 
inducing ligand), another member of the TNF ligand family (discussed in detail in 
1.3.6.1.2 below). BAFF and APRIL share about 50% sequence homology within the TNF 
homology domain (THD), which is a C-terminal domain characteristic of TNFSF. BAFF 
exists in two biologically active forms, a 285-amino-acid transmembrane protein (31.2 
kDa) and as a soluble protein (152 amino-acids, 17 kDa) after release from the membrane 
by a furin-like protease [259, 279, 280]. Furthermore, a shorter isoform termed 
deltaBAFF (ΔBAFF) exists, which is an alternatively spliced form of BAFF. ΔBAFF is 
also a transmembrane protein, but it lacks the furin protease recognition motif and thus is 
insufficiently cleaved from the cell surface. ΔBAFF acts in a dominant negative fashion 
and has suppressive effects on BAFF activity as demonstrated in vivo in ΔBAFF 
transgenic mice [281]. All forms of BAFF adopt a trimeric structure, while the soluble 
homotrimer BAFF can also assemble as an ordered symmetric structure comprising 20 
trimers. Heterotrimers with ΔBAFF or APRIL have also been described, are biologically 
active, and have been found in patients with autoimmune diseases [282] (Figure 1.12).  
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Figure 1.12. Interaction and expression of ligands and receptors in the 
BAFF/APRIL system.  
 
The top part of the figure shows the different types of ligands. From left to right: (1) a 
heterotrimer with ΔBAFF with red road signs indicating the impossibility of this ligand 
to be cleaved; (2) membrane BAFF homotrimers; (3) membrane BAFF homotrimers with 
a cutter indicating potential cleavage into (4) soluble BAFF homotrimer which can also 
form (5) a capsid-like assembly of 20 trimers (60-mer); (6) APRIL cleaved from the golgi 
then released as (7) soluble ligand or (8) the TWE–PRIL fusion protein. Additional forms 
of BAFF/APRIL heterotrimers (9) have also been described. In the middle part of the 
figure, receptors are represented from left to right: BAFF-R, brown; TACI, pink; BCMA, 
blue and heparin sulfate proteoglycans (HSPG), green. Blue solid arrows represent strong 
interactions of BAFF with respective receptors while broken lines represent weak 
interactions. Green solid or broken lines applied to the interaction of APRIL with its 
respective receptors. The lower part of the figure demonstrates a summary of each of the 
BAFF/APRIL receptors function in human. Details are decribed in the text. 
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The expression of BAFF protein was thought to be mainly restricted to cells of myeloid 
origin, such as monocytes, macrophages, monocyte-derived DC and leukemia myeloid 
cell lines (HL-60, U937, and THP-1) which produce both the membrane-bound and the 
soluble forms [279]. However, activated T cells, malignant B cells or B cells activated 
with LPS and CpG can also upregulate BAFF expression and secretion [283]. Whether 
BAFF is produced by normal B cells is uncertain, but most reports agree that normal B 
cells do not express BAFF [284] apart from a report from Kern C et al [285].  
 
In humans, BAFF is produced by monocytes, macrophages and DCs and is upregulated 
upon stimulation with IFN-α, IFN-γ, CD40L or LPS [259]. Recently, neutrophils have 
been shown to synthesise and secrete the highest levels of BAFF, particularly upon 
activation with IFN-γ or G-CSF [280]. However, unlike the classic cleavage mechanism 
as reported in myeloid cells, BAFF undergoes intracellular processing before being 
released by neutrophils [280]. Recent studies also identify some non-haematopoietic cells 
that express BAFF, particularly during chronic inflammatory/autoimmune conditions. 
These include epithelial cells from airway [286], salivary gland of Sjogren’s syndrome 
patients [287], astrocytes of multiple sclerosis patients [288], VCAM-1 positive stromal 
cells from human BM [289], CD105 and CD166 positive stromal BM cells from patient 
with RA and OA [290], SFs of RA patients [291-293] and osteoclasts in patients with 
multiple myeloma [294].  
 
BAFF binds to three known receptors, transmembrane activator and CAML interactor 
(TACI), B cell maturation antigen (BCMA) and BAFF receptor (BAFF-R or BR3). While 
BAFF-R specifically binds BAFF, TACI and BCMA are shared by both BAFF and 
APRIL. Moreover, TACI has been shown to be activated by the membrane bound form 
of these ligands, BAFF/APRIL heterotrimers [282] or oligomeric BAFF [295], but not by 
the soluble forms of these ligands. All three receptors are mainly expressed on B cells 
[296]. In humans, TACI is predominantly expressed on CD27
+
 memory B cells, by PC 
and by certain subsets of naïve and activated B cells. BCMA is highly expressed by PC, 
plasmablasts, tonsillar memory and GC B cells. BAFF-R is expressed by all peripheral B 
cells and its expression is down-regulated in GC B cells and absent in BM PC [297].  
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All BAFF receptors belong to a subgroup of the TNFRSF that triggers intracellular 
signaling events via engaging at least one of the six known TNF receptor associated 
factors (TRAFs). BAFF-R was found to interact only with TRAF3 and activate the 
alternative NF-κB pathway. In the absence of BAFF-R signaling, TRAF3 is distributed in 
the cytoplasm and forms a complex with TRAF2 and with NF-κB inducing kinase (NIK), 
thus inducing proteasome-mediated degradation of NIK, and resulting in the inhibition of 
the alternative NF-κB2 pathway. Following BAFF binding to BAFF-R, TRAF3 is 
recruited to the receptor and then degraded by TRAF2 dependent proteolysis, thereby 
allowing NIK to activate the IκB kinase α (IKKα), which results in phosphorylation of 
the NF-κB2 p100 precursor protein to p52. Along with its heterodimeric partner, RelB, 
p52/RelB dimer translocates to the nucleus and up-regulates anti-apopotic proteins.  
Furthermore, BAFF-R signaling is also reported to inhibit the activation of the pro-
apoptotic protein kinase Cδ (PKCδ), a process that is highly dependent on TRAF3. TACI 
and BCMA signal through the classic NFkB pathway, as well as through the Mek 
pathway to counteract apopotosis and to drive class-switching (JNK/p38) [230].  
 
Initially, BAFF was described solely as a co-stimulatory or growth factor for B cells 
based on its ability to augment anti-IgM mediated B cell proliferation and Ig secretion. 
However, recent data indicates that:  
 
(1) BAFF is a potent survival factor for B cells and essential for the production of 
functional mature B cells. B cell numbers are dramatically reduced in BAFF-deficient 
mice [276] whereas overexpression of BAFF in BAFF Tg mice leads to the opposite 
phenotype [298]. Most of the T1 B cells are eliminated via signals through BCR, which 
trigger apoptosis of immature and T1 B cells. Only those B cells that receive additional 
signal are allowed to survive and such additional signal is delivered by BAFF, since B 
cells mostly remain at the T1 stage in BAFF-deficient mice. Both in vivo and in vitro 
studies have demonstrated that BAFF-signaling induces expression of anti-apoptotic 
molecules such as Bcl-2 in B cells, which appear to be required to keep B cells from 
undergoing apopotosis once they mature beyond the T1 stage [299]. Moreover, BCR 
signaling strength controls the amount of BAFF signal as it generates p100, a component 
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of the alternative NFkB pathway. Indeed, BAFF-R expression is upregulated by BCR 
ligation, thus promoting an increased sensitivity to BAFF-mediated survival signals as B 
cells mature [300]. Noteworthy, even in the absence of BCR stimulation, BAFF 
significantly increases splenic B cell survival in vitro resulting in the expansion of 
peripheral B cells [301]. A recent study, however, showed that even though memory B 
cells express BAFF-R, the survival and reactivation of these class switched memory B 
cells are independent of BAFF under normal physiologic conditions [302]. BAFF can, on 
the other hand, work together with inflammatory cytokines like IL-21 and IL-17 for 
reactivating memory B cells and their differentiation to PC [303, 304]. The overall role of 
BAFF at different stages of B cell development and differentiation is summarised below 
(Figure 1.13). 
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Figure 1.13. Expression of BAFF receptor during human B cell development and 
differentiation.  
 
Within the BAFF network, the expression of the receptors and ligands is spatially, as well 
as temporally, highly regulated at various stages of B cell development and function. The 
expression of BAFF-R, BCMA and TACI at different stages of B cell development 
(immature  transitional) and differentiation (mature B cell  memory B cell/PC) is 
sumarised above. The parentheses indicate differences in expression of BAFF receptor 
between murine and human B cell. Image adopted from Tangye et al Semin Immunol 
Vol18:5 [305] 
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(2) BAFF can also drive MZ B cell differentiation.  Tardivel et al [306] suggested that 
BAFF is a critical differentiation factor for MZ B cells, and Hase et al [307] showed that 
BAFF could upregulate Pax5 activity and its downstream target, CD19. Moreover, a 
recent analysis demostrated the persistence of B cells expressing IgD (a hallmark of T2 
and mature B cells) in BAFF-deficient mice [308]. Also, BAFF-deficient mice have 
shown to retain the ability to mount antigen-specific antibody responses, albeit in a much 
reduced magnitude [274].  
 
(3) BAFF is important for the maintenance of stable GC reactions and antibody 
production. Studies in murine models demonstrated that while the initiation and 
formation of GC was BAFF-independent, the longevity of the GCs was dependent on 
BAFF [277]. Consistent with this observation, a short-lived but not sustained GC reaction 
can be induced in both BAFF-R mutant and BAFF-deficient mice [309]. Of interest, 
BAFF-R deficient mice also display impaired development of the mature FDC within the 
GCs, along with diminished IgG and secondary response [309]. Also, T-I type 2 and T-D 
IgM responses have been shown to require the interaction of BAFF with TACI, and 
BAFF transgenic mice exhibit an increased level of serum Ig of all isotypes and IgG 
subclasses [230]. In addition, in vitro experiments demonstrated that human B cells 
undergo class-switching towards IgG and IgA when stimulated with BAFF alone, and 
this was greatly increased in combination with IL-4 or IL-10. BAFF may further 
contribute to Ig isotype switching by inducing B cells to secret IL-10, a known switch 
factor for the secretion of IgG and IgA by human B cells. The crucial role of BAFF in 
CSR is also evident by the finding that Ig isotype switching can be inhibited by the 
presence of neutralising antibody against BAFF. Also, as mentioned above, the ability of 
EBV to induce the production of BAFF by human B cells may explain how EBV can 
activate CSR, since EBV-mediated switching from IgM to IgG, IgA and IgE has been 
shown to be dependent on endogeneous BAFF production [244]. Although Litinskiy et al 
[259] claimed that secretion of the switched isotype antibodies requires an additional 
signal, such as cross-linking of the BCR, recent evidence [286] demonstrated that EC-
derived BAFF together with IL-10 induced class-switching to IgG and IgA in the absence 
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of a BCR trigger. Of note, the production of these switched isotype antibodies can be 
further increased upon BCR engagement.  
  
(4) BAFF production in response to innate immune stimuli. BAFF is induced in 
myeloid DC by type I interferons (IFNs) [310] and collaborates with IL-6 and TLR 
signals to promote Ig class-switching and PC differentiation [311, 312]. Activation of 
intracellular TLRs in murine B cells by immune complexes or apoptotic material 
containing nucleic acids increased expression of TACI [312] and induced class-switching 
of these cells. On the other hand, activation of B cells via TLR4 up-regulates BAFF-R 
which renders the cells sensitive to Fas-mediated apoptosis [313]. Therefore, there is 
complelling evidence that TLRs, type I IFNs and BAFF may combine to create an 
amplification loop that promotes B cell differentiation and the secretion of antibodies in 
the absence of T cell help.  
1.3.6.1.2 A proliferation-inducing ligand, APRIL 
APRIL (also known as TALL-2, TRDL-1 and TNFSF13a) is expressed by monocytes, 
macrophages, DC and at lower levels by T cells [259], and as recently reported in this 
thesis and by others, by RASFs [291, 314]. Several cytokines such as IFN-γ, IFN-α, IL-
10, GM-CSF, CD40L as well as LPS and peptidoglycan can activate APRIL expression 
in macrophages [259]. Similar to BAFF, APRIL has also been reported to be expressed 
by neoplastic B cells [315, 316]. However, unlike BAFF, the transmembrane APRIL (27 
kDa) is not functional and is processed and cleaved in the Golgi apparatus by a furin-
convertase enzyme before its secretion. Therefore, APRIL only exists and functions as a 
secreted soluble ligand (17 kDa) [317]. Due to alternative splicing in the 
TWEAK/APRIL locus, APRIL can be expressed as a cell surface fusion protein with 
TWEAK, termed TWE-PRIL, which has been detected in human primary T cell and 
monocytic cell lines [318]. In addition, a ΔAPRIL variant has also recently been reported 
but not yet characterised as a protein [319]. 
 
APRIL binds TACI and BCMA with high affinity, but not at all to BAFF-R. Whereas 
BCMA is a high-affinity receptor for APRIL, TACI can be activated by multimerised 
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BAFF, membrane bound BAFF and multimerised APRIL (apart from homotrimers). Also, 
human BCMA has been shown to bind BAFF with low affinity, while only mouse 
BCMA is APRIL-specific [320]. Interestingly, a recent study demonstrated that a short 
variant form of mouse APRIL exhibits weak but detectable binding to mouse BAFF-
receptor [321]. In addition, APRIL also has a private receptor, expressed on both B cells 
and non-B cells, termed heparan-sulfate proteoglycan (HSPG) [322] (Figure 1.12). 
Regarding B cells, APRIL binds preferentially to HSPG at the surface of syndecan-1
+
 
(CD138
+
) PC to induce the expression of pro-survival factors resulting in the 
establishment of long-lived PC. 
 
While BAFF-BAFFR interactions control peripheral B cell survival and homeostasis, 
BCMA function seems limited to the survival of long-lived bone marrow PC. The 
functional activity of the third receptor TACI is, however, ambiguous and has been 
suggested to serve as a positive or negative regulator for B cell responses depending on 
conditions. Sakurai et al firstly proposed that TACI exerted a negative regulation in 
human peripheral blood B cells showing that B cell proliferation, CSR and IgG 
production induced by BAFF and CD40 were inhibited via TACI [323]. 
 
In contrast to BAFF, the role of APRIL in immune regulation is less well defined, but it 
is most likely described as a positive regulator of tumor growth or survival in vitro and in 
vivo [324]. To date, its biological role is more elusive due to the conflicting results 
emerged from different studies. One showed that APRIL-deficient mice display normal T 
and B cell development and normal in vitro functions [325], while another study 
demonstrated a significant decline of IgA basal serum levels with larger GC and 
increased numbers of effector T cells [269]. Furthermore, in vitro data using human cells 
suggestd that APRIL plays a role in IgA class-switching after antigenic challenge [259]. 
Xu et al recently reported that APRIL and BAFF are responsible for class-switching to 
both IgG and IgA via BCMA in pre-switched IgD
+
  B cells in a T-I manner [286]. Finally, 
APRIL, as compared to BAFF, has a marginal effect on the survival of peripheral B cells; 
accordingly APRIL-deficient mice do not show any major alteration in peripheral B-cell 
subsets. 
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1.3.6.1.3 Role of BAFF/APRIL in promoting autoimmunity in RA 
In general, BAFF and APRIL are thought to promote autoimmunity due to their ability in 
promoting the inappropriate survival of autoreactive B cells and PC. A recent study 
demonstrated increased BAFF and APRIL levels in very early RA (VERA) as compared 
to healthy controls as well as in patients with established RA [326]. Importantly, 
BAFF/APRIL levels were observed to be higher in synovial fluid compared to sera, 
suggesting a local up-regulation in the synovium. APRIL has been demonstrated to 
promote IgA class-switching [269] and the differentiation/survival of PC [327], 
suggesting its involvement in maintaining the presence of autoreactive B cells in the 
joints. Accordingly, Dong et al [328] demonstrated a significant association between the 
infiltration of PC and synovial fluid levels of APRIL from RA patients. Furthermore, an 
in vivo experiment demonstrated a close association between BAFF and anti-collagen 
type II antibodies in collagen-induced arthritis (CIA) [329] (an animal model of RA, see 
supplementary information/data, Chapter 8, for further information). Lastly, both BAFF 
and APRIL can also be produced by resident synovial cells [291-293, 314] as discussed 
in detail in Section 1.4. Collectively, increased synovial levels of APRIL and BAFF are 
likely to influence autoreactive B cell activation in the RA joint over and above 
circulating levels 
 
Finally taken together all the above evidences indicate that BAFF and APRIL 
possess antibody-inducing and antibody-diversifying functions that become essential 
in the context of TI B-cell responses  
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1.3.6.2 A Novel factor involved in B cell regulation, secretory leukocyte protease 
inhibitor (SLPI)  
1.3.6.2.1 Biology of SLPI 
Human SLPI is a 12kDa non-glycosylated single chain protein, which is constitutively 
derived from the mucosae, in particular from ECs and cells lining body cavities, and can 
be found in the fluids lining these surfaces, such as saliva, seminal fluid, and cervical, 
nasal,
 
bronchial mucus [330] as well as in blood [331]. It was first named by its 
immunologically activity related to the regulation/inhibition of the activity of serine 
proteases released by
 
leukocytes at site of infection, thus ensuring a tissue protective 
effect by preventing degradation by proteolytic enzymes produced during local 
inflammatory reactions. SLPI is composed by two highly homologous cysteine-rich 
domains termed whey acid protein (WAP). The C-terminal domain contains the 
antiprotease activity whereas the N-terminal domain displays anti-bacterial functions 
and/or the later described immunomodulating function. Apart from acting as a natural 
epithelial product, it has been recently documented that SLPI can also be also produced 
and secreted by a number cells of the immune system, including mast cells, neutrophils, 
B lymphocytes, DC, macrophages (mouse only) [332] as well as by non-immune cells 
such as human chondrocytes [333], keratinocytes (Jacobsen et al 2008) in addition to 
neurons and astrocytes in ischaemic brain tissue [334]. 
 
SLPI exerts its inhibitory activity mainly against serine proteases such as elastase, 
cathepsin G and trypsin from neutrophils or chymase and tryptase from mast cells [332]. 
In normal physiological conditions, these proteases offer regulatory effects towards 
fundamental cellular processes such as cell proliferation/growth, wound healing, innate 
immune response in addition to tissue remodelling (Figure 1.14 and Table 1.6). However, 
sustained expression of these otherwise temporary protective processes have considerable 
potential to harm the host tissue, as observed in the RA joints where degradation of 
proteoglycans and collagen are mediated by excess of proteases and metalloproteinases. 
Moreover, SLPI is well recognised as an antimicrobial factor. Due to the fact that SLPI is 
a cationic protein, and it has been postulated that SLPI can disrupt microbial cell 
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membrane, and can therefore inhibit pathogens such as S. aureus, Staphylococcus 
epidermidis, Ps. aeruginosa and Candida albicans. Lastly, SLPI displayed antivial 
activity which has been reported to inhibit human immunodeficiency virus (HIV) 
replication in monocytes and can interfere with HIV infection of macrophages via 
binding to a phospholipid-binding protein, annexin II [335] (Figure 1.14 and Table 1.6).  
1.3.6.2.2 Immumodulatory role of SLPI 
Apart from acting as an anti-protease, SLPI can act as an “alarm” inhibitor and thus it is 
inducible at the site of injury in response to primary cytokine production, such as IL-1 
and TNF. LPS-stimulated monocytes express SLPI, which acts by reducing inﬂammation 
by suppressing the production of pro-inﬂammatory molecules via interfering with the 
interaction between CD14 and LPS [336]. Although LPS can induce SLPI expression in 
macrophages directly or by way of IL-1β, TNF-α, or anti-inflammatory cytokines such as 
IL-6 and IL-10, SLPI can in return up-regulate macrophage production of the anti-
inflammatory/repair-type cytokines TGF-β and IL-10 [337, 338]. Notably, SLPI 
production can be down regulated by TGF-β in ECs in vitro [339]. In this regard, it is 
worth to note that SLPI can exert its biological inhibitory activity either as extracellularly 
secreted molecules (as mentioned above) or gain access to intracellular compartments to 
alter transcriptional events for inflammatory mediators by suppressing NF-kB activation. 
Taggart et al reported that SLPI could be rapidly internalised by monocytic cells and 
translocated into the nucleus in vitro. Overall, inhibition of NFκB activation has been 
suggested to occur via two possible mechanisms: firstly, SLPI can prevent the proteolytic 
degradation of IRAK-1, IκBβ and IκBα, and secondly, SLPI can bind directly to the p65 
subunit of NF-kB and therefore compete with p65 for occupancy of the promoters of 
NFκB-regulated genes, leading to the reduced expression of pro-inﬂammatory cytokines, 
such as TNF-α [340] (Table 1.6). 
 
In addition to the direct down-regulating effects on innate immune cells as discussed 
above, it has been suggested that SLPI may be involved in the adaptive immunity through 
the maintenance of a mucosal tolerance threshold. Regarding B cell regulation, in vitro 
studies have shown that SLPI can penetrate the cytoplasm and the nucleus of 
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intraepithelial IgD
+
 B cells [286].  SLPI can then interfere with the activation of NF-kB 
in B cells and the class-switching to IgG and IgA. Interstingly, the expression of nuclear 
Oct-1, a ubiquitous nuclear transcription factor that regulates Ig gene expression is not 
affected by SLPI [286]. In agreement with the postulated inhibitory role of SLPI in B cell 
activation, Nakamura et al report that B cells from SLPI-deficient mice (SLPI
−/−
) display 
increased proliferation and IgM production after LPS treatment compare to SLPI
+/+
 B 
cells [341].  
 
Only limited information is available on the role of SLPI in the joints during arthritis. 
SLPI has been shown to be released by RASFs in response to activation with 
microparticles [342]. Of note, treatment with recombinant SLPI has been shown to 
attenuate inﬂammation in a model of bacterial cell wall-induced arthritis [343] (Figure 
1.14). Thus, at present, the relevance and biological properties of SLPI in modulating 
inflammatory responses and B cell activation in RA joints are yet to be defined. 
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Figure 1.14 A scheme of the reported biological functions of SLPI.   
 
The top part of the figure shows that each of the two domains of SLPI (COOH terminal 
and NH2 terminal) have distinct enzyme activities. The bottom part of the figure 
summarised the main biological properties of SLPI. From right to left, SLPI: (1) is a 
potent anti-protease that prevents the activation of complement cascade from protease 
cleavage; (2) protects ECs from deleterious effects exerted by proteases or MMPs; (3) 
decreases the production of prostaglandin, e.g. prostaglandin E2, by monocytes; (4) 
protects against infection such as prevention of HIV replication; (5) is involved in tissue 
repairing such as wound healing; (6) amerloriates joint inflammation and destruction; (7) 
is a key inducer of anti-inflammatory mediators such as IL-10 and TGF-β; (8) 
antagonises the pro-inflammatory activity of bacterial LPS. 
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Table 1.6. Biological functions of SLPI.  
 
AID, activation-induced cytidine deaminase; HGF, hepatocyte growth factor; HIV, 
human immunodeficiency virus; MCP, monocyte chemoattractant protein 1; MMP,  
matrix-metalloprotease; NF, nuclear factor; PGE, prostaglandin E; TGF,  transforming 
growth factor; TNF, tumor necrosis factor; IL, interleukin.  
Table adapted from Nukiwa et al Cancer Sci Vol 99:5 [344] 
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1.3.7 Importance of B cells in RA pathogenesis 
The critical relevance of B cells in the pathogenesis of RA has been clearly demonstrated 
by the clinical effectiveness of B cell depletion using the anti-CD20 monoclonal antibody 
Rituximab. It is now recognised that the role of B cells in RA can be subdivided into two 
processes: autoantibody dependent or independent pathways.   
1.3.7.1 Autoantibody production 
The persistent presence of high affinity autoantibodies is thought to be dependent on a 
chronic antigen-driven activation of B cells that prompt self-reactive B 
proliferation/survival via ongoing CSR and SHM. These antigen-driven processes have 
long been presumed to exclusively occur within the GC of SLO, such as LN. However, 
accumulating observations suggest that CSR and low-level SHM can still occur outside 
GCs at the extrafollicular area of the spleen in autoimmune prone mice, and in humans 
the gut or in follicular structures of chronically inflamed tissue of autoimmune diseases 
with ectopic GC-like structures, such as the salivary gland in Sjogren’s syndrome patients. 
Similarly, a recent report from our lab showed that lymphoid structures invariably 
expressed AID within the FDC network in the RA synovium, at both protein and RNA 
level, while auto-antibodies producing cells surround to these ectopic structures within 
the same tissue [152, 345]. Additional support for the notion that auto-antibodies are 
produced locally in the synovial compartment comes from the observation that these 
antibodies constitute higher levels in RA synovial tissue than in paired serum samples 
[151]. The targets of these autoantibodies are quite diverse and include collagen, cartilage 
linked proteins, heat shock proteins (hsp), enzymes, nuclear proteins and most 
importantly, citrullinated proteins (Table 1.7).  
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Antigen AntiAntibody 
Immunoglobulin G Rheumatoid factors 
Citrullinated proteins 
(fibrin, vimentin, filaggrin) 
ACPA, anti-CCP 
Heterogeneous nuclear 
ribonucleoprotein A2 (RA33) 
anti-RA33 
Collagen II Anti-collagen 
Stress proteins Anti-BiP, anti-hsp90 
Glucose-6 phosphate isomerise (GPI) Anti-GPI 
 
Table 1.7. Autoantigens of potential pathogenetic relevance in rheumatoid arthritis. 
 
Among the various autoantibodies described in RA, only RF, ACPA, and to a lesser 
extent, anti-RA33, have so far proven to be useful for diagnostic purposes. In particular, 
ACPA shows high specificity for RA and considerable prognostic value since their 
presence is significantly associated with the development of bone erosions. As mentioned 
above, their detection years prior the onset of RA disease suggests that alterations in the 
B cell compartment take place at an early stage of RA development [346]. In light of the 
effect of biologic treatments in RA, and particularly of B cell depletion, these 
autoantibodies have acquired a further pathogenetic role. Efficacy of anti-CD20 
Rituximab has firstly been proven in RF
+
 patients and shown to parallel a substantial and 
sustained reduction of IgM-, IgG- and IgA-RF levels [347]. Also, the levels RF and 
ACPA levels reduce upon treatment with Rituximab, where RF production is lowered 
prior to ACPA suggesting that RF (IgM) are preferentially produced by short-lived PC, 
whereas ACPA (IgG) are predominantly produced by long-lived PC.  
 
Although the pathogenic relevance of these antibodies in human RA is still to be 
determined, recent evidence in animal models demonstrate that antibodies with 
specificity for a commonly expressed enzyme of the glycolytic pathway, the glucose-6-
phosphate isomerase (GPI), are pathogenic and can directly induce experimental arthritis. 
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It has been shown that GPI is present on the cartilage surface, thus, the anti-GPI 
autoantibody can bind to the articular surface [348] and form immobilised Ag-antibody 
complexes which are able to activate the complement cascade, enhance local 
inflammation and promote tissue destruction. Furthermore, B cells with specificity for 
self-Ig can indeed bind and internalise Ag-antibody complexes. Therefore, a much 
broader spectrum of peptides is generated for enhancing Ag presenting function. This 
will support further activation and maturation of self-reactive B cells and thereby increase 
the production of high-affinity antibodies with RF specificity [345].  
1.3.7.2 Autoantibody-independent proinflammatory role of B cells in RA 
(1) Production of soluble mediators 
B cells can produce a large series of cytokines that are able to regulate innate and 
adaptive immune responses. In the context of ectopic lymphoid follicles, B cells play a 
fundamental role by producing pro-inflammatory cytokines, such as TNF-α and LT-β, 
which are essential for lymphoid neogenesis [146]. Furthemore, there is increasing 
evidence that a novel subset of B cells, regulatory B cells (Breg), also play an 
immunoregulatory function via production of IL-10 a pivotal anti-inflammatory cytokine 
[349]. Although evidence of Breg in the RA joints is lacking, in human RA, follicular 
synovitis expresses higher levels of IL-10 mRNA compared to the diffuse pattern [350]. 
Therefore, B cells in the RA joints can actively contribute to the production of factors 
that orchestrate synovial lymphoid neogenesis and promote the organisation of GCs in 
inflammatory lymphoid tissues [345]. 
 
(2) Antigen presentation for T cell activation 
B-cells are well known for their capacity to present antigens to T cells in a very efficient 
manner [351]. In the context of follicular synovitis Takemura and colleagues provide 
solid evidence that B cells have the ability to regulate T cell response. Treatment with 
human anti-CD20 monoclonal antibodies in severe combined immunodeficient (SCID) 
mice transplanted with GC
+
 RA synovial tissues led to disruption of GCs, loss of FDC 
networks and impairment of T cell activation, with a fall in the production of T cell-
derived cytokines, such as IFN-γ and IL-1β [352]. This observation indicates that B cells 
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are directly involved in maintaining inflammation within the synovial membrane, and 
that T-cell activation can be B-cell dependent.  
1.4 Role of fibroblast-like synoviocytes in RA pathogenesis 
1.4.1 Activation of RASFs in RA  
Although SF in the normal joint are the main cells that contribute to joint homeostasis, in 
RA, activation of SF by a wide range of soluble factors and cell surface interactions 
overrides this homeostatic function, and in turn RASFs express a broad assay of 
destructive enzymes and proinflammatory mediators as reported in Table 1.8 below.  
 
 
Table 1.8. Representative list of RASFs stimuli and products after respective stimulation.  
 
Table adapted from Noss and Brenner, Immunol Rev, Vol223 [353] 
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Already in 1997, Smith et al suggested SFs could be sentinel cells, based on the 
observation that fibroblasts do not just function as a structural element, but also have 
immuno-regulatory functions, such as synthesis of numerous growth factors, chemokines, 
cytokines and cell adhesion molecules that help in leukocyte recruitment, retention, 
survival and differentiation and the subsequent maintenance of immune responses within 
the joint microenvironment [354].  
 
1.4.1.1 Morphology and altered behaviour of RASFs  
It should be noted that RASFs differ considerably from fibroblasts of healthy joints in 
terms of the distinctive morphological features and stromal abnormalities as described by 
Fassbender earlier in the 1980s [355]. RASFs can proliferate in an anchorage-
independent manner and exhibit defective contact inhibition in vitro [355], with 
expression of a variety of transcription factors such as c-myc that promote cell cycling 
control and metabolic upregulation of MMPs [356]; thus they have been considered as a 
tumor-like cell (also described as 'mesenchymal transformation') [357] (Figure 1.15). The 
intrinsic aggressive and destructive behaviours were convincingly demonstrated in SCID 
mice engrafted with synovium and cartilage, where RA, but not OA, synovium deeply 
invaded cartilage matrix and expressed MMP mRNA at the site of destruction. 
Accordingly, isolated lining RASFs, but not normal SFs (or dermal fibroblast) or SFs 
from OA patients (OASFs), can maintain the invasive and destructive tendancies towards 
healthy human cartilage after multiple passages in cell culture or when engrafted under 
the renal capsule of SCID mice [358]. These data provide strong evidence that SF are 
irreversibly altered in RA allowing them to remain activated even after removal from the 
articular inflammatory milieu or in the absence of help from other cytokine-producing 
cells. Indeed a recent study demonstrated that RASFs are able to spread the pathology by 
invading unaffected joints, an ability seen lacking in non-RASFs [359].  
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Figure 1.15. Differentiation of fibroblasts into tissue-specific cells.  
 
A working hypothesis is illustrated in the upper part of the diagram postulating that 
aggressive RASFs emerge as a consequence of different stages of regulation. SF originate 
from mesenchymal stem cells, which are undifferentiated, multipotent cells capable of 
rapidly mobilising, proliferating, and differentiating into appropriate cell types in 
response to certain envirnmental signals. In the lower part of the diagram, SF are shown 
to translate from a relatively quiescent state into (1) aggressive phenotype of RASFs, 
with the potential of (2) producing matrix degrading enzymes, (3) expressing adhesion 
molecules and facilitating cartilage damage and (4) producing cytokines for the 
recruitment of inflammatory cells to the site of tissue injury.  
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Under the influence of inflammatory cytokines, RASFs produce prodigious quantities of 
enzymes that degrade the extracellular matrix such as serine protease, cathepsins and 
MMPs. MMPs are probably the most important as collagenases (MMP-1, MMP-13) and 
stromelysins (MMP-3), which are especially relevant in RA. Their synthesis and 
activation is induced by various factors including proinflammatory cytokines, growth 
factors as well as TLR ligands. TLR3 and TLR4 stimulation increases MMP production 
in RASFs [110, 360]. Lining layer hyperplasia is characterised by increased numbers of 
RASFs due to increased proliferation and reduced apoptosis. An indication of the rapid 
proliferative capacity of RASFs is provided by the constitutively elevated expression of 
transcription factors such as NF-kB and AP-1, and proto-oncogenes which may 
subsequently alter the expression and function of different tumour suppressor genes (i.e. 
somatic multaion of p53 in RASFs as described by Firestein and colleagues [361]). 
Furthermore, several soluble factors present in the inflamed joint such as platelet derived 
growth factor (PDGF), TGF-β, IL-1 and TNF-α have been implicated in enhancing 
RASFs proliferation. Similarly, resistance to apopotosis contributes significantly to the 
synovial hyperplasia in RA. Several studies suggest that RASFs are resistant to Fas-
lignad (FasL)-induced apoptosis [362]. Moreover, two specific anti-apoptotic molecules, 
termed FLICE inhibitory protein (FLIP) and small ubiquitin-like modified 1 (SUMO-1), 
which can inhibit Fas-mediated apopotosis are markedly expressed in the RA synovium, 
in particular along the synovial lining layer and at the site of cartilage invasion [88].  
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1.4.1.2 Involvement of RASFs as stromal cells that support B cells survival 
Evidence suggests a critical involvement of RASFs in regulating B cell survival. In vitro 
studies showed that cell-cell contact between SF and B cells is required to promote B cell 
proliferation and differentiation of CD20
+
 tonsilar B cells into CD20-CD38
+
 cells, 
consistent with PC morphology [363] (Figure 1.16). Furthemore, synovial nurse-like cells 
have been reported to enhance B cell viability via adhesion molecules such as CD106 
(VCAM-1) in addition to increase B cell Ig production. Similarly, Reparon-Schuijt and 
colleagues showed that RASFs can protect synovial fluid B cells from undergoing 
apoptosis [364]. Moreover, RASFs engagement of the chemokine stromal-derived factor-
1 (SDF-1/CXCL12) and the adhesion molecule VCAM-1, with their respective ligands 
on B cells, CXCR4 and VLA-4, support B cell pseudoemperipolesis (migration under 
RASFs monolayers) [365].  
 
It is highly relevant to this PhD thesis that blockage of the above interactions 
(chemokines, adhesion molecules) can only partially inhibit the downstream effects on B 
cell survival/activation/differentiation, suggesting that additional and yet undefined 
mechanisms regulate the crosstalk between RASFs and B cells. 
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Figure 1.16. Representative examples of RASFs in supporting B cell survival and 
differentiation.  
 
Resting fibroblasts differentiate into aggressive spindle-like RASFs during inflammation 
and exert FDC-like functions (i.e., the capacity to bind GC B cells and to rescue them 
from apoptosis). Representative phase contrast photomicrographs demonstrating (1a) 
pseudoemperipolesis of B cell lines cultured for 2h on RASFs (Linhdout et al [96]) and 
that RASFs can (1b) bind and rescue purified tonsillar GC B cells from apopotosis by 
adhering along the RASFs surface (Burger et al [365]). (2) Co-culture of CD20
+
 tonsillar 
B cells with RASFs demonstrates terminal differentiation of B cells into PC, illustrated 
by Giemsa staining showing one RASF cell surrounded by plasma cells and by FACs 
analysis showing that tonsillar B cells lose their CD20 expression and acquire CD38 
expression (Dechanet et al [363]).  
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1.4.2 Role of Toll-like receptors in RASFs activation 
1.4.2.1 Toll like receptors and the innate immune system 
As RA joints are characterised by chronic inflammation of the synovium, initiation of 
inflammatory arthritis requires a “pre-prime” or “induction” phase that precedes the 
clinically obvious synovitis. It is now believed that regulators of the innate immune 
system play a significant role in this phase. Aberrant TLR signaling recognising 
pathogen-associated molecular patterns (PAMP) is speculated to be involved in the 
initiation and perpetuation of synovitis and the regulation of innate and adaptive immune 
responses within the RA synovium. 
 
TLRs are the best characterised pattern-recognition receptors (PRRs). They were 
discovered on account of their homology with fruit fly Drosophila toll protein (Toll) 
[366]. All TLRs are type 1 integral membrane family glycoproteins and belong to the IL-
1R/TLR superfamily of proteins which all contain a conserved cytoplasmic motif, the 
Toll/IL-1R (TIR) domain. To date, 13 members of the TLR family are known in 
mammals, 10 of which are present in humans. TLRs can be classified into two 
subfamilies according to their cellular localisation, TLRs 1, 2, 4, 5, 6 and 10 are 
expressed on the cell surface while TLR3, 7, 8, and 9 are found on intraceullular 
compartments, such as endosomes and the endoplasmic reticulum. Each TLR has been 
shown to recognise specific conserved components of pathogens and trigger a variety of 
defense mechanisms depending on the receptor and cell type. This includes the 
internalisation of microbes by phagocytic cells, antimicrobial killing mechanisms such as 
production of reactive oxygen species, the production of inflammatory cytokines, 
chemokines and the expression of costimulatory molecules. In addition to direct detection 
of pathogens via the recognition of microbial components, TLRs are also critical for 
linking the innate and adaptive immunity, in particular in the activation of DCs and 
macrophages, for the generatiion of T and B lymphocyte responses. Therefore, the 
activation of TLRs is highly likely to be critical also in the initiation of autoimmunity 
[367].  
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1.4.2.2 TLR ligands and their signaling 
TLRs are type I transmembrane receptor with extracellular leucine repeats and a carboxy 
terminal intracellular tail containing a conserved region called Toll/interleukin1 receptor 
(TIR) homology domain. The extracellular domain is involved in ligand binding but is 
also necessary for dimerisation. A number of ligands have been identified through in 
vitro systems or knockout mice. TLR can recognise natural and synthetic exogenous and 
endogenous ligands in such a way that each TLR, alone, or by dimerisation, can 
recognise different bacterial, fungal and viral PAMPs as well as host-derived components 
[368]. Affinity between TLRs and their ligands appears lower than that between 
cytokines and their receptors. In spite of their low affinity, TLRs seem to recognise their 
ligands specifically. This has been demonstrated by analysing species-specific responses 
to TLR ligands. Generally, two main groups can be identified according to their 
corresponding ligands: 1) cell surface TLRs (except TLR5 and TLR10) recognise lipid-
based PAMPs that are on the surface of microbes; 2) endosomal TLRs recognise nucleic-
acid based PAMPs (double stranded RNA, dsRNA, single stranded RNA, ssRNA and 
CpG DNA). TLR5 and TLR10 do not correspond to either group; TLR5 represents the 
receptor for flagellin, the major structural protein of the flagella of gram-negative 
bacteria, whereas a specific ligand(s) for TLR10 is still unknown (Table 1.9).  
 - 116 -  
TLR Adaptors Ligands 
Pathogen activator Exogenous Class of activator Endogenous 
TLR1 MyD88/TIRAP Bacteria, mycobacteria Triacyl lipopeptides Protein/peptides βdefensin3 
TLR2 MyD88/TIRAP Gram
+
 bacteria Lipoproteins 
PGN, LTA  
Protein/peptides HSP 60,70, gp96, HMGB1, 
HMGB1-nucleosome 
complexes, β-defensin 3, 
Hyaluronan, Surfactant 
proteins A, D, Neurotoxin, 
aPLs, Cardiac myosin, PAUF 
Staphylococcus Modulin Fatty acids/lipoproteins Serum amyloid A, CEP 
Bacteria Lipopeptides Proteoglycans/ 
glycosaminoglycans 
Biglycan, Versican, HA 
fragments  
Mycoplasma, Mycobacteria, 
Spirochetes 
Lipoproteins, lipopeptides Organic molecules Monosodium urate crystals 
Mycoplasma MALP-2 
Spirochetes Glycolipids 
Listeria Heat-killed bacteria 
Mycobacteria Lipoarabinomannan 
Yeast Zymosan 
Trypanosoma cruzi GPI anchors 
Klebsiella Outer membrane protein A 
Synthetic compounds Pam3CSK4 
Virus dsRNA 
TLR3 TRIF Synthetic compounds PIC Nucleic acids/ protein–
nucleic acids complexes 
mRNA 
TLR4 
 
MyD88/TIRAP 
TRIF/TRAM 
Gram- bacteria LTA Protein/peptides HMGB1, Fibronectin EDA, 
Fibrinogen, Heparan Sulphate, 
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Gram
+
 bacteria LPS Hyaluronan fragments 
Tenascin-C (FBG), Surfactant 
proteins A, D, β-defensin 2, 
HSP90, 70, GP96, S100A8 
(MRP8), S100A9 (MRP14), 
NE, aPLs, Lactoferrin, 
Resistin, PAUF 
Plant Taxol Fatty acids/lipoproteins Serum amyloid A, Oxidised 
LDL, Saturated fatty acids 
Respiratory syncytial virus Fusion protein Proteoglycans/ 
glycosaminoglycans 
Biglycan, Heparin sulphate 
fragments, HA fragments 
TLR5 MyD88 Bacteria Flagellin   
TLR6 MyD88/TIRAP Mycoplasma Diacyl lipopeptides   
Yeast Zymosan 
Gram- bacteria LTA 
TLR7 MyD88 Virus ssRNA Protein/peptides aPL 
Synthetic compounds Imidazoquinoline, R848, R847 
synthetic poly U RNA 
Nucleic acids/ protein–
nucleic acids complexes 
ssRNA, RNA immune 
complex, siRNA encapsulated 
TLR8 MyD88 Virus ssRNA Protein/peptides aPLs, Cardiac myosin 
Synthetic compounds R848 Nucleic acids/ protein–
nucleic acids complexes 
ssRNA 
TLR9 MyD88 Bacteria Unmethylated CpG DNA Nucleic acids/ protein–
nucleic acids complexes 
Chromosome DNA, IgG-
chromatin immune complex, 
DNA immune complex 
TLR10 Unknown   Not determined  
HMGB-1: high-mobility group box 1 protein; CEP: omega-(2 carboxyethyl)pyrrole; IgG: immunoglobulin G; PGN: Peptidoglycans; LTA: Lipoteichoic acid; 
aPL: antiphospholipid; LDL: low-density lipoprotein; NE: neutrophil elastase; PAUF: pancreatic adenocarcinoma up-regulated factor; ssRNA: single-stranded 
RNA. 
 
 
Table 1.9.  Human TLR, adapters and the relevant external and internal ligands [369, 370].
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1.4.2.2.1 TLRs and lipid-based PAMPs 
TLRs 2 and 4 have been studied most extensively.  In 1998, genetic analysis revealed that 
TLR4 is a critical signal transducer for lipopolysaccharide (LPS), a glycolipid component 
of the outer membrane of gram-negative bacteria [371]. LPS not only can provoke a 
variety of immunostimulatory responses, but also cause a clinically life-threatening 
condition called endotoxin shock. Apart from lipids, other molecules recognised by 
TLR4 include proteins (F protein) and diterpene (Taxol, the LPS mimetic drug) as well as 
myobacterial components. However, recent evidence suggests that TLR4 also responds 
not only to exogenous but also endogenous factors produced by stress or cell damaging, 
such as heat shock proteins (HSP) [372]. HSPs are released from necrotic cells in certain 
pathological conditions, thereby inducing DC maturation by the activation of NF-κB 
pathway [373]. Such immune activation may provide a molecular basis for the danger 
theory of immune activation as previously proposed by Matzinger et al [374]. According 
to this theory, the immune system does not discriminate between self and nonself per se, 
but rather responds to antigens that are associated with danger signals released from 
damaged or stressed cells. During inflammation or tissue injury degraded extracellular 
matrix components, produced by proteases such as fibronectin [375] and soluble 
hyaluronan [376], can also exert their proinflammatory activity by binding to TLR4.  
 
Microbial recognition by TLR4 can be modulated by other factors. As an example, a 
glycosylphosphatidylinositol (GPI)-anchoring protein, CD14, was identified as a 
facilitator of LPS signaling by binding and retaining LPS on the cell surface. Another 
small secreted molecule, MD-2, has been shown to associate with the extracellular 
domain of TLR4 and evoke a cellular response upon the interaction of TLR4 with LPS 
[377, 378].   
 
TLR2 ligands recognise the widest repertoire of PAMPs due to the heteodimerisation of 
TLR2 with other TLRs (in particular TLR1 or TLR6) in order to optimally detect these 
ligands preceding cellular signaling. TLR2 was found to play a central role in recognising 
ligands associated with Gram-positive bacteria, mycobacteria, protozoan parasites, as 
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well as microbial lipoproteins, glycoproteins, glycolipids and nonenteric LPS. TLR2 
interacts with TLR1 to recognise native mycobacterial lipoprotein and several triacylated 
bacterial lipoprotein such as the synthetic structure S-(2,3-bis(palmitoyloxy)-2(-RS)-
propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys(4)-OH trihydrochloride (Pam3Cys) and 
meningococcal lipoprotein [379].  In contrast, a complex of TLR2 and TLR6 is needed 
for the detection of yeast zymosan and diacylated bacterial components including 
mycoplasma lipopeptide (MALP) and peptidoglycan (PGN) [380].  
 
Recently, endogenous TLR2 ligands have also been identified. Necrotic but not apoptotic 
cells activate fibroblasts and macrophages via TLR2 [381]. This could be mediated by 
uptake of intracellular proteins such as HSP70 which induce IL-12 production via TLR2 
[382]. Therefore the recognition of molecules that are expressed during cellular injury 
may modulate the function of non-immune cells. 
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1.4.2.2.2 Nucleic acid based TLR ligands 
Generally TLRs recognising nucleic acid based PAMPs are localised as intracellular 
receptors, resident on the plasma membranes of endosomal versicles. The signal 
propagation through these receptors depends on internalisation of the ligand to an acidic 
intracellular compartment. As a result, several studies have shown that inhibitors of 
endosomal/lysosome acidification, such as chloroquine and bafilomycin A1, can block 
the activation process through TLR3, TLR7 and TLR9, indicating that these signaling 
pathways require acidification and maturation in the endosome [383-385]. 
 
The ligand for TLR3 was identified as double stranded RNA (dsRNA) [386] whilst TLR7 
and TLR8 recognise single stranded RNA (ssRNA) [387, 388]. Viral replication within 
infected cells results in generation of dsRNA that can provoke antiviral defense, 
suggesting that TLR3 fight against viral infection. Upon recognition of dsRNA, TLR3 
transmits signals via the adaptor protein TIR-domain-containing adaptor inducing IFN-β, 
TRIF. This activates the transcription factors interferon regulatory 3 (IRF3), NF-KB and 
AP-1, leading to the induction of type 1 interferon (especially IFN-β) and 
proinflammatory cytokines. Type 1 interferon in turn activates interferon stimulated 
genes and production of anti-viral proteins, thus amplifying the anti-viral immune 
response. Also, TLR3 can potentially be activated by endogenous host single stranded 
mRNA and by the presence of secondary structures within the mRNA, such as hairpins 
which contain short segments of dsRNA [389]. Conversely, modification of RNA, such 
as methylation, can reduce the signaling through TLR3 compared to minimally modified 
viral nucleic acid [390]. At present, it is generally accepted that RNA from various 
sources can activate TLR3, as long as the RNA displays a secondary structure containing 
double-stranded regions, provided that the RNA is present in the appropriate cellular 
vesicles. TLR3 and TLR7 have been reported to localise in the same intracellular 
compartments that are often found adjacent to phagosomes containing apopototic cell 
particles, suggesting that TLR3 and TLR7 can be triggered by nucleic acid from 
apopototic cells during viral infection [391]. In experimental models, among all the 
synthetic analogs of viral dsRNAs, polyriboinosinic:polyribocytidylic acid (PIC) was 
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found to be the most potent IFN inducer [392] and is therefore utilised as a ligand for 
TLR3 to mimic viral infection. A study on the unmodified nature of PIC strengthened the 
evidence that TLR3 recognises the RNA complex rather than any modification or other 
structures of dsRNA [393]. In contrast to cofactor requirement for TLR4 activation, 
TLR3 simply interacts with dsRNA through the cationic surface of the receptor, while the 
receptor dimer is held in place by intermolecular forces within TLR3 [394].  
 
Briefly, mouse TLR7, human TLR8, and to a lesser extent human TLR7, recognise 
ssRNA viruses such as the influenza, Sendai and Coxsackie B viruses. In addition to viral 
ssRNA and GU-rich ssRNAs, low molecular anti-viral compounds activate TLR7 and 
TLR8. TLR7 is involved in the recognition of imidazoquinoline compounds (imiquimod 
[R837] and resiquimod [R848]) [395]. TLR8 also recognises R848 in humans but not in 
mice, suggesting that TLR8 is nonfunctional in mice [396]. Furthermore, Lee et al. 
reported that guanosine analogs (Loxobribin) activate immune cells via TLR7 but not 
TLR8 [397]. 
 
TLR9 is the main receptor for unmethylated cytosin-guanosin dinucleotide (CpG)-DNA, 
a dinucleotide sequence that has been identified as a stimulatory motif of bacterial and 
viral DNA [398]. CpG motifs are more commonly found in DNA of bacteria and viruses 
rather than vertebrate, in which DNA is usually methylated. CpG rich DNA and 
oligodeoxynucletides carrying the CpG motif induce specific immunostimulatory 
activities on B cells and DC via TLR9, as TLR9-deficient mice lack these responses 
[399]. TLR9 activation on B cells not only induces their proliferation, the crosslinking of 
the surface B cell receptors with TLR9 by immuncomplexes that contain chromatin can 
also triggers T-I secretion of IgG and IgM autoantibodies [400].   
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1.4.2.3 Distribution and expression of TLRs 
TLRs are differentially expressed by a range of cellular subsets in human peripheral 
blood as well as in non-immune cells. A breakdown of each member of TLR mRNA 
expression is listed below [401-404] (Table 1.10):  
 
TLR Expression 
TLR1 Ubiquitously expressed on leukocyte population. Predominantly found 
on monocytes, macrophages, B cells, T cells, DCs, PMN, NK cells; non-
immune cells (fibroblasts, astrocytes, ECs, keratinocytes) 
TLR2 Leukocyte population: monocytes, macrophages, DCs, PMN; non-
immune cells (fibroblasts, astrocytes, ECs, keratinocytes) 
TLR3 Leukocyte population: DCs, macrophages, mast cells, NK cells, mucosal 
B cells; non-immune cells (fibroblasts, astrocytes, epithelial cells, 
keratinocytes)  
TLR4 Leukocyte population: Monocytes, macrophages, DCs, PMN; non-
immune cells (fibroblasts, astrocytes, ECs, keratinocytes) 
TLR5 Leukocyte population: Monocytes, macrophages, T cells, DCs, PMN; 
non-immune cells (fibroblasts, astrocytes, ECs, keratinocytes) 
TLR6 Leukocyte population: Monocytes, macrophages, B cells, T cells, DCs, 
PMN, NK cells; non-immune cells (fibroblasts, astrocytes, ECs, 
keratinocytes) 
TLR7 Leukocyte population: B cells, plasmacytoid DCs 
TLR8 Leukocyte population: Monocytes, myeloid DCs 
TLR9 Leukocyte population: B cells, plasmacytoid DCs; non-immune cells 
(GI ECs, keratinocytes) 
TLR10 Leukocyte population: B cells (highest), plasmacytoid DCs 
Table 1.10. Expression of human TLRs in different cell types.  
Modified from [405]. 
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1.4.2.4 TLR signaling 
Once the TLRs encounter their ligand, TLR usually dimerise (homo- or hetero-) and 
interact with the TIR domain of adapter proteins. Five adaptor molecules interact via TIR 
domains to transmit TLR signaling: (1) MyD88 (myeloid differentiation factor 88); (2) 
Mal/TIRAP (MyD88 adapter-like/TIR domain-containing adapter protein); (3) TRIF 
(TIR domain-containing adaptor-inducing IFN-β); (4) TRAM (Toll-receptor-associated 
molecule); and (5) SARM (sterile α- and armadillo motif containing protein) (Figure 
1.17). Among these, MyD88 is the universal adaptor essential for all TLRs with the 
exception of TLR3. In fact, the signaling pathways activated by TLRs are classified into 
MyD88-dependent and MyD88-independent pathways. The latter pathway starts with 
TRIF and is therefore also called the TRIF-dependent pathway. TRIF is the sole adaptor 
for TLR3 and with the bridging adapter TRAM by TLR4. It signalls in the following 
ways: (1) receptor-interacting protein 1 (RIP1) recruited with TNF receptor associated 
factor 6 (TRAF6) are able to switch on the proinflammatory cytokine pathway, NF-kB; 
(2) RIP1 can also recruits interleukin-1 receptor-associated kinase 1 (IRAK1) leading to 
activation of both the NFkB and activator protein-1 (AP-1) pathways; (3) the TNF 
receptor associated factor 3 (TRAF3) activates interferon regulatory factors (IRFs) and 
thus shifts to the type I IFN pathway for initiation of an antiviral defense.  
 
For the MyD88-dependent pathway, the adaptor activates its own TIR domain or 
activation occurs via TIRAP, where it then recruits IRAK4 and IRAK1 which bind to 
TRAF6, resulting in activation of (1) transcription factor NFkB via IkB kinase (IKK) 
activation and (2) transcription factor AP-1 via activation of mitogen-activated protein 
kinases (MAPKs), including Jun N-terminal kinase (JNK), p38 and extracellular signal-
regulated kinase (ERK).  
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Figure 1.17. TLR-mediated MyD88-dependent and independent signaling pathway.  
 
Both superficial and endosomal signaling are shown. Following activation of extra- and 
intracellular TLRs by various PAMPs or DAMPs, TLRs recruit the adaptor proteins 
MyD88, TRIF, TIRAP, TRAM and SARM as indicated in blue. These then initiate 
signaling cascades involving IL-1R-associated kinase (IRAK) and TNFR-associated 
factor (TRAF) proteins, which finally converge at the activation of the IkB kinase (IKK) 
family members (IKKα, IKKβ and IKKγ/NEMO  [used by MyD88 pathway]; IKKε and 
TBK1 [used by TRIF pathway]). The functions of SARM may be species-dependent. In 
humans, SARM could not activate NF-kB or IRF3 but has been identified as an inhibitor 
of TRIF signaling. As it contains a TIR domain, it binds directly to the TIR domain of 
TRIF, thereby blocking the interaction of TRIF with TLR3 or TRAM with TLR4 
signaling. This interaction prevents the activation of IRF3, IRF7, NF-kB and apoptosis by 
TRIF[406]. NESCA is newly decribed as a NEMO-interacting protein and implicated in 
the NEMO-mediated NFkB activation pathway. All TLRs activate NK-kB and AP-1, 
inducing the proinflammaotry cytokines. Some TLRs can also activate IRK3, IRF5 
and/or IRF7, leading to the production of type I interferon. Modified from image adapted 
from Shotorbani et al World J Biol Chem Vol 2:7 [407]. 
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1.4.2.5 The role of TLRs in RA 
1.4.2.5.1 TLR signaling in animal models of arthritis 
A number of animal models of arthritis support the involvement of TLRs in chronic 
arthritis. Classical animal models of arthritis such as streptococcal cell wall (SCW) 
arthritis are dependent on the activation of TLR ligand, as TLR2 deficient animals exhibit 
a significantly reduced severity of arthritis. Similarly, no SCW-arthritis developes in 
mice that lack the adaptor molecule MyD88 [408]. Moreover, injection of staphylococcal 
peptidoglycan, CpG DNA or dsRNA into joints of mice results in a self-limited form 
arthritis [409, 410]. Furthermore, arthritis may also develop upon transfer of serum-
containing antibodies to glucose-6-phosphate isomerase (GPI) in K/BxN mice. In this 
model, antibody deposits at the intra-articular space and provokes immune complex-
mediated arthritis, which is ameliorated in TLR4
–/–
 mice [411]. In a humanised model in 
which intact RA synovial explants were transplanted into SCID mice, spontaneous 
cytokine production is markedly suppressed upon specific blockade of TLR4 with similar 
efficacy compared to adalimumab treatment, an anti-TNF monoclonal antibody. In 
addition, TLR4 contributes to the development of the highly pathogenic Th17 cells and 
IL-17 production that promotes severe autoimmune spontaneous arthritis in mice [411].  
Another recent study proposed TLR3 to act as the central player in the pristane-induced 
arthritis rat model where TLR3 expression was up-regulated during early disease stages, 
and aggravated disease severity upon TLR3 stimulation. Alternatively, small interfering 
RNA (siRNA) targeting TLR3 in vivo reduced disease severity [412]. These studies 
suggest that: (1) the availability of TLR ligands might be sufficient to initiate arthrtritis in 
a susceptible host; (2) endogenous TLR ligands contribute to arthritis persistence and 
destruction.  
1.4.2.5.2 Local expression of TLR ligands in the rheumatic joint  
Apart from the TLR ligands of microbial origin (cell wall fragment, e.g. peptidoglycan or 
bacterial DNA e.g. dsDNA) that have been detected in joint of RA patients, host derived 
endogenous ligand or damaged “self” molecules known as damage-associated molecular 
pattern (DAMP) might locally activate TLRs in driving inflammation during RA. 
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DAMPs are endogenous molecules that are immunologically silent in healthy tissues but 
become active and expressed within cells upon inflammation. These molecules can also 
be released: (1) under environmental stress even in the absence of apoptosis or necrosis; 
or (2) represent extracellular matrix (ECM) components that may be created by tissue 
damage or proteolysis and (3) ECM molecules that are specifically expressed as a result 
of tissue injury. In normal circumstances they serve as danger signals that alert the host to 
tissue injury and initiate the process of tissue repair. In addition to such a physiological 
role, there is evidence suggesting that DAMPs are also implicated in the pathogenesis of 
many inflammatory and autoimmune diseases characterised by aberrant TLR activation 
including RA. 
 
ECM components including fibrinogen, fibronectin extra-domain A (EDA) [413], 
biglycan [414] and tenacin-C [415] are specifically up-regulated in response to tissue 
injury, and low molecular weight fragments of the ECM, such as hyaluronic acid [376] 
and heparin sulphate might act as endogenous TLR2 and TLR4 ligands within the RA 
joint (Figure 1.18). Furthermore, extravascular deposition of fibrinogen and fibrin clots 
might further trigger the TLR signaling cascade via TLR4. Extracelluar HSPs, such as 
HSP60, 70 and HMGB1, have been reported to be released by activated/necrotic cells 
and are implicated in RA pathogenesis [416, 417]. However, it should be noted that in 
order to activate cell surface TLR2 and TLR4 within the joint, endogenous TLR ligands 
must be present locally in the inflamed joint and gain access to the extracellular milieu 
for subsequent activation. Accordingly, among DAMPs, EDA fibronectin, tenacin-C, 
serum amyloid A, gp96 and HMGB1 have been identified in the synovial fluid. However, 
although significant levels of HSP70 and biglycan were readily detected in the lysates of 
cells from rheumatoid joint, these molecules were not found in synovial fluid. Therefore, 
the molecular mechanism by which these potential DAMPs bind and activate TLRs 
remains to be determined. 
 
Recently, TLR8 has also been shown to be important for the production of TNF-α within 
RA synovium since inhibition of TLR8 prevents “spontaneous”cytokine release by 
synovial tissue [418]. Therefore, stimulation of TLR8 by unknown ssRNA containing 
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components in the RA synovium leads to the expression of pro-inflammaotry cytokines. 
Moreover, blood serum DNA in RA patients is considerably enriched with fragments of 
ribosome repeats containing immunostimulatroy CpG-motifs, suggesting that endogenous 
TLR9 ligands may be increased in RA disease [419]. Notably, the above-mentioned 
studies emphasise the contribution of endosomal TLRs in RA. Accordingly, chloroquine, 
which prevents intracellular TLR function by impairing endosomal acidification, reduces 
cytokine release in synovial cells [418]. The anti-depressant drugs of selective serotonin 
reuptake inhibitors, fluoxetine and citalopram, and the anti-depressant small molecule 
mianserin, can also inhibit TLR3, 7, 8 and 9 activities and are therefore reported to be 
involved in inhibiting synovial cell cytokine release [420] as well as in improving 
symptoms in RA patients [421]. Overall, these studies suggest a significant role for TLR2 
and 4 as well as the endosomal TLRs 3 and 8 in human RA disease. 
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Figure 1.18. Representative molecules derived from injured tissue, blood vessels, 
and necrotic cells that activate TLRs and induce inflammatory response.  
 
Following tissue and cell injury, endogenous ligands of TLRs are generated and/or 
released. Extracellular matrix components (hyaluronic acid, fibronectin, heparan sulfate) 
released from damaged tissue; fibrin and fibrinogen released from injured blood vessels 
and heat shock proteins (HSP) released from necrotic cells, can bind to TLR4. RNA and 
chromatin-associated DNA released from necrotic cells can bind and activate TLR3 and 
TLR9, respectively.  
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1.4.2.6 Expression and function of TLRs on RASFs 
Among the 10 human TLRs, expression of functional TLR2 was first detected in RA 
synovial tissue, and shown to be induced by IL-1 and TNF-α, resulting in the 
translocation of NF-kB and secretion of proinflammatory cytokines and MMPs. Likewise, 
a variety of chemokines found in the synovial fluid of RA patients was found to be 
secreted by TLR2-treated RASFs [422, 423]. Besides TLR2, enhanced expression of 
TLR3, TLR4 and TLR7 in RA synovial tissue has also been demonstrated. In vitro 
stimulation of TLR3 and TLR7 in RASFs resulted in significant up-regulation of 
chemokines, cytokines, metalloproteinases and type I IFNs [110, 360, 424]. More 
recently, Kim and colleagues suggested that TLR2, TLR3 and TLR4 signaling could 
induce RANKL expression on RASFs and promote the subsequent osteoclastgenesis [199, 
200]. Notably, stimulation of TLR3 and TLR8, but not TLR7 or TLR9, increased TNF-α 
release in RA membrane cultures[418]. Conversely, disruption of downstream adaptors 
for TLR such as MyD88 and TIRAP, reduced cytokine synthesis in cultured RA synovial 
tissue, further strengthening the role of TLRs in RA pathogenesis [425]. 
 
Recently, functional TLR1-6, but not TLR7-10, have been shown to be expressed on 
RASFs, with TLR3 being the highest. Accordingly, stimulation of cultured RASFs in 
vitro with TLR2, TLR3 and TLR4 ligands leads to to up-regulated IL-6 expression as 
well as MMPs 1&3, with TLR3 ligand, PIC, be the most effective stimulaton [110, 360]. 
Similarly, activation of TLR3 by dsRNA released from synovial necrotic cells has been 
described, and injection of dsRNA into mice resulted in self-limited arthritis, suggesting 
an arthritogenic role of viral dsRNA. Interestingly, the dsRNA released from necrotic 
cells was demonstrated as an endogenous ligand for the stimulation of proinflammatory 
cytokines and chemokines in RASFs. Since these endogenous ligands are abundant in the 
synovial fluid of RA patients, TLR expression levels and the corresponding 
responsiveness, particularly for TLR3, might be critical factors for the perpetuation of 
RA [110].    
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1.4.2.7 Role of TLR-activated RASFs, as part of an innate immune system, in B cells 
differentiation and survival 
Most studies have focused on the role of cytokines or classic proinflammatory mediators 
on B cell survival and maturation by RASFs. However, one should not exclude the fact 
that complex networks involving innate immunity and cytokines may also account for 
these processes. Previous studies suggested that innate immune responses mediated by 
TLR recognition of bacterial DNA could participate in triggering B cells to secret auto-
antibodies in a TI manner. A recent study from Messer and colleagues demonstrated that 
ligands for TLR2, TLR4 or TLR9 cannot induce the de novo synthesis and release of 
BAFF by RASFs. Moreover, they found that exposure of TLR2, 4 and 9 with ligand to 
their respective ligands exert a negative regulation of BAFF synthesis in IFN--primed 
RASFs [293]. However, their study did not include the influence on BAFF in response of 
the most prominent receptor, TLR3. Therefore, in my PhD project, I aim to dissect the 
role of TLR2, 4, as well as TLR3 on B cell activation/survival within the synovial 
microenvironment. 
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CHAPTER 2 
 
Hypothesis and aims of the project 
Several lines of evidence suggest that humoral autoimmunity within the rheumatoid joint 
is critically regulated by local interactions between infiltrating B cells and resident 
stromal cells. However the mechanisms regulating such processes are largely unknown. 
In particular, the following evidence directly raises various questions, which I aim to 
address in this thesis: 
 
(1) In situ B cell activation and humoral immunity towards RA-associated auto-
antigens are retained for several weeks when RA synovium containing B cell 
follicles is engrafted into SCID mice, suggesting that resident cells are required 
for regulating B cells survival and activation in the ectopic lymphoid structures 
within the RA synovium. 
(2) RASFs are critical candidates to regulate such interactions as they share 
properties of FDCs in rescuing B cells from apoptosis and promoting their 
proliferation and differentiation into antibody-producing cells. However, the 
mechanisms regulating the crosstalk between RASFs and B cells are unclear. 
(3) Recent evidence demonstrated that B cells can be directly activated to undergo Ig 
class-switching in the presence of BAFF and APRIL released at mucosal sites by 
ECs sensing pathogens via toll-like receptors (TLRs), particularly TLR3.  
(4) Accordingly, RASFs can express BAFF and APRIL, although the regulation of 
these factors in RASFs and their effective capacity in supporting AID expression 
and ongoing CSR in B cells is unclear. In particular, although accumulating 
evidence suggests that the activation state of RASFs is critically dependent on the 
expression of TLRs, the relationship between TLRs and BAFF/APRIL expression 
in RASFs is controversial.  
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(5) In addition to B cell pro-survival factors, TLR stimulation can also induce 
counter-immunoregulatory molecules, which negatively affect B cell activation 
and proliferation. In particular, a critical role for TLR3-induced endogenous SLPI 
in down-modulating B cell function has been suggested in airway ECs, but its 
expression/function in RASFs is unknown.  
 
Thus, on the basis of the above, the main hypothesis of this PhD thesis is that RASFs 
play a fundamental role in modulating B cell activation and differentiation in the synovial 
microenvironment via a mechanism regulated by TLR stimulation and involving the 
release of pro (i.e. BAFF/APRIL) and anti-inflammatory factors (i.e. SLPI).   
 
In order to in investigate this aspect, in Chapter 4, I examined the effect of TLR2/3/4 
ligands in modulating BAFF/APRIL expression in RASFs and their role in promoting 
AID expression and CSR in unswitched IgD
+
 B cells. In particular my aims were as 
follows: 
 
 To investigate the expression of B cell survival factors (BAFF and APRIL) in 
RASFs/RADFs/OASFs 
 To examine whether the overexpression of B-cell survival factors in RASFs are 
modulated upon TLR stimulation 
 To assess whether these factors were functional in terms of the promotion of AID 
expression and the production of class-switched antibodies in unswitched IgD
+
 B 
cells 
 To gather direct evidence that the stimulating capacity of RASFs in promoting B 
cell activation is dependent on BAFF and/or APRIL= 
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This hypothesis is summarised in Figure 2.1 below: 
 
RASF
B cell
 
Figure 2.1. Hypothesis I.  
 
Cross talk between stromal cells and B cells is dependent on the release of BAFF/APRIL 
by RASFs and is regulated by TLR stimulation. 
 
The results of the experimental work which I carried out to test this hypothesis are 
presented in Chapter 4 and have been published in Bombardieri, M*, Kam, NW*, 
Brentano, F, et al (2011). A BAFF/APRIL-dependent TLR3-stimulated pathway 
enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig 
class-switching in B cells. (* joint first author) Ann Rheum Dis 
10.1136/ard.2011.150219.  
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In the second part of my experimental work, presented in Chapter 5, I investigated the 
effect of TLR2/3/4 ligands in modulating SLPI expression in RASFs and their subsequent 
role in B cell activation. In particular I aimed to investigate: 
 
 The expression of SLPI in RASFs vs. RADFs 
 Whether SLPI in RASFs was modulated upon TLR stimulation 
 The direct functional impact of SLPI in B cell activation in terms of modulation 
of AID expression, CSR and production of class-switched Ig in mature 
unswitched IgD
+
 B cells (route 1, Figure 2.2) 
 The role of SLPI in modulating the capacity of RASFs to release B cell survival 
factors in response to TLR stimulation (BAFF/APRIL) (route 2a, Figure 2.2) and 
to influence the downstream B cell activation and proliferation (route 2b, 
Figure2.2) 
 To examine in vivo in the collagen-induced arthritis model the therapeutic 
potential of SLPI (data presented in Chapter 7, supplementary results).  
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Figure 2.2. Hypothesis II. 
 
The cross talk between stromal cells and B cells is negatively regulated by RASFs-
released SLPI via direct inhibition of B cell activation (route 1) and/or via down-
regulation of BAFF released by RASFs (route 2). 
 
The results of the experimental work related to this part of my PhD project are presented 
in Chapter 5 and are being finalised for publication. 
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CHAPTER 3 
Materials and methods 
 
3.1 Synovial fibroblasts isolation and culture 
3.1.1 Synovial tissue collection 
Synovial tissues were obtained from patients undergoing total knee/hip replacement. A 
total of 6 RA and 8 OA samples were available at QMUL and used for isolation of 
synovial fibroblasts (SFs). Samples were collected after informed consent (LREC 
05/Q0703/198). Matched synovial and skin fibroblasts from 5 RA patients undergoing 
total knee/hip replacement were obtained from the University of Birmingham (LREC 
5735), as previously reported [426]. All RA patients (10F/1M, mean age 64.1 yrs, 82% 
RF positive) fulfilled the American College of Rheumatology criteria for the 
classification of RA [4] and had long-standing disease requiring joint replacement. All 
patients had received DMARDs (in monotherapy or combination) and 2 patients received 
anti-TNF therapy. Patients had discontinued treatment before surgery for an appropriate 
washout period. Patients with OA had advanced disease and were all diagnosed with 
primary OA.  
3.1.2 Patients samples and preparation 
Synovial tissues obtained from patients were used for isolation of SF. After discarding fat 
and dense fibrous tissues, the synovium was dilacerated with tweezers, cut into small 
pieces with blade and gently mashed under 70-μm nylon mesh cell strainer (Becton 
Dickinson, Oxford, UK). Specimen pieces were collected and  digested with 1.5mg/ml 
Dispase II (Gibco/Invitrogen, Paisley, UK)  at 37°C in complete cell culture medium 
made of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal 
calf serum (FCS), 50 IU/ml penicillin-streptomycin, 10mM HEPES buffer (all from 
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(Gibco/Invitrogen) overnight under rotation. Following enzymatic digestion, the 
remaining finely minced synovial tissues and detached cell-suspension were passed 
through a cell strainer and washed with DMEM complete medium by centrifugation at 
400 x g for 10min. The pellet containing synovial cells was collected, re-suspended in 
DMEM complete culture medium and plated into 75-cm
3
 tissue-culture T75 flasks in a 
5% CO2-humidified incubator at 37°C.  
 
3.1.3 Generation of fibroblast-like synoviocytes from RA and OA patients 
RASFs and OASFs were obtained as previously described [110]. Synovial cells were left 
in culture flask for 7 days including removal of non-adherent cells every other day. 
Although there was variation from line to line, in general, culture medium was 
replenished once weekly. When adherent cells reached 90% confluency, they were 
passaged at dilution 1/3 into fresh T75 culture flasks by 0.25% trypsin/EDTA (Sigma, 
Poole, UK) treatment. The latter agent, EDTA, is a chelator of divalent cations with 
gentle dissociative properties. It acts to increase trypsin efficiency by neutralizing 
calcium and magnesium ions. These two ions are typically found in the extracellular 
matrix for cell-cell adhesion and normally obstruct the peptide bonds where trypsin acts 
on. After gentle trypsinization, FCS was added to the cells for inactivation of trypsin and 
cells were centrifuged for 10 min at 400 × g in order to remove the remaining trypsin. 
Synoviocytes were used between passages 4-8; at this stage the cell culture is devoid of 
contaminating lymphocytes and macrophages [427] (Figure 3.1). Paired control fibroblast 
cultures obtained from the skin of RA subjects undergoing total arthroplasty were kindly 
provided by Dr Andy Filer at University of Birmingham (as mentioned above). Similarly 
to RASFs, the RA dermal fibroblasts (RADFs) were also grown in complete medium, 
maintained in monolayer culture and used between passage 4 and 8 as described above.  
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Figure 3.1 Human synovial fibroblasts from RA patients (RASFs).  
 
At passage 4-8, cells appeared to be a homogeneous population with large, flat, spindle-
shaped or stellate-shaped cells, a typical fibroblast-like morphology. 
 
3.1.4 TLR stimulation of RASFs, OASFs and RADFs  
In study I (Chapter 4), all experiments were carried out with fibroblast cultures at ~90% 
confluence before stimulation. Fibroblasts were seeded into 24-well plates at 4x10
4 
cells/well and stimulated with optimal concentrations of TLR2-4 ligands [360] [300ng/ml 
of bacterial lipopeptide (bLP), 10µg/ml of polyinosinic:polycytidylic acid (PIC) 
(InvivoGen, Toulouse, France), 100ng/ml of lipopolysaccharide (LPS) from Escherichia 
coli J5 (Sigma)] or left untreated for 4, 8, 24, 48 and 72h. Supernatants were harvested 
after the allocated time period and stored at -20
o
C until tested in ELISA. For RNA 
extraction, adherent fibroblasts were first rinsed with phosphate buffered saline (PBS) 
and then lysed in RLT buffer (Qiagen) under vigorous pipetting/vortex-mixing in order to 
lyse the cells thoroughly (see below section of RNA isolation). Lysed cells in RLT buffer 
were kept at -20
o
C until tested. Stimulation scheme is illustrated in Figure 3.2.  
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Figure 3.2. Diagram of the experimental design used to study the interaction 
between TLR-activated RASFs/RADFs/OASFs, B cell survival factors release and B 
cell activation.  
 
Bacterial lipopeptide (bLP) is a TLR2-specific ligand (concentration: 300ng/ml); 
polyinosinic: polycytidylic acid (PIC) is a TLR3-specific ligand (concentration: 
10µg/ml); lipopolysaccharide (LPS) is a TLR4-specific ligand (concentration used: 
100ng/ml). The untreated RASFs/RADFs/OASFs were used to assess the basal 
expression of B cell survival factors.  
 
In study II (Chapter 5), culture conditions were similar with the exception that 
fibroblasts were pre-treated: (a) with or without recombinant human SLPI (R&D 1274-
PI, at a concentration of 50 and 500ng/ml); (b) with or without goat anti-human SLPI 
(R&D AB-260-NA)/goat anti rabbit isotype control (absorbed against human and mouse 
immunoglobulin, Southern Biotechnologies, Birmingham, Alabama, USA), both at a 
concentration of 10µg/ml. After 1h of pre-incubation, cells were stimulated with PIC at 
10µg/ml for 4, 8, 24, 48 and 72h and harvested as mentioned above. A relevant isotype 
control goat anti- rabbit IgG (absorbed against human and mouse immunoglobulins) was 
used.  
 
3.2 Human B cells isolation and culture 
3.2.1 Purification of unswitched IgD
+
 human B cells 
Human B cells were immunomagnetically selected from tonsils obtained following 
routine tonsillectomy. The tonsil specimens were obtained from children attending the 
weekly ENT tonsillectomy Day Surgery Clinic at Barts and the London NHS Trust and 
 - 142 -  
kindly provided by the Human Tissue Resource Centre. Briefly, tonsil tissues were 
washed in a petri dish with chilled (4
o
C) MACS buffer [PBS, 0.5% FCS and 2 mM 
EDTA]. Specimens were cut into smaller pieces followed by gentle mashing through a 
70-μm nylon mesh cell strainer (Becton Dickinson) by the rubber end of a 5ml syringe 
plunger, creating a tonsillar mononuclear cell suspension in the MACS buffer. The 
suspension of dispersed cells was filtrated through the cell strainer, washed and 
centrifuged at 400 x g for 10mins at 4
o
C.   
 
After counting, aliquots of tonsillar mononuclear cells were collected as pre-sorted (PS) 
fraction for subsequent purity analysis (Figure 3.3). IgD
+
 unswitched B cells were 
magnetically sorted by incubating 3x10
8
 tonsillar mononuclear cells with 1 l of anti-IgD 
biotinylated monoclonal antibodies (2032-08; Southern Biotechnologies, 0.5 µg/10
6
 
cells) for 30mins on ice to avoid capping of antibodies on the cell surface during the 
labeling process. The amount of biontinylated antibodies used was optimised for least 
background staining. Cells were then washed, centrifuged at 300g for 10mins at 4
o
C, 
resuspended in MACS buffer and incubated with anti-biotin MicroBeads (130-090-485; 
Miltenyi Biotec, Bisley, UK, 80µl per 10
7
 cells) for 15mins at 4
o
C. After washing, cells 
were subsequently passed
 
through magnetic separation columns (MS; Miltenyi Biotec) 
with a magenetic cell separator. The effluent was collected as flow through (FT) fractions. 
The column was then removed from the separator and the bead-bound cells [positive 
selected, after-sorted (AS) fraction] retained in the columns were eluted and collected as 
enriched, positively selected IgD
+
 unswitched B cells fractions. All sorting procedures 
were performed on ice and under sterile conditions.  The purity of IgD
+
 unswitched B cell 
isolation was checked by fluorescence-activated cell sorting (FACS; Figure 3.3). 
 
 - 143 -  
  
(1) anti-IgD
biotin-
conjugated Abs
(2) anti- biotin 
microbead
Pre-sort After sorted:
IgD+ cells
Flow through:
Negative cells
Purity check:
Flow cytometry  
Figure 3.3. Isolation of IgD
+
 unswitched B cell from human tonsils using MACS B 
cells enrichment kit.  
 
Tonsillar B cells were labeled with anti-IgD biotinylated antibodies and anti-biotin 
MicroBeads. With the use of magnetic separation columns, labelled cells were eluted and 
collected as IgD
+
 B cells. Aliquots of pre-sorted (PS), flow though (FT) and after-sorted 
(AS) fractions were harvested for purity check by flow cytometry. 
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3.2.2 Flow cytometry analysis for B cell surface markers  
Flow cytometry is a technique that uses the principles of light scattering, light excitation 
and emission of fluorochrome molecules to generate specific multi-parameter data from 
cells as they flow in a fluid stream through a beam of light. 
  
The presence of forward scatter channel (proportional to cell-surface area or size), side 
scatter channel (proportional to cell granularity or internal complexity) and separate 
fluorescent channels allow the collection of light reflected by the cells. The combination 
of optical signals (emitted from fluorochrome-conjugated antibody targeting on an 
epitope of interest) derived from different detectors produce electronic signals which 
define multiple phenotypical, biochemical or molecular characteristics of the cells. The 
data can be displayed as single parameter histogram, two parameter dot plots with a 
quadrant marker, a two parameter dot plot with regions and three-dimensional plots.  
 
In this part of my PhD work, flow cytometry was used to confirm purity and quality of 
the B cell separation procedure prior to downstream experiments with isolated IgD
+
 B 
cells.  
 
Aliquots of PS, AS and FT cell fractions were collected, washed and resuspended in 
chilled fluorescence-activated cell sorter (FACS) buffer (PBS supplemented with 0.5% 
FCS). All subsequent processes were performed on ice in order to prevent the modulation 
and internalization of surface antigens which can produce a loss of fluorescence intensity. 
Cells were counted and added into 96-well round-bottom plate (0.5 x 10
6 
cells in 200µl
 
FACS buffer/well) and washed twice by centrifugation at 2,000 rpm at 4
o
C for 3mins. 
After washing, cells were resuspended in 20µl (0.5 x 10
6
 cells) FACS buffer and stained 
with flurochrome conjugated antibodies (see Table 3.1) on ice for 30mins, unless stated 
otherwise.  
 
The identification of B cell subpopulations was based on the expression of defined 
surface markers CD20, CD27 and IgD, whereby unswitched naïve B cells are 
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CD20
+
/IgD
+
/CD27
-
, unswitched memory B cells are CD20+/IgD+/CD27+ and switched 
memory B cells are CD20
+
 IgD
-
/CD27
+
 (as mentioned in the Introduction). A summary 
of staining scheme in each cell fraction is demonstrated in Table 3.1. Firstly, the B cells 
linage was identified based on CD20 expression by incubating each cells fraction 
(PS/AS/FT) with directly conjugated R-phycoerythrin (RPE)-labelled mouse anti-human 
CD20 antibodies (2µl/0.5 x 10
6
 cells in 20µl total FACS buffer; Clone B-Ly1; R7014; 
DAKO, Tube 3).  
 
Additional classification was based on the expression of defined surface markers along B 
cells developmental pathway: (1) unswitched B cell were identified by staining the PS 
cell fraction with anti-IgD biotinylated monoclonal antibodies for 15mins and the 
biotinylated antibodies were detected by using Streptavidin-Flurescein isothiocyanate 
(FITC) (0.5µg/0.5 x 10
6
 cells in 20µl total FACS buffer; 554060; BD Pharmingen, Tube 
2); (2) unswitched B cells were also identified by staining the AS/FT cell fractions with 
Streptavidin–FITC (Tube 2); (3) memory B cells were identified by staining each cell 
fraction (PS/AS/FT) with direct conjugated PE-labelled mouse anti-human CD27 
antibodies (25ng/0.5 x 10
6
 cells in 20µl total FACS buffer; 555441; Clone M-T271; BD 
Pharmingen, Tube 4); (4) to further confirm that the positively selected IgD
+
 unswitched 
B cells expressed the pan B cells marker, CD20, each fraction (PS/AS/FT) was co-stained 
with CD20 and IgD (Tube 5); (5) to confirm that most of the memory B cells were 
eliminated after MACS enrichment for IgD
+
 B cells, each fraction (PS/AS/FT) was co-
stained with CD27 and IgD (Tube 6). This staining approach allows us to determinate the 
efficiency of isolation technique in sorted unswitched B cells (IgD
hi
, CD27
neg/low
, CD20
+
). 
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Tubes  1 
(control) 
2 
(IgD) 
3 
(CD20) 
4 
(CD27) 
5 
(IgD/CD20) 
6 
(IgD/CD27) 
Antibodies  Cell fraction 
Pre-sort fraction 
Biotin-IgD - + - - + + 
Strep-FITC - + - - + + 
CD20-RPE - - + - + - 
CD27-PE - - - + - + 
After-sorted fraction 
Biotin-IgD - - - - - - 
Strep-FITC - + - - + + 
CD20-RPE - - + - + - 
CD27-PE - - - + - + 
Flow through fraction 
Biotin-IgD - + - - + + 
Strep-FITC - + -        - + + 
CD20-RPE - - + - + - 
CD27-PE - - - + - + 
 
Table 3.1. Scheme for purity check by FACS analysis on three different cell 
fractions. 
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After incubation with the relative antibody combinations as in Table 3.1, cells were 
washed twice in FACS buffer and stained cells were resuspended in 500µl of chilled 
FACS buffer and placed into Eppendorf tubes. In order to preserve light scattering signal 
and fluorescence intensity as well as maintain sufficient antigenicity for FACS, 2% 
paraformaldehyde (PFA) was added to the cells suspension. PFA is an aldehyde fixative 
which creates crosslinks between amino acid residues or between proteins. Addition of 
PFA was performed on ice followed by vortexing to prevent cells clumping. Fixed cells 
were stored in the dark at 4
o
C overnight prior to flow cytometric analysis. On the day of 
analysis, fixed cells were transferred into 5ml polypropylene round-bottom tubes (Becton 
Dickinson) and analyzed using a FACSCalibur flow cytometer and CellQuest software 
(BD Biosciences) and FlowJo Cytometry Analysis Software. Initial gating was set 
according to forward and side light scatter to exclude dead cells from the analysis and at 
least 10,000 events were counted for each sample. Spectral overlap between the 
fluorochromes was compensated electronically by single colour control samples. The 
purity of the isolated B cells was ≥97% IgD+, and was used for subsequent in vitro work. 
3.2.3 Stimulation of IgD
+
 B cells 
In preliminary experiments, increasing density (1-2 x 10
6
 cell/ml per well) of unswitched 
B cells (IgD
hi
, CD27
neg/low
, CD20
+
) were seeded into 24-well plate and cultured in 
DMEM supplemented with 10% FCS, 50 IU/ml penicillin-streptomycin, 10mM HEPES 
buffer.  Cells were stimulated with a combination of 1µg/ml recombinant human BAFF 
(310-13; Peprotech) and 100ng/ml recombinant human IL-4 (554605; BD Pharmingen). 
After 24, 48 and 72h of stimulation, cell culture supernatants were collected into 
Eppendorf tubes, and pelleted at 2,000 rpm for 7mins on a benchtop centrifuge. 
Supernatants were then collected for subsequent ELISA analyses (i.e. secreted Ig 
subclasses) while pelleted cells were lysed in RLT buffer for studying AID expression. 
The cell density of 1 x 10
6
 cell/ml/well was chosen for subsequent culture or co-culture 
experiments as an adequate amount of Ig and transcripts were observed at this cell 
density, allowing meaningful comparisons.  
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For inhibition experiments using SLPI, each well containing 1 x 10
6
 IgD
+
 B cells/ml per 
well was incubated with increasing concentrations of recombinant SLPI at 10, 50 or 
500ng/ml (R&D 1274-PI) for 1h. B cells were subsequently treated with or without 
1µg/ml of BAFF and/or 100ng/ml IL-4. After 72h of incubation, cells were harvested in 
RLT buffer, supernatants collected for ELISA experiments, and mRNA extracted (for 
real-time PCR). 
3.3 Co-cultures of fibroblast with IgD
+
 B cells  
3.3.1 Co-culture of RASFs, OASFs and RADFs with B cells 
In study I (Chapter 4), all co-culture experiments were performed on ~90% confluent 
monolayers of fibroblasts. Cultured fibroblasts were detached from culture flask with 
0.25% Trysin-EDTA and re-suspended in DMEM complete culture medium. A cell 
density of 4 x 10
4 
cells/ml/well was seeded into 24-well plate at least 24h prior contact. 
On the day of co-cultures, medium was replenished with 700µl DMEM complete culture 
medium. 
 
Sorted unswitched B cells (IgD
hi
, CD27
neg/low
, CD20
+
) were washed twice in DMEM 
complete culture medium and added into 24-well plate with or without (control) 
fibroblast. In the case of studying direct cell-to-cell interactions, B cells (1x10
6
 
cells/300µl/well) were re-suspended in DMEM complete culture medium and added onto 
the fibroblast monolayers cultured in the presence or absence of 10µg/ml PIC. In the case 
of transwell studies, microporous PET cell culture inserts (1-µm pore, Beckon Dickinson) 
were employed. B cells were seeded in the cell culture insert and PIC treated or untreated 
fibroblasts were grown on the bottom of the culture well. The two separate populations 
were kept physically separated while allowing passage of macromolecules via the porous 
membrane of the cell insert. The co-culture experiments are outlined in Figure 3.4. B 
cells alone in the absence of fibroblasts were used as control to investigate the baseline 
expression of Ig and mRNA transcripts in the isolated IgD
+
 B cells. Cell-free 
supernatants and B cells were collected after 24h, 72h or 8 days. For gene expression 
profiling, B cells were pelleted and lysed in RLT buffer (Qiagen).  
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Figure 3.4 Diagram showing different conditions for RASF/B cell co-cultures.  
 
Co-cultures inserts are constructed of plastic sides with a microporous membrane on the 
base. The interaction between B cells and TLR-activated RASFs/RADFs/OASFs was 
studied either by: (1) direct cell-cell contact or (2) separating them via a transwell.  B 
cells cultured alone and stimulated with PIC or BAFF/IL4 served as a positive control. 
 
In study II (Chapter 5), co-culture experiments were performed in cell-cell contact 
manner. Fibroblasts (4 x 10
4 
cells/well) were seeded into 24-well plates and pre-treated 
for 1h with or without recombinant human SLPI (at a concentration of 50 and 500ng/ml) 
in the presence or absence of 10µg/ml PIC. After 1h of pre-incubation, B cells (1x10
6
 
cells/well) were added onto the fibroblast monolayer. Control co-cultures received no 
fibroblasts. Cell-free supernatants and B cells were harvested after 72h of co-cultures. As 
above, for gene expression profiling, pelleted B cells were lysed in RLT buffer (Qiagen). 
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3.3.2 Blockade of BAFF/APRIL signaling on B cells with anti-BCMA and 
anti-BAFFR neutralizing antibodies 
BAFF/APRIL dependent signaling in B cells was blocked using two different 
neutralizing antibodies: polyclonal goat anti-human BAFFR for neutralizing the 
interaction of BAFF to its specific receptor, and/or goat anti-human BCMA for 
neutralizing the interaction of both BAFF and APRIL to BCMA. The neutralizing 
antibodies (used alone or in combination) and their relevant goat IgG isotype control (all 
from R&D Systems) were used at 10µg/ml and incubated with B cells for 30mins before 
co-culture with RASFs and then throughout the experiment. This concentration of 
neutralizing antibodies was chosen based on the optimal response observed in 
preliminary experiments whereby BAFF/IL4 stimulated IgD
+
 B cells were seeded into a 
24-well plate and incubated with increasing concentrations of anti-BAFFR or anti-BCMA 
antibodies at 3µg/ml, 5µg/ml or 10µg/ml (data not shown). After 72h and 8 days of co-
culture, supernatants and cells were harvested as described above.  
 
3.4 mRNA analysis 
3.4.1 RNA isolation 
Total RNA was isolated using the RNeasy Mini kit (Qiagen) according to manufacturer’s 
instruction. General aseptic techniques were employed when handling RNA. Briefly, 
cells were disrupted with RLT buffer containing 350μl of guanidine isothiocyanate with 
an addition of 10µl of fresh β-mercaptoethanol (M7522; Sigma) per ml of RLT buffer. 
The suspension (cells in lysis buffer) was transferred into Eppendorf tubes and placed on 
benchtop (room temperature) for 5mins with occasional vortex. This step ensures a 
complete disruption of cell walls and plasma membranes of cells and organelles which 
promotes the release of RNA contained in the sample. The endogenous RNases can be 
inactivated by the β-mercaptoethanol. 
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An equal volume of 70% ethanol solution (in RNase-free Baxter water) as the lysis buffer 
was then added to the cell lysate and mixed thoroughly by pipetting several times in order 
to precipitate the RNA from the aqueous phase. An aliquot of sample (total 700μl) was 
added to the RNeasy mini column placed in a 2ml collection tube and centrifuged at 
10,000 rpm for 15sec. This step promotes selective RNA binding onto the silica-based
 
membrane in the spin column. Afterwards, the flow through was discarded and the 
column was washed once with 700μl RW1 buffer, and twice with 500μl RPE buffer. 
After each wash tubes were centrifuged at 10,000 rpm for 15sec and the flow through 
was discarded. The tube was then centrifuged again for 2mins at 10,000 rpm in order to 
dry the RNeasy silica membrane followed by another centrifugation at 14,000 rpm for 
1min to avoid ethanol carry over. For elution, the RNeasy column was transferred to a 
new RNase free 1.5ml collection tube and the RNA was eluted with 30μl of RNase-free 
dH2O, centrifuged at 10,000 rpm for 1min. Extracted RNA was immediately placed on 
ice for subsequent purity assessment and stored at -20
o
C until used.  
 - 152 -  
3.4.2 Quantification of total RNA  
RNA samples can be contaminated with chemicals, proteins, and other molecules that can 
inhibit or interfere with downstream applications such as reverse transcription 
polymerase chain reaction (RT-PCR). Spectrophotmetric measurement of the amount of 
ultraviolet light absorbed by nucleic acids at particular wavelength provides a simple, but 
accurate assay for determining the yield of RNA and the degree of salt, solvent or protein 
contamination during the process of RNA extraction. To assess RNA yield and purity, 
after elution, an aliquot of each RNA sample was placed onto a Nanodrop-1000 v. 3.2.1 
Spectrophotometer (Thermo Scientific) and absorbance was read at 260nm (RNA has its 
absorption peak at 260nm). The quantification of RNA content per sample is determined 
on the basis of optical density (OD) with 1 unit at 260nm corresponding to approximately 
40μg/ml of single-stranded DNA and RNA. For quality assessment, samples are read at 
280nm (proteins have an absorbance peak at 280 nm, mostly due to the presence of 
tryptophan residues). Pure preparations of RNA have a 260/280 OD ratio between 1.8 to 
2. 
3.4.3 Reverse transcription of RNA 
To generate complementary DNA (cDNA), reverse transcription reaction was performed 
using the Thermoscript RT-PCR System for first-strand cDNA synthesis kit (Invitrogen, 
11146-016). Generally, 9µl of the extracted total RNA was mixed with 2μl of 10mM 
dNTP Mix and 1μl of 50µM oligo (dT)20 first strand primer and brought to a final volume 
of 12µl with Baxter water in 0.2ml thin walled-nuclease-free PCR tubes. The 1X first-
strand PCR buffer mix was briefly mixed by centrifugation at 2,000 rpm for 1min before 
placing into a thermal cycle (GeneAmp PCR system 9700, Applied Biosystems) and 
heated at 65
o
C for 5mins to disrupt the secondary structure. Next, the reaction mixture 
was promptly chilled on ice to maintain RNA and oligos annealing. Subsequently, 
reverse transcription of RNA was performed in a total volume of 20µl reaction mix by 
adding 8μl of reverse transcriptase cocktail containing 4µl of 5X cDNA synthesis buffer, 
1µl of DTT (0.1M), 1µl of DEPC treated water, 1µl of Thermoscript Reverse 
 - 153 -  
transcriptase (15U/µl) and 1µl of RNaseOUT
TM
 ribonuclease inhibitor (40U/µl). Samples 
were briefly mixed by centrifugation before incubating at 50
o
C for 1h in the thermal 
cycle. The reactions were terminated at 85°C for 5mins in order to inactivate the reverse 
transcriptase. Because the presence of RNA can interfere with the quantitative real-time 
PCR analysis, samples that contained more than 500ng/µl of total RNA underwent RNA 
digestion with 1µl of E-coli RNaseH (2U/ µl) at 37°C for 20mins. Finally, the completed 
strand of cDNA was diluted with RNase-free Baxter water at a final concentration of 
10ng/μl of cDNA. All cDNA samples were stored at -20°C until used. 
3.4.4 Detection of circular transcripts (CTs) by semiquantitative PCR 
Detection of Iγ1/2-Cμ and Iα-Cμ CTs were performed as previously described with minor 
modifications [152]. Briefly, 20ng cDNA (10ng/µl) were mixed with 0.5U Taq DNA 
Polymerase buffer (MP biomedicals) , 200μM dNTP mix, 1.5mM MgCl, 5pmol/ml of the 
reverse (Cμ) primer, 5pmol/ml of forward Iγ1/2 primer or 2.5pmol/ml of forward Iα 
primer (all from Invitrogen) and the final volume of each reaction was adjusted to 20µl 
with sterile Baxter water. Each reaction was mixed thoroughly before transferring into 
the thermal cycle. The standard PCR condition consists of an initial denaturation step at 
94°C for 5mins, followed by three steps amplification cycle constiting of 
denaturing/annealing/extension at temperature varying among the different set of primers 
used. Primers sequences and PCR conditions are summarised in Table 3.2 and Figure 3.5 
and 3.6. After the final cycle of PCR amplification the reaction mixs underwent a final 
extension at 72°C for 5mins before chilling on ice.  
 
PCR products were analysed by agarose gel electrophoresis..Agarose gel (1%) in 1X Tris 
Acetic acid EDTA (TAE) buffer was prepared by boiling in microwave oven for 1.5 
minutes, followed by addition of 0.5μg/ml ethidium bromide (a dye that binds to nucleic 
acid and emits fluorescent light upon UV stimulation). The solution was then poured into 
a minigel tray where a well-comb was inserted. After polymerizaion, the gel was placed 
into a minigel tank soaked with 1X TAE buffer. Samples were first mixed with blue 
loading dye (dilution of 1:6) to monitor the migration of DNA bands and then were 
loaded into appropriate wells and run at 120V for 30mins. 0.3µg PCR marker (N324, 
 - 154 -  
New England Biolab) was mixed with loading dye (1:1) and loaded into one well of the 
gel in order to estimate the molecular weight of DNA bands. DNA bands were visualised 
under UV light and photographed with Bio-Rad Gel 1000.    
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Figure 3.5. Diagram showed an optimised cycling number for CT Iγ 1/2- Cμ 
(indicating ongoing class-switching from IgM to IgG1/2).  
 
Tonsil, but not RASFs RNA extracts (negative control) expressed CT Iγ 1/2- Cμ. 
Highlighted bands indicate CT Iγ 1/2- Cμ (500 bp) amplified from total tonsillar cells at 
40 cycle which appeared as 2 strong and specific bands representing alternative CSR to 
IgG1 or IgG2. 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Diagram showed an optimised cycling number for CT Iα-Cγ (indicating 
ongoing class-switching from IgG1/2 to IgA). 
 
Tonsil, but not RASFs expressed CT Iα-Cγ. Highlighted band indicates CT Iα-Cγ (502 
bp) amplified from tonsil total RNA extracts after 33 cycles of amplification and 
provided the most specific PCR product compared to 35 and 37 cycles of amplification. 
RASFs did not show any specific band. 
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Table 3.2. List of primers and PCR conditions used to detect circular transcripts. 
Name Primer forward and reverse sequence 
PCR conditions (°C) 
denaturing/annealing/extension 
PCR conditions 
(cycles) 
Amplicon 
size (bp) 
 
Cμ (reverse) 
 
5’-GTTGCCGTTGGGGTGCTGGAC-3’ 
   
 
Iγ1/2 (forward) 
 
5’-GGGCTTCCAAGCCAACAGGGCAGGACA-3 
 
94/60/72 
 
94°C, 1 min 
60°C, 1 min 
72°C, 1 min 
 
40 
cycles 
 
502 
[Iγ1/2-Cμ] 
 
 
Iα (forward) 
 
 
5’-CAGCAGCCCTCTTGGCAGGCAGCCAG-3’ 
 
 
94/58/72 
 
 
94°C, 20 sec 
 
 
3 
cycles 
 
 
666 
[Iα-Cμ] 58°C, 20 sec 
72°C, 1 min 
 
94°C, 1 min 30 
cycles 58°C, 1 min 
72°C, 1 min 
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3.4.5 Gene expression analysis by quantitative real-time PCR (QT-PCR)  
To determine the relative expression levels of a specific gene product, quantitative real-
time PCR (QT-PCR) was performed on cDNAs obtained as in 3.4.3. According to the 
content of RNA obtained, 10ng of cDNA (but sometimes varying depending on the gene 
expression level of the target gene) was used in each PCR reaction to determine the levels 
of BAFF, BAFFR, APRIL, SLPI, IL-10, AID and TLR3 (Table 3.3). The gene expression 
profiling of QT-PCR was performed using 20x sequence-specific Taqman primers and 
probes diluted in 2x AmpliGold PCR master mix (Applied Biosystems, cat no: 4304437).  
PCR was performed in 384-well plates (Applied Biosystems) and for each well the final 
volume was adjusted to 10µl with sterile Baxter water. The PCR plate was sealed and 
centrifuged for 2min at 1,000 rpm to remove any air contamination. Afterwards, real-time 
PCR (Taqman) assay was performed in an ABI PRISM 7900HT Sequence Detection 
System Version 2.3 (SDS 2.3).  
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Table 3.3. List of Taqman primers and probes used for real-time PCR 
 
 
 
Gene  RefSeq ABI Gene expression Assay ID 
 
AID 
 
NM_020661 
 
Hs00221068_m1 
APRIL NM_003808 Hs00182565_m1 
BAFF NM_006573 Hs00198106_m1 
BAFFR 
BCMA 
SLPI 
NM_052945 
NM_001192 
NM_003064 
Hs00606874_g1 
Hs00171292_m1 
Hs00268204_m1 
TLR3 
Human 18S 
Human β actin 
 
NM_003265 
X03205.1 
NM_001101 
Hs00152933_m1 
Hs99999901_s1 
Hs99999903_m1 
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The Taqman PCR reaction exploits a 5’ nuclease activity of the DNA polymerase which 
binds with the primer, resulting in cleavage of the Taqman MGB (minor groove binder) 
probe. Within the probe, a FAM reporter dye is conjugated at the 5’ end and linked to a 
non-fluorescent quencher at the 3’ end. During the reaction, cleavage of the probe allows 
the separation of the reporter dye from the quencher, resulting in increased fluorescence 
signal. Therefore, the fluorescence emitted during the reaction is directly related to the 
amount of specific amplicon generated during each cycle (in real time). This approach is 
opposed to the endpoint detection by the conventional quantitative PCR methods. The 
result generated from the real-time reaction is based on the detection and quantification 
of a fluorescence reporter where the increased fluorescence signal is directly proportional 
to the amount of PCR produced in the reaction. The thermal cycling condition consists of 
an initial UNG activation at 50
o
C for 2min and a Taq polymerase enzyme activation step 
at 95
o
C for 10min, followed by 45 amplification cycles consisting of denaturation at 95
o
C 
for 15sec and primer annealing and extension at 60
o
C for 60sec with fluorescence 
acquisition during each annealing and extension stage.  
 
Where appropriate, the constitutively expressed human housekeeping genes 18S and 
beta-actin were used as internal controls for normalization. Tonsil cDNA was used as 
positive controls in each experiment, while RNAase-free dH2O was used as negative 
control. A threshold cycle (CT value) was obtained from each amplification curve for 
relative quantification (Comparative CT Method). Relative mRNA expression analysis 
(calculations of the fold difference of a gene-of-interest) was conducted
 
where the 
amount of target, normalised to an endogenous reference gene (18S/beta actin) and 
relative to the control sample (usually untreated sample in each different time point), was 
given by 2
−ΔΔCT
. The amount of target and endogenous genes were first calculated from 
an average of triplicates, and a deltaCt (ΔCt) value was then obtained by substracting the 
average Ct of the endogenous control from the averaged Ct value of the target gene. 
Thereafter, a ΔΔCt value was calculated by subtracting a chosen reference sample (as 
calibrator) from the ΔCt value of each sample. The relative quantification was then 
calculated from using the equation RQ=2
−ΔΔCT
, where 2 represents doubling of the 
amount of the PCR product after each cycle of amplification.  
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3.5 Protein analysis 
3.5.1 ELISA for human immunoglobulin 
Total IgA, IgG and IgM were detected using the Human IgA/IgG/IgM ELISA 
quantitation set (Bethyl laboratories) according to manufacturer’s instructions, with 
minor modifications.  
 
ELISA is a sensitive and specific method for quantification of antibodies or antigens 
present in cell culture supernatants, serum, plasma etc. The ELISA used for the 
determination of human Igs is based on an indirect detection method. Briefly, a 96-well 
flat bottom polystyrene plate was coated with 100µl of individual capture antibody 
specific for the relevant antigen of interest (IgA or IgG or IgM) diluted 1:100 in coating 
buffer and incubated overnight at 4
o
C. On the next day, the coating buffer was removed 
by decanting and coated plates were washed three times with TBS, 0.05%Tween-20 
(TBS-T), pH 7.6. At the last wash, residual solution was removed by inverting the plate 
and blotted it against a clean paper towel. Afterwards, each well was blocked with 100µl 
of 1% BSA in TBS for 30 min at room temperature. The blocking step not only reduces 
the background noise by inhibiting non-specific binding to uncoated regions of the plate 
and “sticky” sections of the absorbed protein, but also stabilises the antigenic and 
functional regions of the adsorbed protein. After incubation, the blocking solution was 
removed and the plate was washed five times with TBS-T. After washing 100µl of each 
supernatant at 1:4 dilutions and of serial dilutions of the appropriate standards for the 
calibration curves were added to the appropriate wells and incubated at room temperature 
for 1h. Standards and test samples were diluted in 1%BSA in TBS, 0.05%Tween-20. 
Both standards and samples were done in duplicate.  
 
After incubation and 5 washes, 100µl of the relevant HRP-conjugated detection 
secondary antibody was applied to each wells and incubated for 1h at room temperature 
in the dark. The HRP conjugate antibody was used at the following concentrations: 
1:20,000 for IgA; 1:50,000 for IgG; 1:20,000 for IgM. After five washes, 100µl of 
chromogenic substrate TMB (mixture of equal volume of two substrate-reagents) was 
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added to each well and incubated at room temperature in dark. Plates were allowed to 
develop at room temperature (with developing times varying among different Ig isotypes) 
and the enzymatic reaction stopped upon the addition of 100µl/well of 2M H2SO4. The 
OD of each well was determined by measuring the absorbance wavelength of 450nm 
using an ELISA plate reader (Genio).  
 
Standard curves were generated using reference serum containing a known concentration 
of antibodies. Each standard was diluted to concentrations of 500ng/ml, 250ng/ml, 
125ng/ml, 62.5ng/ml, 31.25ng/ml 15.63ng/ml, 7.8 ng/ml and 0ng/ml, defining a variable 
reference curve. A third-order nonlinear polynomial regression curve was fitted to 
characterise the relationship between OD and standard dilution (Graphpad Prism) and 
only curves with r
2
 values of ≥0.99 were used in subsequent analyses. Ig concentrations 
were determined by reading sample dilutions that fell within the standard curve. The 
resulting value was multiplied by the dilution factor of the sample to correct for the final 
concentration. 
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3.5.2 ELISA for BAFF, APRIL and SLPI 
In study I (Chapter 4), the cell-free supernatant was collected from each well of 24 
wells plate for the analysis of soluble BAFF and APRIL protein concentrations which 
were measured using the Quantikine human BAFF/BLyS/TNFSF13B (R&D Systems) 
and the human APRIL (eBioscience) ELISA kits, respectively.  
 
In study II (Chapter 5), the cell-free supernatant were collected from each well of 6-
wells and soluble SLPI protein concentration was analyzed using the human SLPI 
Quantikine ELISA Kit (R&D Systems). All ELISAs were performed following the 
manufacturers’ instructions. 
 
Known standards curves were included for each determination, and concentrations of 
BAFF, APRIL and SLPI in culture supernatants were estimated
 
by third-order nonlinear 
polynomial regression analysis. The resulting value was multiplied by the dilution factor 
of each sample (according to kit instructions) to correct for the final concentration. 
3.5.3 Flow cytometry 
3.5.3.1 FACS analysis for membrane-bound BAFF in RASFs 
RASFs were seeded into 24-wells plate and treated with 10µg/ml of PIC or left untreated 
(4 wells per each treatment) when cells reached 90% confluency. After 24h incubation, 
supernatants were removed from adherent culture cells and the cells were washed twice 
with magnesium-calcium-free ice cold PBS and then detached by exposure to cold 
Versene (EDTA solution with PBS, 200μl per well) for 10min at 37oC. Cells from each 
of the 4 wells with identical treatment were pooled together for subsequent FACS 
profiling. Cells were regularly vortexed in order to keep them in single cell suspension. 
Cells were then washed twice and pelleted by centrifugation (5min at 1,500 rpm, 4
o
C) in 
cold FACS buffer containing PBS + 2%FCS. Subsequently, cells were blocked with 1% 
goat serum in FACS buffer on ice for 20min. Following two washes, the cells were 
resuspended in cold FACS buffer, equally divided (100μl each) and transferred into a 5ml 
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polystyrene round-bottle tube. The tube was centrifuged at 15,000 rpm for 5min. Cell 
pellets were resuspended in cold FACS buffer and incubated with primary antibody 
(100μl, 2μg/ml) on ice for 1h: rabbit anti-human BAFF polyclonal antibody (Buffy-2, 
Abcam), or irrelevant rabbit antibody control (Santa Cruz) . Cells were then washed 
twice and incubated with RPE-labelled goat anti-rabbit Ig (100μl, 1μg/ml) for 30 min on 
ice in the dark. Mouse anti-human ICAM-1 conjugated with PE (eBioscience) was used 
as a positive control for membrane-bound staining. Additional controls (irrelevant RPE-
labelled goat anti-rabbit Ig) were run in addition to the unstained control (to correct for 
cell autofluorescence) in order to evaluate the non-specific binding of the secondary 
polyclonal antibody to dead or sticky cells. After washing, samples were fixed with 2% 
PFA and stored in the dark until samples were run using the FACSCalibur flow 
cytometer (BD Biosciences) and analysed with the FlowJo Cytometry Analysis Software. 
An overflow of the staining scheme is shown in Table 3.4.  
 
Table 3.4. An overflow of staining scheme for membrane BAFF and ICAM-1. 
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3.5.4 Western blot analysis for BAFF and APRIL protein expression 
Western blot is a technique which allows detection of specific proteins in complex 
samples according to the size of the protein. It uses gel-eletrophoresis from tissue/cell 
protein extracts to separate native or denatured proteins followed by transfer into 
membranes for immunodetection of relevant target proteins using specific antibodies. 
3.5.4.1 Total cell protein extraction 
RASFs and RADFs were seeded into 6-well plates and half of each plate (total of 3 wells) 
was either treated with 10µg/ml of PIC or left untreated. After treatment, culture 
supernatants were collected at indicated time points and maintained at -20
o
C for 
subsequent ELISA (BAFF, APRIL and SLPI, see relevant sections) while adherent cells 
were used for protein extraction. All procedures were performed at 4ºC using pre-cooled 
reagents. Briefly, cells were rinsed twice with ice-cold PBS and whole cells lysates were 
prepared on ice by adding 200μl fresh disruption buffer/sample [50mM Tris (pH8), 
150mM NaCl, 1% Nonidet P-40 (NP-40), 5mM sodium fluoride (NaF), 2mM EDTA, 
2mM phosphatase inhibitors (Phosphatase inhibitor cocktail set II, Calbiochem), 1X 
protease inhibitors (Complete Mini protease inhibitor cocktail, Roche)]. Each sample 
(one single sample was considered by pouring 3-wells of cell lysate from each treatment) 
was disrupted with a soft cell scraper, transferred into 1.5ml centrifuge tube and lysed on 
ice for 1h with frequent vortexing and pipetting. Subsequently, the cell lysate was spun at 
4
o
C for 15min at 15,000 rpm. The recovered supernatant was aliquoted, labelled as 
cytosol fraction (total whole cell lysate) and stored at -80
o
C. The remaining pellet mainly 
containing nuclear fractions was discarded.  
 
Total tonsil cells were used as positive control. The cells were lysed similarly as above 
with the exception that cells were lysed with 40μl of ice cold RIPA buffer every 2 x 106 
cells.  
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Table 3.5. List of components of the lysis buffer used for protein extraction and 
their functions. 
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3.5.4.2 Protein quantification (BCA protein assay) 
Protein concentration was determined using the Peirce BCA (bicinchoninic acid) Protein 
assay (Thermo Fisher Scientific) according to manufacturer’s instruction. Briefly, in 
order to calibrate the standard curve, bovine serum albumin (BSA, 2 mg/ml) standards 
were prepared at serial concentrations of 0, 0.025, 0.125, 0.25, 0.5, 0.75, 1, 1.5, 2mg/ml 
with the same disruption buffer as in the cell lysate. The cell lysate samples were 
prepared at three differention dilutions (ratios of 1, 1:3 and 1:9) with disruption buffer 
and added at 10μl/well to a 96-well plate. Next, 200μl of BCA working reagent was 
added to each well and the plate was covered and incubated at 37
o
C for 30 min.  
Absorbance reading at 560nm was measured using a spectrophotometer (Tecan Genio). A 
standard curve of absorbance versus micrograms of protein was then used to quantify the 
amount of protein in each lysate.  
 
3.5.4.3 Immunoblotting 
3.4.4.3.1 Electrophoresis 
Equal amounts of proteins (max 40 g/lane) were diluted with 5x Lammeli loading buffer 
[10% SDS, 7.7% dithiothreiotol, 10% glycerol, 0.44M Tris (pH 6.8), 0.04% bromophenol 
blue] and boiled for 5min at 95
o
C for protein denaturation. Lysates were then mixed by 
brief vortexing and microcentrifugation. Samples were subsequently resolved by 
Polyacrylamide (13% acrylamide) gel electrophoresis (SDS-PAGE), composed of a 
stacking gel, comprising of 5% acrylamide mix, 0.125M Tris pH6.8, 0.1% SDS, 0.1% 
ammonium persulfate (APS), 0.1% TEMED, and a resolving gel, comprising of 13% 
acrylamide mix, 0.375M Tris pH 8.8, 0.1% SDS, 0.1% APS, 0.04% TEMED, in which 
proteins are separated according to their molecular weight (the length of polypeptide).  
The polyacrylamide gels are formed by polymerization of monomeric acrylamide into 
polymeric polyacrylamide chains with crosslinking of the chains by N-N’ 
methylenebisacrylamide. The upper (low percentage 5%) stacking gel consists of large 
pore where the protein were quickly concentrated onto the bottom of the wells and the 
lower (high percentage 13%) resolving gel, with smaller pore size was where the protein 
separated. The acrylamide concentration utilised was selected according to the molecular 
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weight of the protein being tested. Generally, a low percentage gel is selected for 
resolving high molecular weight proteins. The above 13% resolving acrylamide was 
optimised for human BAFF (32 and 17 kDa) and APRIL (30 and 17 kDa). 
 
As proteins have different electrical charges that affect their mobility, the SDS in the 
samples and buffers confers a negative charge to all protein which ensure that all the 
protein migrate through gel pores toward the positively charged anode when placed under 
an electrical field. SDS was also used to break up any remaining aggregates and non-
covalently bound multimers. For determination of the size of separated proteins, a protein 
ladder (Precision plus protein all blue standards, Bio-Rad) was loaded in the first well of 
each gel (8μl/well). Each gel contained appropriate positive controls consisting of tonsil 
total cell lysates and 2ng human BAFF (Peprotech). The Bio-Rad electrophoresis 
chamber was then immersed in Tris-glycine electrophoresis buffer (see appendix for 
details), covered and electrophoresis was accomplished at 100V for 2hr at room 
temperature. 
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3.4.4.3.2 Transfer of protein to PVDF membrane 
After separation, protein were transferred onto polyvinylidenfluoride (PVDF) 
microporous membrane (Immobilon-P, Millipore) by “wet transfer” in transfer buffer 
(see appendix for details) by utilizing a Bio-Rad-Tank. Methanol in the buffer system is 
necessary to achieve efficient binding to the PVDF membranes, possibly by decreasing 
the SDS affinity to immobilised proteins. The Immobilon-P membrane required a pre-
treatment step by soaking in 100% methanol for 1-2min, followed by equilibration of the 
membrane for at least 5min in the transfer buffer before the transfer of proteins. Briefly, 
the gel was carefully removed from its running cassette, thereafter, the gel and methanol 
soaked PVDF membrane were assembled together ensuring that no air bubbles were 
found between the gel and the membrane. Next, the gel/membrane was sandwiched 
between filter paper and blotting pads and assembled within the blot module that was 
tightly locked in the cell. The inner buffer chamber was fully filled up with transfer 
buffer and the outer chamber was half-filled with transfer buffer. Finally, the transfer of 
protein was carried out at 150V for 2hr in a cold room at 4
o
C. The correct transfer was 
verified by the colorisation of the membrane with Ponceau red solution (0.2% Ponceau S 
in 3% trichloroacetic acid) for 1-2 min and followed by several rinses with deionised 
water to reveal transferred proteins as multiple bands. Due to its property as a negatively 
charged dye, Ponceau S binds to the positively charged amino groups of the proteins, 
resulting in a clear background and red protein bands. This staining technique is 
reversible allowing downstream immunological detection by immunoblotting. This 
technique has a sensibility of 250ng of protein after separation by eletrophoresis in 
polyacryamide gels and transfer to PVDF membrane.  Before immunoblotting, each 
membrane was blocked using 2.5% milk powder in wash TBS-T buffer comprising 
0.05% tween-20 in TBS (20mM Tris base, 150mM NaCl in deionised water, pH7.5) for 
at least 30min at room temperature, placed on a rocking platform, and subsequently 
stored overnight at 4
o
C in blocking buffer to minimise non-specific bindings.  
3.5.4.3.3 Immunostaining for BAFF and APRIL protein detection 
For primary antibody incubation, membranes were inserted into 50 ml falcon tubes 
containing 10ml of TBS-T, 2.5% milk power, and incubated on a roller for 2hrs with the 
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following primary antibodies: 0.5μg/ml rabbit anti-human BAFF polyclonal antibodies 
(Abcam), 0.05μg/ml mouse anti-human APRIL polyclonal antibodies (Aprily-5, Enzo 
Life Science). Afterwards, membranes were extensively washed 6 times for a total of 1h 
in TBS-T and subsequently incubated with secondary antibodies conjugated with HRP, 
diluted in TBS-T/2.5% milk power solution for 1h at room temperature. The following 
secondary antibodies were used at a concentration of 1:1000: goat anti rabbit polyclonal 
antibodies (for BAFF) and goat anti mouse polyclonal antibodies (for APRIL, HAF008 
and P0447, respectively, both from R&D system). After further 6 washes, the protein 
bands were finally detected using enhanced chemiluminuescence (ECL) Western blotting 
detection reagents (GE Healthcare) according to the manufacturer’s instructions. The 
signals were exposed and detected, under red light, by the exposition of autoradiography 
film, Hyperfilm ECL (GE Healthcare) using Fuji C-ray processor for appropriate 
exposure times. The film was then serially washed in Developer and Fixer buffers. If 
proteins of interest were present, a black band would appear on the film. The stained 
membrane was then stored in humid chambers with TBST at 4
o
C protecting from light 
for subsequent stripping and re-probing. Alternatively, the blot could also be placed 
inside an air-tight plastic bag at room temperature in the dark as an alternative method for 
long term storage. 
3.4.4.3.4 Stripping of western blot 
The process of stripping was used to remove the primary and secondary antibodies from a 
western blot membrane. Therefore, the blot could be reused by stripping and re-probing with 
an anti-human beta-actin antibody. Stored membranes were firstly soaked in TBS-T and then 
washed 3 times under agitation for at least 30min at room temperature. Afterwards, the 
membrane was re-blocked with 2.5% milk power for 15min under agitation at room 
temperature. The membrane was then submerged in a pre-warmed (50
o
C) stripping buffer 
(100mM 2-meracaptoethanol, 2% SDS, 62.5mM Tris HCl, pH6.7), and incubated for 30 
minutes at 50
o
C in a water-bath, with occasional shaking. The blot was washed 
extensively in TBS-T 3 times (15mins each) and was then probed with mouse anti-human 
beta-actin monoclonal primary antibody (Sigma, A2228) diluted 1:5000 in TBST. After 6 
washes for a total of 1h at room temperature, the membrane was incubated with 1:1000 
goat anti-mouse polyclonal antibodies conjugated with HRP (P0447, R&D system), 
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diluted in TBS-T/2.5% milk power solution for 1h at room temperature. Subsequently, 
the blot was detected as mentioned above. 
3.5.5 Immunocytochemistry 
Immunocytochemistey is a technique which allows direct visualization of specific 
antigens in the cultured cells by the use of antibodies conjugated with enzymes or 
fluorescent dyes. 
3.5.5.1 Detection of BAFF, APRIL and SLPI expression in fibroblasts using 
immunocytochemistry 
Fibroblasts were seeded at 5x10
4
 cells/200µl onto cover slides. They were placed onto 
petri-dish covered with lid to prevent evaporation and allowed to grow to 90% 
confluence before treatment. Cells were stimulated with 10µg/ml PIC or left untreated. 
After 24h (for BAFF and APRIL detection) or 72h (for SLPI), adherent cells were 
washed in PBS and fixed and permeabilised with ice-cold 1:1 acetone/methanol for 
15mins if staining was performed on the same day, or stored in coplin jar containing the 
above fixative at -20
o
C until used. Staining scheme is outlined in Figure 3.7. 
 
 
 
Figure 3.7. Diagram showed a staining design on a coverslide.  
 
Adherent fibroblasts were treated with 10µg/ml PIC or medium only. Immunochemical 
staining for BAFF, APRIL or SLPI on PIC-treated fibroblasts was done in triplicates. 
Untreated fibroblasts served as control. As negative control, respective isotype antibodies 
were employed. 
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To ensure immobilization of antigens on the target cells while retaining authentic cellular 
and subcellular architecture, the cells undergo adequate fixation. A mixture of two 
organic solvents was chosen, acetone and methanol, which are both recognised as 
dehydrating agent and thus they compete with water for protein hydrogen bond. This 
preserves cellular architecture by fixing proteins via precipitation/coagulation. In an 
attempt to gain advantages of both reagents, acetone, which is a gentler fixative and 
methanol, which is a better fixative, were mixed 1:1 (vol: vol) and used at -20
o
C. Both 
fixatives can also dissolve lipids from cell membrane making them permeable to 
antibodies allowing free access of antibodies for binding to their specific antigens. On the 
day of staining, slides were removed from the coplin jar and excess fixative was flicked 
off before placing promptly into a humidified chamber, thus preventing cells from drying 
out. Afterwards, each well on the coverslide was encircled with a PAP pen hydrophobic 
marker before soaking the slide in TBS containing-coplin jar for 5mins under agitation. 
Labelled StrepAvidin-biotin immunohistochemical (LSBC) method was applied for 
amplifying staining signals based on high affinity binding effect of biotin (a low 
molecular weight vitamin H) for avidin (a large glycoprotein). This technique involves a 
three steps staining procedure: the first layer is an unlabeled primary antibody, the second 
layer consists of a biotinylated secondary antibody and the third layer is a complex of 
StrepAvidin-biotin conjugated with a fluorescent dye. Signals are amplified using this 
system because several biotins are conjugated to antibodies and each biotinylated residue 
can bind to more than one molecule of streptavidin, as illustrated in Figure 3.8. 
 
 
 - 172 -  
 
Figure 3.8. Diagram showed the use of biotinylated antibodies to amplify 
immunocytochemcial reactions by Labelled StrepAvidin-biotin 
immunohistochemical (LSBC) method.  
 
(1) The first step of the procedure is to incubate the section with primary antibodies 
raised against the antigen of interest; (2) Next,  biotin-labelled secondary antibodies are 
added; (3) In the last step of the procedure, the antigen is localised by incubation with 
streptavidin conjugated with a fluorescent dye . 
 
 
 
B 
B 
(1) Unlabelled 
primary antibody  
Antigen  
(2) Biotinylated        
secondary antibody 
- Many biotin molecules can be 
attached to a single molecule of 
protein  
(3) Fluorescent dye-
Streptavidin 
- The biontinylated protein 
can thus bind to more than 
one molecule of streptavidin   
Signal amplification 
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Because cells may contain endogenous biotin resulting in autofluorescence, a blockage 
step is essential and can be performed by pre-treating the cells with unconjugated avidin 
followed by saturating the remaining avidin binding site with free biotin (avidin-biotin 
block).  For this purpose, before primary antibody incubation, fixed cells were depleted 
of endogenous biotin using a commercial avidin-biotin blocking kit (Vector laboratory). 
Briefly, slides were incubated for 10mins with unconjugated avidin to block endogenous 
biotin; after washing, slides were incubated for 10mins with unconjugated biotin moieties 
to block the remaining biotin-binding activity of the avidin molecule. Slides were then 
washed three times with TBS under gentle agitation after each blockage step for 5mins 
each. To inhibit non-specific binding, slides were further incubated for 10mins with 
DAKO serum-free protein block. This solution contains casein, a hydrophilic protein 
which is more effective than the classic normal serum block. Any excess protein block 
was flicked off and wiped away with tissue paper. Without any washing step, cells were 
then incubated with rat anti-human BAFF (Buffy-2, Enzo Life Sciences) or mouse anti-
human APRIL (Aprily-2, Enzo Life Sciences) or their respective isotype controls at 
10μg/ml for 1h at RT. Goat anti-human SLPI (R&D) or its respective isotype control 
were applied at 4μg/ml for 1h at RT.  After the primary antibody reaction, the slides were 
washed and appropriate biotinylated antibodies (donkey anti-rat, Serotec, for BAFF, 
rabbit anti-mouse, Dako, for APRIL, both at 3μg/ml or rabbit anti-goat, Dako, for SLPI at 
2μg/ml) were added for 1h at RT. Primary and secondary antibodies were all diluted in 
DAKO Antibody Diluent (S3022, DAKO). Afterwards, slides were washed and 
incubated for 30mins in the dark with Strepavidin ALEXA 555 at 1:100 dilution, 
(detected on the TRITC channel, for BAFF and SLPI) or Strepavidin ALEXA 488 at 
1:300 dilution (detected on the FITC channel for APRIL) followed by three washing 
steps. For nuclear counterstaining, cells was incubated in the dark with DAPI (1:1000 
dilutions) for 10mins and rinsed with TBS for 10mins under gentle agitation. The cells 
were mounted in an aqueous-based anti-fading mounting medium
 
Mowiol 4-88 reagent 
(Calbiochem, cat no: 475904) with a coverslip for preservation of the fluorescence tags. 
Slides were then examined under an Olympus BX60 microscope.  
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3.5.5.2 Detection of membrane-bound BAFF and ICAM-1 expression in fibroblasts 
using confocal microscopy 
Fibroblasts were seeded at 5x10
4
 cells/200µl onto cover slides and grown to 90% 
confluence. Cells were then stimulated with 10µg/ml PIC or left untreated. After 24h, 
cells were washed in PBS and fixed using 4% paraformaldehyde (PFA) at RT for 10mins. 
PFA is a non-permeabilizing cross-linking reagent which forms intermolecular bridges 
via free amino acid residues, thus creating a network of linked proteins. After three 
washing in TBS, unreacted aldehyde can be quenched by incubating slides with 0.1M of 
amino-containing reagent, glycine, for 10mins at room temperature in order to reduce 
free aldehyde groups of PFA. This can effectively lower the fluorescent signal to noise in 
the staining. After further washing, slides were blocked with avidin-biotin blocking kit 
(Vector laboratory) intercalated by washes with 0.1% BSA in TBS, for 10mins each at 
RT. Slides were then incubated with rat anti-human BAFF (Buffy-2, Enzo Life Sciences) 
followed by a rabbit anti-rat biotinylated antibody (DAKO, 1:300) and streptavidin Alexa 
488 (Invitrogen). In selected stainings, in order to colocalise membrane-bound BAFF, a 
mouse anti-human ICAM-1 antibody conjugated with PE (eBioscience) was added at 
1:100 dilutions after BAFF staining. Slides were analysed with a Leica DM5500Q 
confocal microscope (Leica, Wetzlar, Germany).  Matching isotype controls were used at 
the same concentration to exclude non-specific staining. As above, all antibodies were 
diluted in DAKO Antibody Diluent and all incubation steps were performed at RT in a 
humidified chamber. 
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3.6 Statistical Analysis 
Differences in quantitative variables were analysed by the Mann Whitney U test when 
comparing 2 groups and by Kruskal-Wallis with Dunn’s post test when comparing 
multiple groups. Wilcoxon’s signed-rank test was used to analyse repeated measurements 
at different time-points. All analyses were performed using GraphPad Prism version 5.01, 
GraphPad Software, USA. A p value <0.05 was considered statistically significant. 
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CHAPTER 4 
Results 
A BAFF/APRIL-dependent TLR3-stimulated pathway 
enhances the capacity of rheumatoid synovial 
fibroblasts to induce AID expression and Ig class-
switching in B cells 
 
In this part of my PhD project, I demonstrated that signaling between TLR3 and B cell 
survival factors (BAFF and APRIL) enables autoreactive B cell activation by RASFs: i) 
BAFF and APRIL were produced by RASFs at mRNA and protein level; ii) BAFF and 
APRIL were induced by TLRs, particularly TLR3; iii) these cytokines displayed dynamic 
gene expression (early vs. late gene induction) upon TLR stimulation; iv) RASFs-derived 
BAFF and APRIL were required for inducing functional B cell activation (AID, IgG/A/M 
production), v) interfering with signaling through both BAFFR and BCMA on the B cell 
surface downregulated these processes in the activation of functional B cells. 
4.1 TLR3-stimulated induction of BAFF and APRIL mRNA in RASFs, 
OASFs and RADFs 
 
I first examined whether stimulation of synovial fibroblasts from OA and RA patients (to 
dissect disease specificity) as well as paired RA dermal fibroblasts (to investigate site 
specificity) with TLR ligands was capable of inducing mRNA expression of BAFF and 
APRIL. Since others and I have shown that TLR2, TLR3 and TLR4 are strongly 
expressed on RASFs and OASFs [360], I focused on specific ligands for these receptors 
using optimal concentrations as previously established [110]. Fibroblasts were treated 
with TLR agonists: bLP (TLR2 ligand), PIC (TLR3 ligand) and LPS (TLR4 ligand) and 
harvested at 4, 8, 24, 48 and 72 h.  
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BAFF mRNA expression in RASFs and OASFs was markedly induced by PIC (Figure 
4.1a, e), whilst there was a more modest induction with LPS and no upregulation with 
bLP. The exposure of RASFs to PIC triggered a rapid induction of BAFF transcripts at 4h, 
which peaked at 8h and gradually decreased afterwards. Similar to RASFs, a comparable 
increase in BAFF mRNA was induced by PIC in RADFs (Figure 4.1c), suggesting that 
BAFF mRNA upregulation in response to PIC is not disease specific or dependent on the 
anatomical localisation of the fibroblasts. However, in my experiments I noticed that at 
baseline RASFs and OASFs displayed increased expression of BAFF mRNA; between 4 
and 8-fold higher than RADFs (Figure 4.2a), as previously reported [428]. Conversely, I 
showed that RADFs were capable of producing significantly higher levels of BAFF 
mRNA in response to TLR4 stimulation as compared to RASFs or OASFs, and similar to 
that obtained with PIC (Figure 4.1).  
 
In comparison with BAFF, APRIL was weakly modulated by TLR3 stimulation in 
RASFs (Figure 4.1b) and OASFs (2.5-fold increase, Figure 4.1f) with no apparent 
modulation in RADFs (Figure 4.1d). Interestingly, although modestly increased, APRIL 
displayed a different kinetic of expression compared to BAFF, with a later peak of 
induction at 24h (Figure 4.1b). Differently from BAFF, no difference in baseline mRNA 
expression of APRIL was observed in RASFs compared to OASFs and RADFs (data not 
shown). I finally investigated whether there was a differential expression of TLR3 
mRNA in RASFs compared to OASFs and RADFs and I found no difference among 
these cells in basal TLR3 expression (Figure 4.2b). 
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Figure 4.1. Induction of BAFF and APRIL mRNA in RASFs, RADFs and OASFs in 
response to TLR ligands.  
 
Quantitative Taqman real-time PCR analysis of BAFF and APRIL mRNA expression in 
response to TLR ligands.  RASFs (a and b), RADFs (c and d) and OASFs (e and f) were 
stimulated with 10μg/ml PIC (TLR3), 100ng/ml lipopolysaccharide (TLR4), 300ng/ml 
bLP (TLR2) or medium alone for 4, 8, 24, 48 and 72 h. Results are expressed as 
mean±SEM of the mRNA fold increase calculated at each time point relative to the 
baseline unstimulated expression. Data were normalised using mammalian 18S as an 
endogenous control gene (18S). *p<0.05, **p<0.01 compared with unstimulated.  
 
OASF, synovial fibroblast from osteoarthritis patient; PIC, polyinosinic:polycytidylic 
acid; RADF, rheumatoid arthritis dermal fibroblast; RASF, rheumatoid arthritis synovial 
fibroblast; TLR, toll-like receptor. 
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Figure 4.2. Comparative expression of BAFF and TLR3 mRNA in RASFs and 
RADFs.  
 
Box and whisker graph showing quantitative Taqman real-time analysis for basal (a) 
BAFF and (b) TLR-3 mRNA expression in RASFs (n=5) vs. RADFs (n=5). Data are 
expressed as the difference in threshold cycle (dCt) following normalisation for the 
endogenous controls. The lower and upper margins of the box represent the 25
th
 and 75
th
 
percentile, respectively, while the extended arms represent the 10
th
 and 90
th
 percentiles. 
The mean is indicated as a horizontal line within the box.  
 
RADF, rheumatoid arthritis dermal fibroblast; RASF, rheumatoid arthritis synovial 
fibroblast; TLR, toll-like receptor. 
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4.2 RASFs but not RADFs release high levels of BAFF in response to 
TLR3 stimulation 
 
I next examined whether the over-expression of BAFF mRNA in response to TLR3 was 
mirrored by increased protein expression and release of soluble BAFF. As shown in 
Figure 4.3a, upon PIC stimulation, high amounts of soluble BAFF was released in the 
supernatant of RASFs in a time-dependent manner reaching 600pg/ml at 72h. Similar 
levels were observed in the supernatant of OASFs (Figure 4.3b). Strikingly, despite 
strong up-regulation of BAFF mRNA, RADFs produced only modest amounts of soluble 
BAFF in response to PIC, ~10-fold lower compared to RASFs (Figure 4.3a).  Similar 
differences were observed analysing the basal (i.e. unstimulated) levels of BAFF released 
in the supernatant of RASFs vs. RADFs. While unstimulated RASFs constitutively and 
time-dependently released BAFF, reaching 200pg/ml at day 3, negligible BAFF 
production was seen in RADFs (Figure 4.3a). Overall, these data indicate that increase 
production of BAFF, either at basal level or upon TLR3 stimulation, is characteristic of 
synovial fibroblasts and dependent on anatomical location.  
 
To further confirm that RASFs and RADFs differ in their capacity to produce BAFF at 
protein level, I next investigated the intracellular localisation of BAFF upon TLR3 
stimulation by immunofluorescence. As shown in Figure 4.3c, weak and granular 
perinuclear BAFF immunoreactivity was detected in untreated permeabilised RASFs. 
Upon incubation with PIC for 24h a strong increase in cytoplasmic BAFF as well as 
membrane-bound BAFF was observed. The strong increase in BAFF staining intensity 
was observed with the relocation to the periphery of the cells accompanied by 
transformation of RASFs from a spindle shape into an aggressive stellate phenotype 
[429]. Similar data were observed in OASFs (Figure 4.3d, result was performed by my 
collaborator, Dr Brentano). In contrast, following exposure to PIC, RADFs failed to 
increase the intensity or modify the pattern of BAFF cytoplasmic staining which 
remained weak and barely detectable. Overall, our histological data corroborate the 
findings of ELISA data showing that increased production of BAFF, at basal level or 
upon TLR3 stimulation, is characteristic of SFs but not DFs.  
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While the ELISA data reflected a processed soluble form of BAFF, I illustrated the 
presence of cell surface transmembrane BAFF by using flow cytometry and 
immunofluorescence staining. As revealed by flow cytometry, RASFs constitutively 
expressed transmembrane BAFF, which was modestly upregulated upon PIC stimulation 
(Figure 4.4a). The confocal microscopy images showed that the localisation of BAFF 
along the periphery of the RASFs, as illustrated by the overlapping staining with cell 
surface adhesion molecule, ICAM-1 (Figure 4.4b). I further used a Western blot approach 
to discriminate between the transmembrane and processed forms of BAFF. As controls, I 
ran soluble recombinant BAFF (Peprotech) or tonsillar cells, which identified as a source 
of mononuclear cell. As shown in Figure 4.5, the antibody used for flow cytometry also 
worked in Western blot analyses, which was capable of recognising both the full-length 
as well as the soluble forms of BAFF (corresponding to amino acids 83-285 of human 
BAFF). Analysis of lysates obtained from RASFs and RADFs revealed a 32kDa band, 
suggesting the expression of endogenous full-length BAFF (Figure 4.5, lane 1 and 3). 
The presence of the 32kDa band in RASFs, but not RADFs, became more prominent 
after 48h of PIC stimulation (Figure 4.5, lane 2 and 4). This result further demonstrating 
that the increased production of BAFF at basal level or upon TLR3 stimulation was a 
characteristic of SFs but not DFs. Interestingly, an albeit but modest full-length BAFF in 
RASFs and RADFs remained low and did not up-regulated upon 24h and 72h incubation 
with PIC (data not shown), suggesting the mechanism of membrane externalisation 
appears in a selective kinetic process. In addition to 32kDa species, the anti-BAFF 
antibody can also recognise a lower molecular weight form of 17kDa, representing the 
processed form of BAFF. However, my Western blot experiments could not detect the 
soluble form of BAFF in all the tested lysates. A plausible explanation might be the fact 
the cleavage of membrane BAFF was dependent on the amount of surface expression and 
activity of the pro-protein convertase furin, which cleaves and in turn releases surface-
bound BAFF to the extracellular medium as soluble form of BAFF at a specific time 
point. Therefore, the time-point of cell harvesting as well as tissue variability and cell 
concentration may influence the detection of the 17kDa lower molecular weight form of 
BAFF in my system. 
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Figure 4.3. TLR3 stimulation induces intracellular and soluble BAFF in RASFs and 
OASFs but not RADFs. 
 (a) Column-bar graph showing the amount of soluble BAFF released in the cell culture 
supernatant from RASFs and RADFs conditioned for 24, 48 and 72h in the presence or 
absence of 10μg/ml PIC. RASFs produce significantly higher amounts of BAFF, both in 
resting and stimulated conditions, than RADFs. Results are represented as mean±SEM of 
minimum three experiments.  
 
(b) Column-bar graph showing the amount of soluble BAFF released in the cell culture 
supernatant from RASFs and OASFs conditioned for 24h in the presence or absence of 
10μg/ml PIC. RASFs produce similar amounts of BAFF as compared with OASFs, both 
in resting and stimulated conditions. Results are represented as mean±SEM of minimum 
three experiments. 
 
(c) Representative microphotographs of BAFF immunostaining on RASFs and RADFs 
before and after stimulation with PIC. RASFs/RADFs were grown on coverslips and 
processed for immunofluorescence as described in the Methods. Nuclei are 
counterstained in blue (DAPI) and BAFF in red (Alexa-555). Primary RASFs/RADFs 
were left untreated (medium only) or stimulated for 24 h with PIC (10μg/ml). 
Appropriate isotype control was used to confirm specificity. Images were captured at 20x 
magnification and with the same exposure time for both conditions.  
 
(d) Representative microphotographs of BAFF immunostaining on OASFs before and 
after stimulation with PIC. OASFs were grown on coverslips and BAFF (brown) was 
detected based on the activity of colorimetric horseradish peroxidase (HRP). Primary 
OASFs were left untreated (medium only) or stimulated for 24h with PIC (10μg/ml). 
Appropriate isotype control was used to confirm specificity. Images were captured at 
200x magnification and with the same exposure time for both conditions. Result was 
performed by my collaborator, Dr Brentano 
 
PIC, polyinosinic:polycytidylic acid; OASF, osteoarthritis synovial fibroblast RADF, 
rheumatoid arthritis dermal fibroblast; RASF, rheumatoid arthritis synovial fibroblast; 
TLR, toll-like receptor. 
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Figure 4.4. Expression of membrane-bound BAFF in RASFs.   
(a) FACS analysis demonstrating membrane-bound expression of BAFF and ICAM-1 (as 
positive control) in RASFs in resting conditions (UnS) and upon TLR3 stimulation (PIC). 
Voltage settings for the fluorescence photomultiplier tubes were set so that unstained 
cells lie close to the origin of an FL1/FL2. FL2 refers to recorded fluorescence after light 
emitted from the sample has passed through a PE/RPE filter (i.e., orange fluorescence). 
Stained (and accordingly more fluorescent) cells appear further along the axes than do 
unstained cells. Top row right: Histogram with the number of particles (counts) against 
the relative fluorescence intensity of RPE. Membrane-bound BAFF in unstimulated (light 
grey line) and TLR3 stimulated (dark grey line) RASFs. An irrelevant antibody control 
was used to exclude non-specific binding (black line). Top row left: Quantitative Dot-
plot analysis of irrelevant antibody staining. Middle and bottom row: Quantitative Dot-
plot analysis of BAFF (left) and ICAM-1 (right) membrane expression in the presence or 
absence of TLR3 stimulation (PIC). The percentage of positive cells for each quadrant is 
indicated within each plot. 
 
 
(b) Confocal microscopy images of RASFs immunostained for BAFF and ICAM-1. 
Representative images of RASFs stained with Alexa-488-conjugated antibodies (green) 
to detect BAFF immunoreactivity (left panel). Identification of surface antigen on 
RASFs by PE-conjugated mouse-anti-human ICAM-1 antibody (red, middle panel). 
Merged double staining for BAFF (green) and ICAM-1 (red) highlighted their 
appearance on the membrane of RASFs by yellow colour (right panel, asterisks). 
Original magnification 200x. 
 
PIC, polyinosinic:polycytidylic acid; RADF, rheumatoid arthritis dermal fibroblast; 
RASF, rheumatoid arthritis synovial fibroblast; TLR, toll-like receptor. 
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Figure 4.5. Expression of full-length BAFF in RASFs and RADFs.  
 
Assessment of RASFs and RADFs on the expression of transmembrane and soluble form 
of BAFF. RASFs and RADFs conditioned for 48 h in the presence (+) or absence (-) of 
10μg/ml PIC. Protein was separated in 13% SDS-PAGE and the cell lysate were analysed 
by western blot using anti-BAFF Buffy-2 polyclonal antibodies (higher molecular weight 
of 32kDa represented full-length BAFF; lower molecular weight of 17kDa represented 
the processed soluble form of BAFF). Beta actin was used as endogenous control to 
confirm equal loading (lower membrane). Tonsil cells and recombinant human BAFF 
were used as positive controls.  
 
PIC, polyinosinic:polycytidylic acid; RADF, rheumatoid arthritis dermal fibroblast; 
RASF, rheumatoid arthritis synovial fibroblast; TLR, toll-like receptor. 
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4.3 RASFs but not RADFs constitutively produce large amounts of 
APRIL 
 
I next investigated the ability of RASFs and RADFs to release APRIL in resting and 
stimulated conditions. Unlike RADFs, RASFs produced abundant basal levels of soluble 
APRIL, reaching ~900pg/ml on day 3 (Figure 4.6a). In keeping with the previous gene 
expression analysis showing that APRIL transcripts were poorly modulated by TLR3, 
only a marginal increase in soluble APRIL was observed upon PIC stimulation (Figure 
4.6a). However, APRIL was released at a higher rate within the first 24h in PIC-
stimulated RASFs. In contrast to RASFs, APRIL levels in RADFs were extremely low in 
basal conditions and remained low following TLR3 activation. Finally, in contrast with 
previous data [314], I did not detect expression of BCMA mRNA in RASFs (or RADFs, 
data not shown).  
 
Due to the higher basal production of APRIL protein in RASFs compared to RADFs, I 
then wanted to confirm differential expression of APRIL by immunocytochemistry. As 
shown in Figure 4.6b, immunofluorescence staining for APRIL demonstrates that while 
resting RASFs express intense cytoplasmic immunoreactivity with bright perinuclear 
localisation, possibly corresponding to vesicle-sequestered or Golgi-associated APRIL 
[317], whilst RADF were characterised by a significantly weaker staining. Overall, our 
findings indicated that even after several passages, RASFs (but not RADFs) retain the 
capacity to release constitutively high levels of APRIL, which can only be modestly 
increased upon TLR3 stimulation. 
 
To further confirm the above argument, I used a western blot approach to determine the 
expression of APRIL in RASFs and RADFs. As controls, I ran tonsillar cells, which are a 
source of mononuclear cells. As shown in Figure 4.7, the polyclonal antibody recognised 
the 30kDa unprocessed form of APRIL, which is prominently expressed in resting 
RASFs early at 24h. This finding mirrored the ELISA data above that RASFs 
constitutively express high levels of APRIL. In contrast, RADFs expressed a much less 
APRIL, both at the basal level and upon PIC stimulation. Similar observations were 
obtained throughout the time-course for both RASFs and RADFs, where the level of 
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expression was dampened at later time points of 48h and 72h. In addition to the 30kDa 
species, the anti-APRIL antibody recognised a lower molecular weight 17kDa form of 
APRIL (processed form of APRIL), which was only evident after conditioning RASFs 
for 72h (data not shown). Undetectable levels of the soluble form of APRIL in my cell 
lysates from these experiments might be due to the fact that APRIL is cleaved in the golgi 
apparatus by a furin convertase before secreted as a soluble ligand.  
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Figure 4.6 Intracellular and soluble APRIL expression in RASFs vs. RADFs. 
(A) Column-bar graph showing the amount of soluble APRIL released in the cell culture 
supernatant from RASFs and RADFs conditioned for 24, 48 and 72h in the presence or 
absence of 10μg/ml PIC. Data are presented as mean±SEM of at least three experiments. 
 
(B) Representative microphotographs of APRIL immunostaining on RASFs and RADFs 
in resting conditions. RASFs/RADFs were grown on coverslips and processed for 
immunofluorescence as described in the Methods. Nuclei are counterstained in blue 
(DAPI) and APRIL is stained in green (Alexa-488). Appropriate isotype control was used 
to confirm specificity. Images were captured at 20x magnification and with the same 
exposure time for both conditions.  
 
PIC, polyinosinic:polycytidylic acid; RADF, rheumatoid arthritis dermal fibroblasts; 
RASF, rheumatoid arthritis synovial fibroblasts. 
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Figure 4.7. Expression of full-length and processed form of APRIL in RASFs and 
RADFs. 
 
Assessment of RASFs and RADFs on the expression of transmembrane and soluble 
forms of APRIL. RASFs and RADFs conditioned for 24h in the presence (+) or absence 
(-) of 10μg/ml PIC. Protein was separated in 13% SDS-PAGE and the cell lysates were 
analyzed by western blot using anti-APRIL polyclonal antibodies (higher molecular 
weight of 30kDa represented full-length APRIL; lower molecular weight of 17kDa 
represented the processed soluble form of APRIL). Beta actin was used as endogenous 
control to confirm equal loading (lower membrane). Tonsil cells were used as a positive 
control.  
 
PIC, polyinosinic:polycytidylic acid; RADF, rheumatoid arthritis dermal fibroblasts; 
RASF, rheumatoid arthritis synovial fibroblasts. 
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4.4 Purification of ≥97% IgDhi naïve unswitched human B cells from 
tonsil by positive selection using magnetic-activated cell-sorting 
(MACS) 
 
Given the capacity of PIC to induce high levels of BAFF in RASFs, I next investigated 
whether TLR3 stimulation was capable of enhancing the well established capacity of 
RASFs to promote Ig production in B lymphocytes [363]. In addition, because TLR3 
promotes the release of significant levels of soluble BAFF, with RASFs constitutively 
producing high amount of soluble APRIL, I investigated whether the capacity of RASFs 
to activate B cells was dependent on direct cell-cell interactions or could also be mediated 
by soluble mediators. To this aim, I first isolated IgD
+
 unswitched B cells isolated from 
human tonsils (and peripheral blood). By using well established MACS separation 
protocols I achieved a preparation of freshly isolated B cells with ≥97% purity for surface 
IgD (Figure 4.8).  
 
Flowcytometric analysis of B cells distinguishes different subpopulations using a 
combination of surface markers: IgD, CD20 and CD27. In pre-sort population: (1) CD20 
expression was used to distinguish between three B cell populations, where CD20
lo
 
defined the resting B cell populations where CD20 intermediate the GC founder cells and 
CD20
hi  
the GC cells (second panel left row); (2) IgD surface expression distinguished 
two populations, IgD
lo
, representing centroblasts/centrocytes where IgD
hi 
indicated 
mature resting B cells (first panel left row); (3) Double staining with IgD/CD27 
demonstrated four populations: class switched memory B cells (CD27
+
, IgD
-
), pre-
switched memory B cells (CD27
low
, IgD
hi
), non-class switched mature resting B cells 
(CD27
-
, IgD
hi
), and cells negative for both CD27 and IgD (CD27
-
, IgD
-
)  (last panel left 
row). 
 
After enrichment, ≥97% of these B cells showed strong surface expression for IgDhi 
(Figure 4.8, first panel in central row), and around 94% surface expression for CD20 
(Figure 4.8, last panel in central row), indicating almost all cells in the after-sort fractions 
are of B cells origin. <2% were CD27-positive cells demonstrating a lack of memory B 
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cells in the purified fraction (Figure 4.8, third panel in central row). Moreover, although 
the majority of the cells in the purified fraction expressed CD20 at intermediate level, a 
feature of GC founder cells, this population also expressed IgD in high amounts, 
suggesting our selected population (IgD
hi
 CD20
+
 CD27
neg/low 
B cells) represented 
unswitched resting mature B cells and was selected for subsequent culture experiments. 
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Figure 4.8. FACS characterisation of tonsillar B cell subpopulations before and 
after isolation of IgD
+
 cells by magnetic-activated cell-sorting (MACS).  
 
A forward scatter/side scatter (FSC/SSC) plot showing the “live” gate used to exclude 
cellular debris and dead cells; this gate is then applied to all subsequent plots (Left 
panel). Voltage settings for the fluorescence photomultiplier tubes are set so that 
unstained cells lie close to the origin of an FL1/FL2. FL1 refers to recorded fluorescence 
after light emitted from the sample has passed through a FITC filter (i.e., green 
fluorescence) and FL2 refers to fluorescence recorded after the light has been passed 
through a PE/RPE filter (i.e., orange fluorescence). Stained (and accordingly more 
fluorescent) cells appear further along the axes than do unstained cells. Tonsillar 
mononuclear suspensions before (pre-sort, second panel) and after (after-sorted, third 
panel and flow-through, fourth panel) IgD
+
 MACS isolation were single or double 
stained with FITC-conjugated anti-IgD (horizontal axis), RPE-conjugated anti-CD20 or 
PE-conjugated anti-CD27 Ab (vertical axis). Fluorescence analysis was performed on the 
total lymphocyte gate based on forward and 90
o
 scatter profile. The percentage of 
positive cells in each quadrant is indicated beside each plot. A purity of ≥97% IgD+ B 
cells was obtained after sorting with the vast majority of IgD-CD27
+
 switched memory B 
cells in the flow-through.  
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4.5 BAFF and IL-4 induced Ig production, AID expression and Iγ-Cµ 
circular transcripts in tonsillar IgD
+
 B cells.  
 
To examine the possible role/involvement of TLR3 engagement on fibroblasts in B cell 
survival, proliferation and activation, I first constructed a system to clarify the basis of 
regulation on activated human unswitched IgD
+
 B cells. I evaluated the ability of well-
described activating cytokines, BAFF and IL-4, to induce the expression of AID, a gene 
that is exclusively expressed in active B cells, in the selected B cell populations.  
 
In my initial study, increasing cells densities of 1 x 10
6
 and 2 x 10
6
 IgD
hi
 CD20
+
 
CD27
neg/low 
unswitched resting B cells were cultured in the presence or absence of 
1µg/ml BAFF and 100ng/ml IL-4 for 24h and 72h and cells were collected for 
determination of AID at transcriptional levels. AID transcripts were detectable within 24h 
of BAFF and IL-4 stimulation and the expression were presented at least up to 72h, 
where a weak expression was observed in unstimulated B cells (Figure 4.9).  Compared 
with untreated cells, increased cell density was associated with increased AID expression, 
where the application of BAFF and IL-4 induced an almost 200-fold increase of AID 
mRNA with 1 x 10
6
 IgD
+
 B cells and 300-fold increase with 2 x 10
6
 IgD
+
 B cells 
following 72h of incubation. These results suggested that BAFF synergised with IL-4 
induced AID gene expression in human B cells. 1 x 10
6
 IgD
+
 B cells has been chosen for 
all subsequent culture experiments, allowing meaningful comparisons. 
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Figure 4.9. Effect of different B cell densities on AID induction in purified IgD
+
 
naïve human tonsillar B cells.  
 
Purified B cells (1 x 10
6
 and 2 x 10
6
 /well) from tonsil were cultured with 1µg/ml BAFF 
and 100ng/ml IL-4 (+) for 72h or left untreated (-). Cells were then harvested, RNA 
extracts and QT-PCR performed to evaluate AID transcripts. AID mRNA expression, 
normalised to 18S, was affected by both stimuli and population density. Application of 
BAFF/IL-4 displays a clear comparable AID mRNA expression.  
 
 
 - 202 -  
My results revealed that BAFF and IL-4 induced AID expression in IgD
+
 tonsillar B cells, 
and as AID is required for class-switching, I further determined whether its expression 
was associated with the ability to induce class-switching.  1 x 10
6
 of IgD
+
 B cells were 
stimulated in culture in the presence or absence of BAFF and IL-4. As shown in Figure 
4.10a, cultures treated with BAFF and IL-4 strongly enhanced IgG synthesis. The release 
of IgG was regulated time-dependently and reached the maximal level after 72h of 
stimulation. Treatment of BAFF and IL-4 resulted in a 4-fold increase of IgG levels (~80 
ng/ml) compared to untreated control (~20ng/ml). Conversely, IgA production was 
unaffected by the treatment. Constitutive production of polyreactive IgM was observed, 
and treatment with BAFF/IL-4 provided an enhancing effect on IgM secretion, 
suggesting the maintenance of B cell survival/proliferation in my culture system. Figure 
4.10b demonstrated that AID expression was induced by BAFF and IL-4 in a time-
dependent manner. AID transcript was found to be induced by ~20-fold at 24h and ~300-
fold after 72h of incubation. The specificity of the AID and endogenous control PCR 
products were confirmed by agarose gel electrophoresis (Figure 4.10c). In order to 
confirm that AID was functional, I determined the presence of Iγ 1/2 -Cμ CTs, specific 
by-products of ongoing CSR from IgM to IgG1/2 in B cells, which are reported to 
disappear 48h after CSR [263]. In my system, a weak basal expression of Iγ 1/2 -Cμ CTs 
was detected throughout the incubation period, and the addition of BAFF and IL-4 
markedly upregulated CT expression in B cells (Figure 4.10d). Iγ 1/2 -Cμ CTs were 
strongly expressed at 24h, and expression was dampened but maintained up to 72h of 
incubation.   
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Figure 4.10. BAFF/IL-4 induce Ig production, AID expression and Iγ-Cµ circular 
transcripts in tonsillar IgD
+
 B cells. 
 
(a) BAFF and IL-4 increased the production of IgG and IgM in tonsillar IgD
+
 B cells in a 
time-dependent manner. IgA synthesis was not modulated by the treatment. For 
comparison, cells were left in medium only (-).   
 
(b) QT-PCR performed to evaluate AID mRNA expression, normalised to 18S, before 
and after BAFF/IL-4 stimulation. Baseline expression was set as 1.  
 
(c) 1.8% agarose gel showing AID, 18S and BAFFR PCR products to confirm specificity 
of the PCR. Bands of the corrected size were observed for all the genes analysed AID (99 
bp), BAFFR (150 bp), 18S (187 bp). Expression of AID, but not BAFFR, was induced by 
BAFF/IL-4.  
 
(d) CT Iγ-Cµ expression was determined by running PCR amplified product on 1% 
agarose gel (inverted colour, amplicon 502 bp, upper gel). 18S was used as endogenous 
control to confirm equal loading (lower gel). Tonsil cells were used as a positive control. 
Results are represented as mean ± SEM. * p<0.05, **p<0.01 compared to unstimulated. 
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4.6 TLR3 stimulation of RASFs, but not RADFs, enhances class-
switched immunoglobulin secretion from IgD
+
 human B lymphocytes 
 
Tonsil IgD
+
 unswitched B cells at ≥97% purity (Figure 4.8) were co-cultured either in 
cell-cell contact or in a transwell system (see method for details) with RASFs, OASFs or 
RADFs. As shown in Figure 4.11a, tonsillar IgD
+
 B cells cultured alone produced low 
amounts of IgG and IgA, which were not significantly modified after incubation with PIC, 
suggesting that TLR3 stimulation is not sufficient per se to trigger Ig production. 
Conversely, when the same numbers of B cells were culture together on a confluent 
monolayer of RASFs, spontaneous IgG was enhanced (two-to-threefold increase in IgG 
production already at 72h) and IgG levels were further increased upon TLR3 stimulation 
(Figure 4.11a), indicating that RASFs following PIC stimulation releases factors capable 
of triggering class-switched Ig production in B cells. Similar, albeit more modest 
induction of IgA was also evident. Paired RADFs were not capable of significantly 
enhancing IgG production either in resting or stimulated conditions (Figure 4.11b), while 
OASF displayed a similar behaviour compared to RASFs (Figure 4.12, result was 
performed and obtained from my collaborator, Dr Brentano).  
 
I next determined if IgG class-switching induced RASFs in B cells required direct cell-
cell interactions. As shown in Figure 4.11, a cell-cell contact was not necessary, since 
CSR to IgG/IgA still occurred (albeit with slightly lower efficiency) when tonsillar 
IgD
+
/CD27
- 
B cells cells (but also from IgD
+
/CD27
- 
peripheral blood mature B cells, 
Figure 4.13, result was performed and obtained from my collatorator, Dr Brentano) were 
cultured in transwells system without physical contact with RASFs in the culture system, 
indicating that soluble factors released by RASFs are sufficient to promote CSR. Overall, 
the treatment of RASFs with PIC, either in the cell-cell or transwell system, selectively 
induced the production of IgG, and to a much lesser extent IgA , but did not augment the 
secretion of polyreactive IgM. The phenomenon that the treatment of RASFs with PIC 
minimally modulated IgM production suggests that RASFs do not simply enhanced the 
survival/proliferation of B cells, but rather induced functional activation as indicated by 
the increased IgG/IgM ratio after 8 days compared to 24h and 72h (Figure 4.14d). 
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Figure 4.11. TLR3 stimulation of RASFs but not RADFs enhances their capacity to 
promote the production of class-switched antibodies in IgD
+
 B cells (purified from 
tonsil) 
 
Purified tonsillar IgD
+
 B cells were cultured with fibroblasts for 72h. B cells were 
cultured alone (open bars) or in co-culture fibroblasts in direct physical contact (grey 
bars) or a transwell system (black bar). All cultures were incubated with (+) or without 
(−) 10μg/ml PIC. IgG, IgA and IgM levels in supernatants were measured by ELISA. 
Results are presented as mean±SEM of at least three experiments. *p<0.05, **p<0.01 
compared with unstimulated.  
 
PIC, polyinosinic:polycytidylic acid; RADFs, rheumatoid arthritis dermal fibroblasts; 
RASFs, rheumatoid arthritis synovial fibroblasts; TLR, toll-like receptor. 
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Figure 4.12. TLR3 stimulation of OASFs enhances their capacity to promote the 
production of class-switched antibodies in IgD
+
 B cells (purified from tonsil) 
 
Purified tonsillar IgD
+
 B cells were cultured with fibroblasts for 72h. B cells were 
cultured alone (open bars) in co-culture fibroblasts in direct physical contact (grey bars) 
or a transwell system (black bar). All cultures were incubated with or without 10μg/ml 
PIC. IgG, IgA and IgM levels in supernatants were measured by ELISA. Results are 
presented as mean±SEM of at least three experiments. *p<0.05, **p<0.01 compared with 
unstimulated. 
 
Result was performed and obtained from my collaborator, Dr Brentano. 
 
PIC, polyinosinic:polycytidylic acid; OASF, osteoarthritis synovial fibroblast. 
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Figure 4.13. TLR3 stimulation of RASFs enhances their capacity to promote the 
production of class-switched antibodies in IgD
+
 B cells (purified from peripheral 
blood). 
 
Purified IgD
+
 B cells from peripheral blood were cultured with fibroblasts for 72h. B 
cells (black bars) or RASFs (grey bars) were cultured alone or RASF were co-culture 
with B cells in direct physical contact (open bars). All cultures were incubated with or 
without 10μg/ml PIC. IgG, IgA and IgM levels in supernatants were measured by ELISA. 
Result was performed and obtained from my collaborator, Dr Brentano. Results are 
presented as mean±SEM of at least three experiments. *p<0.05 compared with 
unstimulated. 
 
PIC, polyinosinic:polycytidylic acid; RASF, rheumatoid arthritis synovial fibroblast. 
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4.7 TLR3-stimulated RASFs induce up-regulation of AID and circular 
transcripts in B cells 
 
Although the above data strongly pointed towards the ability of RASFs to actively induce 
class-switching in B cells, a formal demonstration of the capacity of RASFs to induce 
class-switching requires evidence of AID expression, which is the enzyme required to 
initiate CSR, as well as the appearance of circular transcripts (CTs).  
 
RASFs strongly induced AID mRNA after 24h and 72h of co-culture in cell-cell and 
transwell systems, a capacity further enhanced upon TLR3 stimulation (Figure 4.14a, b). 
Importantly, IgD
+
 B cells alone (Figure 4.14a, b) or cultured with RADFs (data not 
shown) displayed no or barely detectable levels of AID mRNA. The specificity and the 
correct size of the AID and endogenous control PCR products were confirmed by agarose 
gel electrophoresis (Figure 4.10c). Interestingly, there was a trend towards increased 
expression of AID when RASFs were physically separated from B cells in a transwell. 
The mechanism by which AID mRNA is increased in the co-cultures remains to be 
defined. One possible explanation could be due to some unidentified cell surface 
molecules, which may influence the production of AID. Indeed, it has been demonstrated 
that RASFs expressed cell surface death receptors, such as Fas/CD95, and that 
crosslinking of these receptors by antibodies can induce apoptosis [104]. Therefore, I 
hypothesised that the cell surface expression of death receptors may positively correlate 
with the stimulation of PIC. Accordingly, the transwell co-culture system, in which B 
cells are cultured in the absence of direct cell-cell contact with RASFs, may potently 
impair apoptosis induced by the death receptors expressed on RASFs. Nevertheless, my 
current data demonstrates that, in the presence of PIC and RASFs, IgD
+
 B cells up-
regulate the expression of AID more than IgD
+
 B cells cultured with un-treated 
fibroblasts.  
 
Next, in order to confirm that AID was functional, I determined the presence of Iγ1/2-Cµ 
CTs. I investigated their expression 72h after co-culturing B cells with RASFs. As shown 
in Figure 4.14c, no Iγ1/2-Cµ CTs were detected in IgD
+
 B cells alone at 72h, while co-
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culture with unstimulated RASFs was sufficient to induce their expression. Importantly, 
TLR3 triggering strongly enhanced CSR from IgM to IgG (Figure 4.14c, top gel, lane 4), 
a result in keeping with evidence of increased IgG production upon PIC stimulation. 
RASFs-dependent induction of Iγ1/2-Cµ CTs and IgG production was similar to that 
observed using recombinant BAFF and IL-4 (Figure 4.10d) where I confirmed that 
sustained expression of CT Iγ1/2-Cµ up to 72 h was dependent on the presence of the 
agonist, indicating the importance of an activated state of IgD
+
 B cells for active CSR at 
72h in my co-culture system.  While no Iγ1/2-Cµ CTs were detected in IgD
+
 B cells alone, 
co-culture with unstimulated RASFs was sufficient to induce CTs expression up to 72h, 
which was clearly enhanced upon TLR3 stimulation (Figure 4.14c, top gel, lane 4).  
 
Overall, these data provide conclusive evidence that RASFs release soluble factors able 
to directly activate and sustain the expression of AID and induce the molecular 
machinery required for ongoing CSR in unswitched B cells and that TLR3 stimulation 
enhances this effect. 
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Figure 4.14. TLR3 stimulation of RASFs enhances activation-induced cytidine 
deaminase (AID) expression and ongoing class-switching in co-cultured IgD
+ 
tonsillar B cells. 
 
(a and b) Purified tonsillar IgD
+
 B cells were cultured with RASFs for 24h (a) and 72h 
(b) with 10μg/ml PIC or left untreated in the presence (transwell) or absence (cell–cell 
contact) of a cell insert. AID mRNA expression was determined by quantitative real-time 
PCR normalised to an endogenous control gene (18S) and the fold difference relative to 
baseline expression was calculated by setting AID expression in B cell alone as 1. 
*p<0.05, **p<0.01 compared with unstimulated.  
 
(c) Representative 1% agarose gel (inverted colour) of Iγ-Cμ circular transcripts (CTs; 
amplicon 502 bp, upper gel), specific by-products of ongoing class-switching from IgM 
to IgG. The lower gel represents the endogenous control, mammalian 18S (amplicon 187 
bp). CTs were amplified from B cell cDNA using specific primers (Methods). B cells 
were cultured alone or in transwell with RASFs for 72h in the presence or absence of 
10μg/ml PIC. Tonsil was used as a positive control.  
 
(d) Progressive production of IgG over IgM in B cells co-cultured in transwell with 
TLR3-stimulated RASFs after 24h, 72 h and 8 days, demonstrating. Data are presented as 
mean IgG to IgM ratio ±SEM of at least three experiments per time point. *p<0.05, 
**p<0.01 compared with unstimulated.  
 
PIC, polyinosinic:polycytidylic acid; cel:cel, cell to cell contact; trans, transwell; RASF, 
rheumatoid arthritis synovial fibroblast; TLR, toll-like receptor. 
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4.8 Dual blockade of BAFFR and BCMA abrogates TLR3-induced AID 
expression and class-switching  
 
I finally wondered whether the activating capacity of RASFs to induce AID expression, 
CSR and IgG production in IgD
+
 B cells in response to TLR3 was dependent on the 
release of BAFF and/or APRIL. In order to test this possibility, I inhibited BAFF/APRIL-
dependent signal transmission by using neutralising antibodies. By using neutralising 
antibodies against BAFFR (specific for BAFF) and BCMA (binding both BAFF and 
APRIL) alone I showed that in the transwell system individual receptor blocking 
displayed significant but partial inhibition of TLR3-dependent IgG and IgA production 
(with BCMA interference appearing more efficient than BAFFR blockade at the same 
dose of neutralising antibody), while the combination of anti-BAFFR/anti-BCMA 
completely suppressed TLR3-induced IgG and IgA production (Figure 4.15a).  
 
In addition, blockade of BAFFR and/or BCMA downregulated TLR3-induced RASFs-
dependent AID mRNA expression as well as the production of Iγ1/2-Cµ CTs (Figure 4.15 
b and c, respectively). Experiments in cell-cell contact displayed similar results, although 
the inhibitory effect was slightly smaller (data not shown). Overall, these findings suggest 
that the molecular machinery for CSR induced in IgD
+
 B cells by RASFs via TLR3 
stimulation is mostly dependent on the production of BAFF and APRIL and can be 
blocked by interference with their specific receptors. 
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Figure 4.15. Blockade of BAFFR and/or BCMA reverses TLR3 induced RASFs-
dependent IgD
+
 B cell activation. 
 
(a) IgG, IgA and IgM production by tonsillar IgD
+
 B cells cultured in transwell with 
RASFs for 72 h in the presence of 10μg/ml of either anti-human BCMA or anti-human 
BAFF-R blocking antibodies or the two combined. Suppression of IgG and IgA 
production is expressed as the percentage of reduction of the effect induced by TLR3 
stimulation. *p<0.05, **p<0.01 compared with PIC stimulated.  
 
(b) Modulation of activation-induced cytidine deaminase mRNA expression in B cells 
co-cultured in transwell with RASFs for 72h after blockade of BAFFR and/or BCMA 
signaling. Results are expressed as mean±SEM of the mRNA fold increase calculated by 
setting the baseline expression as 1. *p<0.05, **p<0.01 compared with PIC stimulated. 
 
(c) Representative 1% agarose gel (inverted colour) of Iγ-Cμ circular transcripts (CTs, 
amplicon 502 bp, upper gel) expression in B cells co-cultured in transwell with RASFs 
for 72 h after blockade of BAFFR and/or BCMA signaling. Endogenous control, 
mammalian 18S (amplicon 187 bp) is shown in the lower gel.  
 
PIC, polyinosinic:polycytidylic acid; cel:cel, cell to cell contact; trans, transwell; aBCMA, 
anti-human BCMA blocking antibody; aBAFFR, anti-human BAFF-R blocking 
antibodies; RASF, rheumatoid arthritis synovial fibroblast; TLR, toll-like receptor. 
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CHAPTER 5 
Results 
Dual role of SLPI as a negative regulator of TLR3-
induced BAFF expression in rheumatoid synovial 
fibroblasts and of B cell functional activation 
 
SLPI has been previously described as an anti-inflammatory protein that is constitutively 
expressed in multiple cell types where it functions to counteract localised tissue 
destruction by its anti-inflammatory, antimicrobial and anti-protease properties. Recently, 
SLPI has been demonstrated to restrain BAFF production released by the activated ECs 
[286]. In this part of my PhD project, I demonstrated that TLR induced expression of 
SLPI in RASFs where it functions to downregulate functional B cell activation: i) SLPI 
was abundantly produced by RASFs at mRNA and protein level and its basal expression 
level was around 60-fold higher than RADFs; ii) SLPI expression was induced by TLRs 
particularly TLR3; iii) SLPI displayed a different dynamic gene expression as compared 
to BAFF (SLPI transcripts level peaked at 72h vs. 8h for BAFF) ; iv) RASFs-derived 
SLPI downregulated BAFF mRNA/protein; v) RASFs exerted a direct and indirect 
refractory effect on functional B cell activation via (AID, IgG/A/M production). 
5.1 TLR3-stimulated induction of SLPI mRNA in RASFs, OASFs and 
RADFs 
 
I first examined whether TLR stimulation of RASFs and paired RADFs (to investigate 
site specificity) induced SLPI mRNA. SLPI mRNA was significantly and markedly 
modulated by TLR3 stimulation in RASFs (Figure 5.1a), while there was a modest 
induction with LPS and bLP stimulation. Interestingly, in comparison with BAFF mRNA, 
which was rapidly induced by PIC and peaked at 8h post-stimulation (see Chapter 4, 
Figure 4.1), TLR3 stimulation provoked a much delayed and gradually increased 
induction of SLPI transcripts, which peaked 72h after stimulation. Importantly, although 
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a comparable increase in SLPI mRNA from basal expression could be induced by PIC in 
RADF (Figure 5.1b), RASFs displayed a significantly higher basal expression (over 60-
fold) of SLPI mRNA as compared to RADFs (Figure 5.1c). Thus, these data 
demonstrated i) that RASFs are able to produce this homeostatic regulator at transcript 
level with a basal expression significantly higher compared to matching RADFs, and that 
ii) SLPI induction can be further induced after sensing the TLR3 ligand PIC, a process 
common to both synovial and dermal fibroblasts. 
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Figure 5.1. Induction of SLPI mRNA in RASFs, RADFs and OASFs in response to 
TLR ligands.  
(a, b) Quantitative Taqman real-time PCR analysis of SLPI mRNA expression in 
response to TLR ligands. RASFs (a), RADFs (b) were stimulated with 10μg/ ml PIC 
(TLR3), 100ng/ml lipopolysaccharide (TLR4), 300ng/ml bLP (TLR2) or medium alone 
for 4, 8, 24 and 72h. Results are expressed as mean±SEM of the mRNA fold increase 
calculated at each time point by setting the baseline unstimulated expression as 1. Data 
were normalised using mammalian 18S as an endogenous control gene (18S). *p<0.05, 
**p<0.01 compared with unstimulated. PIC, polyinosinic:polycytidylic acid; RADFs, 
rheumatoid arthritis dermal fibroblasts; RASFs, rheumatoid arthritis synovial fibroblasts; 
TLR, toll-like receptor. 
 
(c) Comparative expression of SLPI mRNA in RASFs and RADFs. Box and whiskers 
graph showing quantitative Taqman real-time analysis for basal SLPI mRNA expression 
in RASFs (n=5) vs. RADFs (n=5). Data are expressed as the difference in threshold cycle 
(dCt) following normalisation for the endogenous controls. The lower and upper margins 
of the box represent the 25
th
 and 75
th
 percentile, respectively, while the extended arms 
represent the 10
th
 and 90
th
 percentiles. The median is indicated as a horizontal line within 
the box. ***p<0.001 compared with RADFs. 
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5.2 RASFs, but not RADFs, produce high levels of SLPI constitutively 
and in response to TLR3 stimulation 
 
I next investigated the ability of RASFs and RADFs to release SLPI in resting and 
stimulated conditions. Unlike RADFs, RASFs time-dependently produced abundant basal 
levels of soluble SLPI in the supernatant of RASFs reaching up to ~500 pg/ml on day 3 
and on average ~10-times higher than RADFs (Figure 5.2a). Upon TLR3 stimulation 
further increase in SLPI production by RASFs was observed, resulting on average in a 2-
fold increase in SLPI concentration (Figure 5.2a) and up to ~2ng/ml on day 3. Consistent 
with the low basal expression of SLPI in RADFs, TLR3-induced SLPI production by 
these cells was 10-times lower compared to RASsF.  
 
In order to confirm SLPI expression in RASFs and to investigate its intracellular 
localisation in basal conditions and upon TLR3 stimulation, I performed 
immunofluorescence on RASFs and RADFs cell monolayers. As shown in Figure 5.2b, 
resting permeabilised RASFs (see Chapter 3 for methods) expressed an intense 
perinuclear and cytoplasmic SLPI immunoreactivity which was strongly increased upon 
incubation with PIC. In contrast, RADFs were characterised by a significantly weaker 
SLPI staining, and, following exposure to PIC, its expression remained barely detectable 
in RADFs. Overall, ELISA and IF data indicate that RASFs, but not RADFs, are capable 
of releasing high level of SLPI in basal and TLR3 stimulated conditions.  
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Figure 5.2. TLR3 stimulation induces intracellular and soluble SLPI in RASFs but 
not RADFs. 
 
(a) Column-bar graph showing the amount of soluble SLPI released in the cell culture 
supernatant from RASFs and RADFs conditioned for 24, 48 and 72 h in the presence or 
absence of 10μg/ml PIC. RASFs produce significantly higher amount of SLPI both in 
resting and stimulated conditions than RADFs. Results are represented as mean±SEM of 
minimum three experiments.  
 
(b) Representative microphotographs of SLPI immunostaining on RASFs and RADFs 
before and after stimulation with PIC. RASFs/RADFs were grown on coverslips, 
permeabilised and processed for immunofluorescence as described in the Methods. 
Nuclei are counterstained in blue (DAPI) and SLPI in red (Alexa-555). Primary 
RASFs/RADFs were left untreated (medium only) or stimulated for 72h with PIC 
(10μg/ml). Appropriate isotype control was used to confirm specificity. Images were 
captured at 20x magnification and with the same exposure time for both conditions.  
 
PIC, polyinosinic:polycytidylic acid; RADF, rheumatoid arthritis dermal fibroblast; 
RASF, rheumatoid arthritis synovial fibroblast; TLR, toll-like receptor. 
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5.3 SLPI attenuates B cell activation via direct inhibition of Ig 
production and AID expression  
 
I next examined whether SLPI could directly attenuate the capacity of B lymphocytes to 
produce class-switched Ig and down-regulate AID expression. As mentioned in Chapter 4, 
I showed that stimulation with a combination of BAFF and IL-4 significantly and 
markedly induced the expression of AID, and the release of class-switched IgG 
production in tonsillar IgD
+
 B cells (Figure 4.10). Thus, in this part of my project I used 
the same experimental conditions in order to dissect the possible role of SLPI in 
modulating B cell activation. IgD
+
 tonsillar B cells were treated with or without graded 
concentrations of recombinant SLPI at 10, 50 and 500ng/ml in the presence or absence of 
BAFF/IL-4 stimulation. As shown in Figure 5.3a, I found that SLPI markedly down-
regulated the production of IgG production induced by BAFF/IL-4, in a dose-dependent 
manner, with a reduction from ~500ng/ml down to ~300ng/ml at the highest dosage of 
SLPI used (500ng/ml).  Importantly, the basal (i.e. unstimulated) production of IgG by 
IgD
+
 tonsillar B cells was also partially suppressed after treatment with SLPI (Figure 
5.3a).  Similarly, albeit a more modest significant reduction in basal IgA production was 
also evident following SLPI treatment, while 500ng/ml SLPI completely abrogated the 
effect of BAFF/IL-4 on IgA production. Conversely, treatment of B cells with SLPI only 
minimally modulated IgM production, suggesting that SLPI promotes functional 
suppression of B cell activation rather than simply affecting the survival/proliferation of 
B cells.  
 
In keeping with notion that SLPI has a direct suppressive effect on the molecular 
machinery involved in Ig class-switching, I next demonstrated significant downregulation 
of AID mRNA expression in stimulated B cells following incubation with SLPI (Figure 
5.3b). All doses of SLPI were able to downregulated AID expression by 40-50%; 
however, in contrast to Ig production AID expression was not modulated in a dose-
dependent manner and no further decrease in AID could be observed at increasing doses 
of SLPI. Thus, it is possible that SLPI may exert additional mechanisms that affect Ig 
secretion over and above inhibition of CSR. Nevertheless, these in vitro findings clearly 
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demonstrate that CSR activity induced in IgD
+
 B cells by a combination of BAFF/IL-4 
can be directly attenuated by SLPI, confirming the immunoregulatory capacity of this 
factor. 
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Figure 5.3. SLPI attenuated BAFF/IL-4-induced AID expression and class-switching.  
 
(a) SLPI decreased the production of IgG induced by BAFF/IL-4 in tonsillar IgD
+
 B cells 
in a dose-dependent manner. IgA synthesis was weakly modulated by the treatment. For 
comparison, cells were left in medium only (-). Suppression of IgG is expressed as the 
percentage of reduction of the effect induced by BAFF/IL-4 stimulation. Results are 
represented as mean ± SEM. * p<0.05, **p<0.01, ***p≤0.001 compared with 
unstimulated and BAFF/IL-4 stimulated. 
 
 (b) QT-PCR performed to evaluate AID mRNA expression. Data were normalised using 
mammalian beta actin as an endogenous control gene, before and after SLPI treatment. 
Baseline expression was set as 1.  
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5.4 SLPI directly inhibits TLR3-stimulated induction of BAFF in 
RASFs 
 
Previously in this thesis I reported that RASFs can produce B cell survival factors, at both 
mRNA and protein level, upon TLR stimulation (Chapter 4, Figure 4.1, 4.3-4.7). 
Therefore, in this part of my PhD project I sought to determine whether SLPI can restrain 
B cell survival factors expression upon TLR3 stimulation in RASFs. Here I specifically 
focused on TLR3 since I showed that BAFF expression in RASFs is mainly modulated 
by the TLR3 ligand PIC. I investigated two aspects of SLPI in regulating the expression 
of BAFF. Firstly, RASFs were treated with the TLR3 agonist, PIC, with/without pre-
incubation with recombinant SLPI at 50 and 500ng/ml and subsequently harvested at 4, 8, 
24, 48 and 72h. As shown in Figure 5.4a, treatment with recombinant SLPI rapidly 
elicited an inhibitory effect on the expression of BAFF mRNA as early as 4h in a dose-
dependent manner. The inhibitory effect was somewhat decreased at 8h post-stimulation 
and was lost afterwards (data not shown). Conversely, SLPI did not induce any 
significant modulation of APRIL mRNA (data not shown), suggesting a distinct function 
of SLPI on BAFF vs. APRIL expression in RASFs. 
 
I next aimed to confirm whether SLPI-induced downregulation of BAFF mRNA was 
mirrored by decreased protein expression. As shown in Figure 5.4b, treatment with SLPI 
significantly reduced the amount of soluble BAFF release at 72h in a dose-dependent 
manner. Conversely, only marginal suppression was observed at 24 and 48h. Secondly, in 
preliminary experiments, RASFs were treated with PIC with/without pre-incubation with 
an anti-human SLPI blocking antibody. As shown in Figure 5.4c, blocking of endogenous 
RASFs-released SLPI resulted in increased expression of BAFF mRNA both in 
unstimulated conditions and after TLR3 stimulation at 4h. This effect was somewhat 
decreased at 8h post-stimulation and was lost afterwards (data not shown). Overall, 
transcript and protein analysis consistently demonstrated that RASFs-released SLPI can 
directly control the production of BAFF induced by TLR3 stimulation.  
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Figure 5.4. SLPI attenuated TLR3-induce BAFF expression in RASFs. 
(a) RASFs were stimulated with 10μg/ ml PIC (TLR3) in the presence of 50ng/ml or 
500ng/ml SLPI or medium alone for 4h. Results are expressed as mean±SEM of the 
mRNA fold increase calculated at 4h by setting the baseline unstimulated expression as 1. 
Data were normalised using mammalian 18S as an endogenous control gene (18S). 
*p<0.05 compared with PIC stimulated.  
 
(b) Column-bar graph showing the amount of soluble BAFF released in the cell culture 
supernatant from RASFs conditioned for 24, 48 and 72h in the presence or absence of 
10μg/ml PIC and with or without 50ng/ml or 500ng/ml SLPI. SLPI suppressed the level 
of BAFF release from RASFs in a dose-dependent manner at 72h of incubation. Results 
are represented as mean±SEM of minimum two experiments. 
 
(c) RASFs were stimulated with 10μg/ ml PIC (TLR3) in the presence of 10μg/ml anti-
human SLPI/relevant isotype control or medium alone for 4h. Results are expressed as 
mRNA fold increase calculated at 4h by setting the baseline unstimulated expression as 1. 
Data were normalised using mammalian 18S as an endogenous control gene (18S).  
 
PIC, polyinosinic:polycytidylic acid; RASF, rheumatoid arthritis synovial fibroblast; 
SLPI, secretory leukocyte protease inhibitor. 
 - 234 -  
5.5 SLPI suppressed AID expression and class switched 
immunoglobulin secretion from IgD
+
 human B lymphocytes in culture 
with TLR3-stimulated RASFs    
 
The evidence obtained from the experimental work in sections 5.3. and 5.4 led me to 
hypothesise that SLPI may exert a dual regulatory role on RASF/B cell interactions 
whereby it may act at two different cell levels; the first in RASFs where it modulates the 
release of BAFF and the second at the B cell level where it can antagonise AID 
expression and IgG/A production. Thus, in this final part of my PhD project I 
investigated whether the capacity of RASFs to induce AID expression and class-switched 
Ig production in IgD
+
 B cells in response to TLR3 was regulated by SLPI.  
 
By using graded concentrations of recombinant SLPI, I showed that exogenous addition 
of SLPI completely suppressed TLR3-induced IgG and IgA production (Figure 5.5a). Of 
note, the levels of class-switched Ig were suppressed by SLPI in a dose-independent 
manner, both in the absence and presence of TLR3 stimulation. In contrast to anti-
BAFFR and/or anti-BCMA, a minimal reduction effect was also observed in IgM levels, 
suggesting that, in this context, SLPI influences not only the class-switching machinery 
(see below) but may also alter the mechanisms of Ig secretion and/or the survival of B 
cells.  
 
I next investigated whether the ability of SLPI to restrain the production of class-
switched Ig in B cells was associated with the concurrent downregulation of AID 
expression. As shown in Figure 5.5b, I found that SLPI was able to downregulate the 
expression of AID.  
 
Importantly, the concentration of SLPI in the synovial fluid of RA patients is ~80ng/ml 
(Figure 5.6), which falls within the selected dosage range of recombinant SLPI I used to 
treat RASFs (10, 50, and 500 ng/ml). Therefore, my in vitro system resembles the 
physiological condition and is biological relevant.  
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Figure 5.5. SLPI attenuated activation-induced cytidine deaminase (AID) expression 
and class-switching in co-cultured TLR3-stimulated RASFs and IgD
+
 tonsillar B 
cells. 
 
(a) IgG, IgA and IgM production by tonsillar IgD
+
 B cells cultured in cell-cell contact 
with RASFs for 72h in the presence of SLPI. An increasing concentration gradient of 
drug (50ng/ml or 500ng/ml) was represented by the grey triangle. Suppression of IgG of 
is expressed as the percentage of reduction of the effect induced by TLR3 stimulation. 
*p<0.05, **p<0.01 compared with PIC stimulated.  
 
(b) Modulation of activation-induced cytidine deaminase mRNA expression in B cells 
co-cultured in cell-cell contact with RASFs for 72h after treatment with SLPI. Results are 
expressed as mean±SEM of the mRNA fold increase calculated by setting the baseline 
expression as 1. *p<0.05 compared with PIC stimulated. 
 
PIC, polyinosinic:polycytidylic acid; RASF, rheumatoid arthritis synovial fibroblast; 
SLPI, secretory leukocyte protease inhibitor. 
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Figure 5.6. SLPI concentrations in the synovial fluid from RA and OA patients. 
 
SLPI concentrations in the synovial fluid (syn fluid) of RA patients is significantly higher 
(***p<0.001) compared with OA patients. Results are represented as mean±SEM from 
18 of RA patients and 18 of OA patients.  
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CHAPTER 6 
Discussion 
 
In situ autoreactive B cell activation and autoantibody production within the RA 
synovium is a typical feature of a subset (~50%) of RA patients in which synovitis is 
characterised by the formation of ectopic lymphoid structures (ELS) [152]. It has long 
been shown that within RA lymphoid aggregates infiltrating B lymphocytes undergo 
antigen-driven affinity maturation, clonal expansion, Ig isotype switching and PC 
differentiation [153, 430, 431]. Our group recently showed that these processes: (i) 
require the expression of AID, the enzyme responsible for the initiation of SHM and CSR 
of the Ig genes, (ii) are self-sustained for several weeks in the SCID/RA chimeric model 
in the absence of recirculating immune cells and (iii) develop in the context of prolonged 
expression of B cell survival and proliferating factors, BAFF and APRIL [152]. In 
addition, the functionality of synovial B cell follicles is dependent on the interaction with 
networks of stromal cells, which express CD21 [141, 146] and closely resemble FDC in 
secondary lymphoid organs (SLO) [432]. Accordingly, the diffuse form of synovitis, 
characterised by the absence of B cell aggregates, lacks AID expression and ongoing Ig 
class-switching [152]. Despite strong evidence that ELS support the production of 
autoantibodies within the RA synovium is correlate with, our group and others 
demonstrated that circulating autoantibodies in RA do not associate with the presence of 
synovial ELS [148, 152, 433], suggesting that SLO are also important sites for 
autoreactive B cell activation. 
 
Although it is currently unclear whether synovial FDC differentiate from resident stromal 
cells [96], fibroblast-like synoviocytes isolated from the RA synovium (RASFs) have 
been shown to display features of FDC, such as the capacity to promote the survival of B 
cells by rescuing them from apoptosis [364, 365, 434, 435] and their differentiation into 
Ab-producing cells [363, 365, 434, 436]. It is tempting to suppose that when the 
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requirement for FDC increases in the GC during immune response, SFs may migrate to 
lymphoid follicles in response to certain chemokines and differentiate to FDCs as a result 
of interaction with GC B cells. Lindhout et al have demonstrated that SFs could be 
induced to express the FDC phenotype by treatment with IL-1β and TNF-α. Because 
fibroblasts are ubiquitous cells, it remains to be elucidated whether all kinds of fibroblasts 
have the ability to differentiate into FDCs or whether this property is limited to certain 
types of fibroblasts.  
 
Despite previous works clearly highlighting a critical and direct role for RASFs in B cell 
activation and differentiation, the specific factors regulating these interactions have not 
been fully investigated. Cell-dependent mechanisms involving adhesion molecules (i.e. 
VCAM-1) and chemokines (i.e. SDF-1) only partially account for the observed B cell 
activation [365], suggesting a critical contribution of additional factors. In addition, 
because previous works invariably used total B cells for co-culture experiments, in which 
they did not differentiate between naïve, switched and unswitched memory B cell subset, 
therefore the actual capacity of RASFs to induce the molecular machinery required for Ig 
class-switching in naïve B cells was questionable.  
 
In Chapter 4, I provided a series of novel observations which contribute to the 
understanding of key mechanisms in regulating the crosstalk between RASFs and B cells 
within the RA synovium. First, I demonstrated that RASFs constitutively produce high 
levels of B cell survival, activating and proliferating factors BAFF and APRIL, both at 
mRNA and protein level, confirming and expanding previous evidence of over-
expression of these factors at mRNA level in RASFs [292, 314, 428]. Furthermore, I 
showed that TLR3 stimulation was able to induce strong (between 200- and 600-fold) 
and rapid up-regulation of BAFF mRNA. Of particular interest is the dynamic expression 
of BAFF mRNA in RASFs in response to TLR3, in which an increased expression was 
already observed at the earliest time-point of 4h, with peak expression seen at 8h and 
progressively returning to the basal level at 72h. In contrast, APRIL was more modestly 
modulated by TLR3 and displayed a delayed kinetic of expression, with high transcripts 
at 24-48h post-stimulation.  
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In contrast to our observation that BAFF mRNA peaked at 8h and progressively 
decreased up to 72h (Figure 4.1a), previous reports demonstrate that after the stimulation  
of RASFs with TNF-α or IFN-γ, BAFF mRNA peaked at 24h and maintained this level 
for at least 2 days [428]. The differential expression of BAFF transcripts in response to 
TLR3 as compared to TNF-α ans IFN-γ agonists could be due to: (1) the requirement for 
a rapid response to recognise the acute challenge by dsRNA activation, (2) the existence 
of a rapid homeostatic function of TLR3 in cells turnover (3) a unique feature of how 
TLR3 recognises and binds its ligands (i.e. different association and dissociative rate of 
agonist-receptor interaction). Moreover, the mechanisms by which TLR3 recognises 
extracellular viral dsRNA is currently unknown. While TLR2 and TLR4 have been 
proposed to exert their role as cell surface receptors, TLR3 expression and localisation 
are regulated in a cell-type specific manner [383, 437]. For instance, human TLR3 has 
been demonstrated to be localised to the endosomal compartments in myeloid DCs, while 
it localised to both the cell surface and endosome of human fibroblasts cell line MRC5 
[438], ECs [439]and macrophages [440].  
 
Although the localisation of TLR3 on human SF is not well clarified, a recent study from 
Brentano et al showed that the expression of IFN-β mRNA and the production of pro-
inflammatory cytokines and chemokines (IL-6, CXCL10 and CCL5) in RASFs were 
inhibited when pretreating the cells with chloroquine [110]. This phenomenon suggesting 
that TLR3 may localise in the interior of the fibroblast from arthritic joints, and that the 
TLR3 signaling arising in an intracellular compartment, requires endosomal maturation. 
However, the mechanism by which dsRNA is delivered from the extracellular fluid to the 
intracellular dsRNA sensors remains unresolved.  
 
TLR3 is specific for dsRNA and the synthetic analog PIC. The dsRNA ligands may be 
derived from genomes of viruses that are detected only by endosomal TLRs, and the 
endosomal TLRs are particularly crucial to their containment. Host cells internalise 
microbes into different endocytic pathways: (1) phagocytosis, including the mannose 
receptor, Fc receptor and scavenger receptors; (2) fluid phase 
endocytosis/macropinocytosis, allowing uptake of suspended or cell-adherent particles; 
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(3) receptor-mediated endocytosis, mediated by caveolae (taken place at membrane rich 
in cholesterol and sphingolipid) or clathrin which absorbs a variety of particles and 
molecules; (4) fusion with the plasma membrane and later being swept into the 
endosomes either before or after the process of replication. Ultimately, the vesicles form 
at the plasma membrane and will quickly uncoat and allow fusion with endosomes [441].  
 
Of interest, it has been demonstrated that IFN-β production was inhibited by pre-treating 
monocyte-derived immature DCs with cytochalasin D (a phagocytosis inhibitor) and 
chlorpromazine (a clathrin-mediated endocytosis inhibitor) but not with methyl-β-
cyclodextrin (a caveolae-mediated endocytosis inhibitor), suggesting that the clathrin-
dependent endocytic pathway may participate in the dsRNA-mediated TLR3 activation 
[442]. The same group further demonstrated that a major cytoplasmic lipid raft protein, 
Raftlin, is translocated from the cytoplasm to the plasma membrane where it colocalises 
with PIC, and thereafter associates with clathrin to participate in cargo sorting and 
mediate cell entry of PIC to the TLR3-positive endosome [443].  
 
On the other hand, it remains to be clarified whether TLR3 could shuttle between the 
cellular surface and other intracellular compartments and where its exact location is when 
TLR3 accumulates intracellularly. It has also been illustrated that TLR3 localises to 
unidentified intracellular vesicles and that it initiates intracellular signaling in conjunction 
with endosomal maturation [444]. Furthermore, the engagment of cell surface or 
intracellular TLR3 with its respective ligands could activate different signaling pathways 
[445]. Therefore, a distinct localisation and downstream signaling pathway of TLR3 
might possibly explain why the incubation of RASFs with PIC, but not bLP or LPS, 
could lead to a high induction of BAFF mRNA. Finally, it remains to be determined 
whether there is an alternative sensor for dsRNA, because PIC can still induce IFN 
responses in the absences of TLR3 or TRIF. The newly discovered cytosolic dsRNA 
receptor called retinoid-indicible gene (RIG-1) like receptor might be one of the possible 
candidates for this, as it has been reported to recognise both virus-derived RNA and PIC 
[446]. Interestingly, it has been demonstrated that TLR3 activation was associated with 
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elevated levels of RIG-1, suggesting the possibility of a crosstalk between two models of 
dsRNA detection [447].  
 
Despite RASFs over-expressing TLR4 [360], LPS treatment (as well as TLR2 
stimulation) induced only limited levels of BAFF mRNA (Figure 4.1a and 4.1c), 
consistent with recent data on airway fibroblasts [448]. These results are in keeping with 
previous evidence that TLR4 can even down-regulate BAFF mRNA expression in RASF 
in the presence of IFN-γ [293]. Because TLR2 and TLR4 mainly signal through a 
MyD88-dependent pathway, these data suggest that BAFF (and APRIL) transcription is 
under the control of TRIF (Toll/IL-1R domain-containing protein inducing IFNΒ) rather 
than MyD88-dependent pathways.  
 
Although the mechanisms behind the increased expression of BAFF by TLR3 stimulation 
have not been fully elucidated, it is likely that the preferential activation of the TRIF-
mediated pathway downstream of TLR3 activation is required to switch on the 
proinflammatory pathway (ultimately via NF-kB) for BAFF/APRIL production in 
addition to the unique induction of type I IFN and IFN-responsive gene expression (via 
IRF). In this regard, increased expression of IFN-βknown to be upregulated in the RA 
synovium [117], might also contribute to the pathogenesis of RA by exacerbating Th17, 
as recently suggested [449].  
 
Interestingly, the modest but reproducible induction of BAFF in TLR4-activated RASFs 
and OASF may be explained by the evidence that TLR4 can also signal via a MyD88-
independent pathway involving TRAM as a bridging adaptor for TRIF (Figure 6.1). 
Based on these findings, I can therefore hypothesise that TRIF-mediated signaling is the 
main pathway involved in the marked induction of BAFF in TLR3-activated RASFs and 
OASF. Further plans for the investigation of this signaling pathway in RASFs will be 
discussed in detail in Chapter 7 (Future plans). 
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Figure 6.1 Participation of TIR-domain containing adaptor molecules in TLR2, 
TLR3 and TLR4 signaling pathway.  
 
Green box highlights TRIF, an essential component in the MyD88-independent pathway. 
Modified image adapted from Aikra et al Biochem Soc Trans Vol 31:3 [450]. 
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Importantly, I showed that the capacity of synoviocytes to respond to TLR3 and release 
high levels of BAFF was not restricted to RASFs, as OASFs displayed similar expression 
of BAFF/APRIL in resting and stimulated conditions. Conversely, RADFs produced 
negligible amounts of BAFF/APRIL constitutively and failed to significantly increase 
their protein expression despite similar mRNA induction in response to TLR3. Overall, 
this suggests that the over-expression of BAFF and APRIL in SFs is dependent on 
epigenetic abnormalities related to the anatomical localisation rather than disease 
specificity [426]. In addition, the importance of TLR3 is relevant to RA pathogenesis as 
RASFs can be activated in the synovial microenvironment by RNA released from 
necrotic synovial cells [110].  
 
Autoimmune or autoinflammatory diseases develop when self DNA or RNA in 
extracellular milieu bind to host nucleic acid sensors, therefore, a unique system should 
exist in order to ensure that the damaged cells and their endogenous TLR ligands are 
silently eliminated. Under normal circumstances, host DNA is sequestered in 
nuclei/mitochondria, and the release of free nucleic acid are hydrolysed by extracellular 
and endosomal DNases and RNases in order to prevent improper activation of the innate 
immune system. Accordingly, nuclease-resistant phosphorothioate-stabilised or 3’-
polyguanosine oligonucleotides, which are resistant to nuclease degradation, have been 
reported to be strong activators for TLR9 [451, 452]. Several studies have reported an 
interplay between host nucleic acid and autoimmunity: (1) dysfunction of Flap 
endonuclease 1 has been shown to result in residual un-digested self DNA within 
apoptotic bodies leading to chronic inflammation and autoimmunity [453]; (2) 
deficiencies in extracellular DNase I results in systemic lupus erythematous (SLE)-like 
disease in mice [454]; (3) a low DNase I activity with minor mutation within the DNase 1 
gene have also been detected in sera from human SLE patients [455]; (4) dysfunction of 
lysosomal DNase II also results in insufficient degradation of DNA, leading to a variety 
of autoimmune syndromes including arthritis [456]. Recently, it has been reported that (B 
Zimmermann Ann Rheum Dis 2012;71:Suppl 1 Article 89) extracellular RNA (exRNA) 
is present in the synovial lining layer and that the RNase activity in the synovial fluid 
seems to be reduced in RA patients as compared to OA. Accordingly, the reduced RNase 
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activity may explain the accumulation of dsRNA released from the necrotic synovial 
fluid cells, which subsequently activates TLR3 signaling within the arthritic joint.  
 
Next, I confirmed that RASFs express BAFF at protein level, both at surface-bound and 
soluble form. This is of critical importance as BAFF can elicit its biological functions 
both in a transmembrane and a soluble form [457]. Interestingly, the soluble BAFF 
concentrations observed in resting and TLR3 activated RASFs were comparable or 
higher to those released by other activated cell types, such as DC and airway EC, which 
express biologically functional amounts of BAFF and efficiently respond to TLR3 
stimulation [279, 458]. Of interest, the limited increase in the amount of transmembrane 
BAFF expression on RASFs after PIC stimulation was not mirrored with the respective 
high release of soluble BAFF, suggesting that BAFF is continuously cleaved from the 
cell membrane. An alternative explanation could be that processing of BAFF in RASFs 
occurs intracellularly before being released as soluble protein, as previously observed in 
neutrophils [279].  Despite strong mRNA upregulation, it is tempting to suppose that the 
failure of RADFs in releasing BAFF protein may be due to an inactive/desensitised state 
of the furin protease, and that the regulation of such cleavage may be critical to the 
ultimate levels of soluble form of BAFF. Another interesting observation is that despite 
the huge upregulation of BAFF mRNA (~1000-fold) (Figure 4.1) in TLR-stimulated 
RASFs, there is only 4-5 fold increase in soluble BAFF (Figure 4.3), suggesting that 
there is a non-linear relationship between mRNA and protein induction of BAFF which 
likely undergoes profound post-transcriptional/post-translational modifications in 
fibroblasts. Indeed, recent analyses indicate that mRNA levels only partly correlate with 
the corresponding protein concentration and it has been postulated that the differences in 
protein concentrations are only 20%–40% attributable to variable mRNA levels, 
underlining the significance of post-transcriptional regulation [459]. Additionally, I 
provided the first demonstration that RASFs constitutively release high levels of soluble 
APRIL (approximately 10-folds higher for APRIL as compared to unstimulated RADF at 
72h). In keeping with the mRNA data, although TLR3 activation did not induce a large 
induction of APRIL in RASFs, APRIL was released at a higher rate within the first 24h 
of stimulation, reflecting a possible role for TLR3 in the early mobilisation of 
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intracellular APRIL. Interestingly, immunostaining of resting RASFs demonstrated that 
APRIL was not homogeneously expressed among RASFs, demonstrating some 
heterogeneity within the RASF population. 
 
One important aspect that I carefully considered in my experimental work was to exclude 
the presence of contaminating myelomonocytic cells as a possible alternative source of 
BAFF/APRIL, both constitutively and in response to TLR stimulation in RASFs. Indeed, 
I only used RASFs between passages 4-8 in which the culture is devoid of contaminating 
lymphocytes and macrophages, and SFs maintain a fully activated and stable phenotype. 
In order to further confirm that the culture synoviocytes are devoid of contaminating 
lymphomononuclear cells, I investigated the expression levels of IL-10 mRNA, which 
was undetectable in all the RASFs cultured that I examined. This is of particular 
relevance as synovial macrophages, rather than SFs, are known to produce considerable 
amount of IL-10, and therefore, IL-10 production can be taken as a contamination 
measurement for the presence of synovial macrophages [427]. In keeping with this 
evidence, Ritchlin and colleagues demonstrated that IL-10 could still be detected in 
RASFs up to passage 3 [460].  
 
As described throughout in this thesis, BAFF and APRIL are critically involved in 
promoting functional B cell activation, AID expression and Ig class-switching [244, 259, 
461], Thus, in my PhD project I next investigated whether: (1) RASFs are capable of 
supporting AID expression and class-switching in co-culturing with tonsillar unswitched 
IgD
+
 B cells; and (2) this effect is dependent on the release of BAFF/APRIL by RASFs. 
It should be pointed out that the use of unswitched B cells allowed me to dissect the 
actual capacity of RASFs to enable the molecular machinery for CSR rather than just 
simply enhance the survival/proliferation of class-switched B cells as previously reported. 
By these means, I showed that RASFs and OASFs, but not RADFs, in co-culture with 
IgD
+
 mature human tonsillar B cells (but also from IgD
+
/CD27
- 
peripheral blood mature 
B cells, Figure 4.13), are sufficient in inducing class-switched antibodies, primarily IgG 
and to a lesser extent IgA. Further stimulation of RASFs with TLR3 ligands strongly 
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enhanced the production of IgG and IgA in co-cultured B cells, an effect directly 
dependent on RASFs as IgD
+
 B cells alone did not respond to PIC.  
 
The production of isotype class-switching requires AID and occurs via excision of switch 
circles following the introduction of double strand breaks in the Ig switch regions of 
DNA, with the subsequent substitution of IgM and IgD with IgG, IgA, or IgE [253]. 
Accordingly, I showed that RASFs, but not RADFs, induced a rapid and sustained de 
novo expression of AID in co-cultured IgD
+
 B cells, an effect significantly potentiated by 
by TLR3 simulation. Subsequently, I demonstrated that AID expression induced Iγ-Cμ, 
being transiently produced for up to 48h after [263]. Therefore, the increased detection of 
Iγ-Cμ CTs after over 72h of co-culture demonstrated that class-switching from IgM to 
IgG was actively ongoing and that TLR3 stimulation of RASF potentiated CSR in IgD+ 
B cells. Accordingly, the IgG/IgM ratio was over 10-fold higher 8 days after co-culture in 
TLR3-stimulated conditions than after 24h. Of relevance, TLR3-induced RASFs-
dependent B cell activation was maintained when B cells and RASFs were physically 
separated via a cell insert, suggesting that soluble factors are sufficient to induce B cell 
activation. This evidence is of particular importance as BAFF can elicit its biological 
functions both in a membrane-bound and in a soluble form [457]. Of importance, Figures 
4.3-4.5 demonstrated constitutive expression of membrane-bound BAFF in resting 
RASFs, confirming previous results by Rochas et al [292], and my data further showed 
increased membrane expression upon TLR3 stimulation. However, I would like to point 
out that in my transwell system, AID expression, CT production and Ig class-switching 
could still be detectable in the absence of direct cell-cell contact between RASFs and B 
cells, similar to what has been shown in epithelial/B cell co-cultures [244, 286]. 
Furthermore, I also showed that this effect is dependent on soluble BAFF/APRIL, as 
shown in Figures 4.11-4.13. This confirms the original work by Schneider et al [457], 
who showed that both membrane and soluble forms of BAFF are biologically functional. 
Moreover, my work is the first to show increased expression of the processed form of 
APRIL in resting RASFs compared to RADFs, as shown by ELISA, which is important 
(together with soluble BAFF) to explain B cell activation in the transwell system.  
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Importantly, although previous reports [259, 457] pointed out that BCR triggering (such 
as incubation with anti-IgM and/or treatment with soluble CD40 ligand (CD40L) or 
CD40 mAb) is essential, together with BAFF and/or APRIL stimulation in order to 
induce class-switching in B cells, later work has clearly shown that BAFF/APRIL can 
induce Ig class-switching independently from BCR triggering in the presence of other 
factors (i.e. cytokines such as IL-4, IL-6, IL-10). It was previously shown that RASFs can 
contribute to B cell activation via IL-6 [292] and potentially IL-10 [363] and IL-6 is most 
likely also contributing to B cell activation in my co-culture system. In agreement with 
the independency from the BCR trigger, stimulation with BAFF/IL-4 is sufficient to 
induce AID, CT and Ig class-switching (Figure 4.10). This conclusion is also supported 
by previous work demonstrating that in the absence of BCR, TLR3 activation of oral and 
intestinal ECs induces Ig class-switching in B cells via soluble BAFF and/or APRIL [244, 
286].  
 
Given the high amount of soluble BAFF and APRIL released by RASFs, I finally 
questioned whether these factors are critically involved in promoting functional B cell 
activation, AID expression and Ig class-switching. Using a set of comprehensive 
experiments, I showed that TLR3-dependent IgG and IgA production was completely 
inhibited after interfering with signaling through both BAFFR (specific for BAFF) and 
BCMA (binding both BAFF and, with greater affinity, APRIL) on the B cell surface. Of 
relevance, only minimal effects on IgM production were observed, suggesting that 
reduced B cell activation rather than survival was responsible for the down-regulation of 
IgG/IgA. Accordingly, BAFFR/BCMA blockade can also down-regulated the expression 
of AID and the production of Iγ-Cμ CTs. These in vitro data support in vivo observations 
in the RA/SCID model, in which functional niches of autoreactive B cells required BAFF 
and APRIL for Ig production, AID expression, ongoing class-switching and production 
of ACPA antibodies [152].  
 
Importantly, the freshly isolated tonsillar B cells rapidly die when cultured in the absence 
of proliferative and/or survival stimuli. The viability of B cells is controlled by activation 
of an internally coded suicidal program called programmed cell death/apoptosis, an active 
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characterised by specific morphologic and biochemical changes leading to in vitro 
endonucleolytic degradation of the DNA at nucleosomal intervals. Therefore, in cultured 
B cells, the culture media is supplemented by fetal bovine serum.  
 
My established co-culture system indicate that the presence of stromal cells (OASFs, 
RASFs, and RADFs) can promote the production of secreted Ig from B cells, suggesting 
that soluble factors or cytokines provided by the stromal cells is able to support/induce B 
cells survival in vitro. In addition, when B cells cultured without the presence of stromal 
cells, an albeit but modest level of IgM remains detectable, indicating that the isolated B 
cells become able to survive alone in vitro. It could be argued that the enhanced survival 
seen in the B cell cultures reflects an increased number of viable cells due to more cell 
division rather than reflecting protection from death. Nevertheless, in the future, an 
aliquot of the collected B cell samples can be assayed fro viability (intact plasma 
membrane) and cell death (damaged plasma membrane) by dye exclusion method. Cells 
with disturbed plasma membrane permeability are stained, while undamaged (viable) 
cells are not stained with dyes that do not penetrate the plasma membrane (“exclusion 
dyes”). The most frequently used dye for exclusion tests is trypan blue. In addition, a 
fluorescent dye, propidium iodide (PI), is membrane impermeant and therefore does not 
enter undamaged cells with intact membranes. When PI does gain access to nucleic acid, 
it become highly fluorescence and is therefore used to identify dead cells. The stained 
and unstained cells are counted with a light microscope (trypan blue), or flow cytometer 
(PI). 
 
In an effort to understand the specific roles of BAFF/APRIL during later stages of B cell 
differentiation, it is also necessary to understand the expression of BAFF/APRIL 
receptors in B-lineage cells at various stages of maturation. Expression of BAFF-R has 
been found on most B-lineage cells, with low levels of expression on GC B cells and 
absence in long-lived PC. In contrast, the precise developmental stage(s) at which B cells 
express TACI and BCMA remains controversial. Regarding BCMA, Darce et al [462] 
recently proposed that the balance between the expression of BAFFR/BCMA on the B 
cell surface may be involved in B cell’s decision to either differentiate into a memory cell 
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or PC. They showed that upregulation of BCMA develops in parallel with a loss of 
BAFF-R during B cell differentiation into rapidly-dividing Ig-secreting cells 
(plasmablast) and PC. This result reinforces evidence from Zhang et al showing that 
human tonsillar B cells receive BAFF signal through different receptors as they 
differentiate into PC, whereby naïve B and GC-B cells utilise BAFF-R, differentiated PC 
precursors and PCs use BCMA and TACI [329].  In regard to TACI, its expression on 
human B cells remains controversial. It has been occasionally reported that TACI is 
expressed on: (1) tonsillar memory B cell alone, [329] (2) both mature naïve and memory 
B cells [463], or (3) all tonsillar B-lineage cells [464]. Despite its unclear expression on 
human B cells, it has been recently demonstrated that TACI expression is required for 
CSR in humans [465].  
 
Unlike BAFF, APRIL does not bind to the BAFF-R and thus it is not involved in the 
selection or survival of naïve B cells. In turn, APRIL has a unique function in class-
switching to IgA via the interaction with TACI, allowing the maintenance of mucosal 
immunity. APRIL is also essential for the survival of PCs in neonatal bone marrow. 
Interestingly, Sakurai et al showed that TACI has a dual role depending on the ligand, as 
it acts as a positive regulator in the case of APRIL-induced IgA production and as a 
negative regulator of BAFF-induced B cell responses, such as B cell proliferation and 
production of IgA and IgG in human peripheral blood B cells in vitro [323]. In addition, 
the same group demonstrated that cell surface HSPG is essential for APRIL-induced B 
cell responses. HSPG is widely expressed throughout the B cell lineage as a 
transmembrane protein in association with molecules such as CD44 and syndecan-1. 
Moreover, syndecan-2 has been reported to be widely expressed in mesenchymal cells 
including RASFs. Thus, the expression of APRIL by RASFs may not only have a 
paracrine effect on infiltrating B cells, but might also act as an autocrine stimulus for 
RASFs themselves, most likely upon interaction with the cell surface HSPG expressed on 
RASFs. Therefore, it is possible to hypothesise that APRIL might exert different 
regulatory functions on two cell levels (i.e. B cells and RASFs) in my co-culture system. 
Finally, Nagatani et al reported that BCMA, but not BAFFR/TACI can be expressed on 
RASFs; further suggesting that APRIL may act on RASFs in an autocrine manner via 
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direct interactions with its main receptor BCMA [314]. However, despite extensive 
investigations, I consistently failed to detect BCMA expression in RASFs after passage 4 
(data not shown). Therefore, based on my own data (possibly obtained in “cleaner” 
experimental conditions compared to previous reports), it is unlikely that BCMA 
expression may have a major impact in the autocrine signaling of APRIL on RASFs. 
 
Apart from the interaction with B cells, BAFF/APRIL has been shown to exert diverse 
and profound effects on other leukocytes and thus contribute to the amplification of 
inflammation at the site of injury. For instance, BAFF-R has been reported to be 
expressed on some T cells and may thereby modulate T cell activation by promoting the 
production of IFN-γ and IL-17 production [466, 467]. Moreover, activated monocytes 
and DC are reported to be primarily express TACI intracellularly, but cell surface TACI 
expression may be induced upon inflammatory response. BAFF/APRIL inhibitors have 
been recently been shown to exert clinical efficacy in human trials. The rationale for 
targeting BAFF/APRIL is not only related to their diverse immunoregulatory functions, 
but also to the evidence that they are overexpressed in several autoimmune diseases and 
have been successfully targeted in murine models of autoimmunity [275].  
 
Despite considerable immunologic differences between rodents and humans, the results 
of the human studies are largely in line with those of the mouse studies. In humans, 
BAFF blockade preferentially depletes naïve and transitional B cells, while little effect is 
observed on class switched memory B cells and long-lived PC [468]. Selective BAFF 
blockade has less effect on serum Ig levels as compared to the blockade of both BAFF 
and APRIL, and both agents decrease the serum levels of IgM preferentially. The 
increased serum BAFF levels in RA patients together with the observation that high 
levels of both BAFF and APRIL, and their respective receptors, are found in the 
rheumatoid synovium [469], suggesting the need for BAFF inhibitors in RA treatment. 
However, the clinical use of both belimumab (a monoclonal antibody specific for soluble 
BAFF) and atacicept (TACI-Ig fusion protein, acts as a dual BAFF/APRIL inhibitor) 
have shown only modest effect [470], in contrast with the promising data obtained from 
murine studies where down-modulation of both DC and T cell functions was observed 
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along with the reduction of local BAFF expression within the affected joints [466]. It is 
interesting to ask why atacicept, as compared to belimumab, has no discernible effect on 
clinical benefit even though it eliminates ARPIL in addition to BAFF. It is tempting to 
speculate that: (1) RA is a heterogeneous disease characterised by the presence of ELS in 
RA synovium and is maintained in the presence of high expression levels of BAFF and/or 
APRIL. Accordingly, different degrees of cellular organisation (phenotype of diffuse, 
aggregates and GC) may be associated with different requirement of BAFF/APRIL in 
different RA patients. Indeed, Humby et al reported that there is no difference in the 
expression pattern of BAFF when comparing CD21
+
 and CD21
- 
synovial tissues, but an 
up-regulation of APRIL mRNA in GC
+
 synovitis [152]. It is therefore possible that: (1) 
atacicept is an ideal agent only for targeting those RA patients with GC
+
 synovitis; (2) 
atacicept may only neutralise circulating BAFF and APRIL, but not those that are tightly 
bound to their respective receptors within the synovium. Therefore it may only be an 
ideal agent to those patients who objectively exhibit B cell hyperactivity at the time of 
treatment.  
 
A recent phase II clinical trial of a different anti-BAFF antibody, Tabalumab 
(LY2127399), that targets both transmembrane and processed forms of BAFF has shown 
efficacy in RA and further trials are now in progress [471] (M Genovese, abstract 1923). 
Thus, the observations provided in my current study have profound relevance, not only in 
the understanding of the pathophysiological processes regulating BAFF/APRIL 
expression/function within the rheumatoid joint, but may also in understanding the role of 
stromal-derived B cell survival factors in the mechanism of response/resistance to novel 
biological targeting of BAFF/APRIL.  
 
In addition to BAFF/APRIL, this work highlights a fundamental role for TLR signaling 
in the induction and maintenance of the activated phenotype by RASFs. In particular, 
apart from the traditional pathogen-associated ligands, there is increasing evidence 
showing that the endogenous breakdown products from the extracellular matrix, such as 
hyaluron or intracellular components, are released when cells rupture, thereby, playing an 
important pathogenic role in the inflammatory arthritis. Therefore it would be of interest 
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to further investigate the function of TLRs in sensing tissue damage signals during 
chronic inflammatory responses. There are some new treatment strategies for targeting 
tissue regeneration applications, such as CQ-07001, an endogenous human protein that 
has been shown to be a powerful agonist for TLR3. This drug is currently in preclinical 
development (Clinquest Group obtains exclusive worldwide rights to clinical 
development of this drug - Amsterdam, the Netherlands, 06-03-2007), in which it is used 
for anti-inflammatory and tissue regeneration applications. In terms of treating RA, 
hydroxychloroquine, which has been reported to be efficacious in combination with 
methotrexate compared to the treatment with methotrexate alone, is also able to modulate 
TLR function by preventing intracellular TLR activation [472]. Furthermore, effective 
targeting of TLRs in RA is supported by a phase II clinical trial with chaperonin 10 that 
reacts against TLR2 and TLR4 signaling [473]. Based on my current work, it is possible 
to speculate that novel, yet undeveloped TLR3 antagonists might have significant 
potential in modulating RASFs function, synovial B cell activation and humoral 
autoimmunity in RA synovium.  
 
In the second part of my experimental work (Chapter 5), I uncovered a novel 
counterimmunoregulatory pathway centered on an endogenous expression of SLPI by 
RASFs upon TLR stimulation. I proposed that SLPI, which is primarily known for its 
antiprotease and antibacterial activities at mucosal barriers, plays a key role in 
modulating RASFs functions, B cell survival factor production and downstream B cell 
activation with the net result of contributing to the control of inflammation within the 
joint microenvironment (see also Chapter 8). In this thesis I am the first to show that 
SLPI is expressed and secreted by the resident stromal cells isolated from the RA 
synovium. I demonstrated that RASFs produced significant levels of SLPI, both at the 
mRNA and protein level, in resting conditions. Furthermore, I showed that TLR3 
stimulation, but not TLR2 or TLR4, was able to induce a further strong up-regulation of 
SLPI mRNA.  
 
Similar to BAFF, RADF produced negligible amounts of SLPI and failed to increase their 
protein expression despite similar mRNA in response to TLR3. It is of interest to note 
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that baseline SLPI transcript levels in resting RASFs are around 60-fold higher compared 
to RADFs from the same patients, again, suggesting that profound epigenetic 
abnormalities confer the activated state of synovial stromal cells over fibroblast as 
different anatomical localisations. Of interest, the dynamic of SLPI mRNA expression in 
RASFs in response to TLR3 demonstrated that SLPI is induced at a late stage, with a 
progressive peak of production at 72h in response to TLR3 stimulation. This delayed 
kinetic of expression is opposed to the one observed for BAFF which is characterised by 
early expression at 4-8h. 
 
In addition to mRNA expression, I demonstrated that the levels of soluble SLPI secreted 
from resting RASFs at 48h appeared to be much higher than those described in human 
mast cells and a lung EC line (A549) after 96h of culture [474]. Moreover, the expression 
of SLPI mRNA was paralleled by a similar pattern of SLPI protein expression, 
suggesting that a transient time is required for the induction of SLPI mRNA transcription, 
translation, and the subsequent intracellular transport, protein secretion as well as protein 
accumulation into the culture supernatant. 
 
Overall, the above observations raised the question of whether BAFF mRNA expression 
could be, at least partially, under the transcriptional control of SLPI (BAFF mRNA peaks 
at 8h whereas SLPI mRNA peaks at 72h). In keeping with this hypothesis, I provided 
compelling evidence to support such conclusion by demonstrating that, i) the 
administration of exogenous SLPI to TLR3-stimulated RASFs downregulated the 
production of BAFF mRNA and protein expression and that, ii) incubation with a anti-
SLPI blocking antibody significantly upregulated BAFF mRNA in resting and stimulated 
conditions. This futher suggests that endogenous RASFs-derived SLPI is biologically 
relevant in modulating RASFs activation. Previous reports showed that SLPI is able to 
reduce LPS-induced TNF-α production in a macrophage cell line [338, 475], suggesting 
that SLPI might preferentially interfere with members of the TNF-family. However, I 
showed that this inhibitory effect was specific for BAFF, as it was not associated with the 
close homolog of BAFF, APRIL (data not shown). 
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Although the exact mechanisms by which SLPI could interfere with the production of 
BAFF in RASFs remains to be determined, it is well established that SLPI can penetrate 
into several cell types and downregulate critical transcription factors, such as NF-kB. 
Whether this is also true for RASFs is an interesting area that I am currently pursuing 
(See Chapter 7 for details).  
 
Another interesting observation worth noting is that despite the high constitutive 
expression of SLPI mRNA and protein by RASFs in resting conditions, which are further 
increased upon PIC stimulation, such levels of endogenous SLPI are not sufficient to 
completely counterbalance the activation state of RASFs, although its selective blockade 
clearly showed that endogenous SLPI contains some biologically inhibitory functions in 
the culture system that I used. The exact biological contribution of SLPI in the broader 
control of synovial inflammation remains under investigation.  
 
An additional mechanism by which SLPI might modulate BAFF release by RASFs is 
related to its strong and broad antiprotease activity. In this regard, as the soluble form of 
BAFF is secreted upon the cleavage of the membrane-bound BAFF by a protease termed 
furin, it is possible to speculate that SLPI might inhibit the production of BAFF in RASFs 
also by inhibiting proteases that are necessary for the release of BAFF. Whatever the 
prevalent mechanism, my findings imply that a negative feedback loop exists between 
SLPI and BAFF, resulting in the fine and selective tuning of BAFF production in RASFs 
with potential consequences on BAFF-dependent downstream B cell activation. 
 
In addition to its regulatory activity on RASFs, I also demonstrated that exposure of 
human B cells to exogenous SLPI resulted in the inhibition of class-switching by 
interfering with the expression of AID and the molecular machinery for CSR. My 
observation is in line with recent finding by Xu et al. who showed that SLPI from 
tonsillar ECs restrained class-switching by inhibiting AID in B cells. Interestingly, the 
same group demonstrated that SLPI can penetrate into the B cell nucleus and cytoplasm. 
Furthermore, Taggart et al demonstrated that SLPI enters the U937 monocytic cell line or 
 - 257 -  
peripheral blood monocytes and rapidly localises into the cytoplasm and nucleus where it 
affects NF-κB activation by direct binding to NF-κB sites in a site-specific manner. 
 
I first confirmed in my study that SLPI could inhibit the expression of AID and IgG 
class-switching in tonsillar B cells induced by BAFF/IL-4. In addition, my data suggest 
that SLPI may exert its inhibitory activity on Ig class-switching via two different levels of 
regulation by affecting both Ig transcriptional regulation (AID expression) and the post-
transcriptional control of gene expression (Ig production). This is reflected by the fact 
that SLPI showed a dose-dependent response in terms of progressive inhibition of 
IgG/IgA production, this was only partly mirrored by the downregulation of as AID 
expression, which was already maximally reduced at the lowest dosage of SLPI 
(10ng/ml) and its expression remained the same throughout the different dosage of SLPI 
treatment.  
 
Having demonstrated that SLPI exerted its inhibitory effects both by (1) dampening the 
expression of RASFs-derived BAFF in resting conditions and upon TLR3 stimulation 
and (2) inhibiting B cell activation directly, I finally investigated the next effect by 
adding exogenous SLPI to my co-culture systems of RASFs and B cells and analysed the 
downstream effects on AID expression and production of class-switched Ig. By these 
means, I showed that TLR3-dependent IgG/IgA production was significantly inhibited 
after altering signaling with exogenous SLPI. Of relevance, a minimal reduction effect on 
IgM production was observed, in this context, SLPI likely to influence not only the class-
switching machinery (see below), but also alter the mechanisms of Ig secretion and/or the 
survival of B cells. Accordingly, SLPI can also downregulate the expression of AID in 
co-cultured B cells.   
 
Importantly, it would be of interest to investigate whether blocking the TLR3-stimulated-
RASFs derived SLPI in the RASFs/B cell co-culture system with a blocking antibody 
could upregulate the production of BAFF by RASFs and the subsequent Ig production by 
B cells. Studies on this point are in progress and are discussed in Chapter 7.  
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In summary, in this thesis I demonstrated that (Chapter 4) i) RASFs, but not RADFs, 
constitutively release high levels of BAFF and APRIL; ii) BAFF expression is strongly 
induced by TLR3 ligands, a very relevant observation for RA synovitis as RASFs have 
been shown to be continuously activated in the synovial microenvironment by RNA 
released by necrotic cells [110]; iii) TLR3 stimulation strongly enhance the capacity of 
RASFs to directly promote AID expression, isotype class-switching and IgG/IgA 
production in unswitched IgD
+
 B cells; iv) these effects can be efficiently blocked by 
inhibition of BAFF/APRIL signaling through their receptors on the B cell membrane. 
Overall, the first part of my PhD thesis contributes to significantly increase my 
knowledge of the mechanisms regulating the crosstalk between stromal cells and B cells 
in the synovial microenvironment and highlights the importance of the BAFF/APRIL 
system in sustaining the functionality of synovial niches of autoreactive B cells, with 
relevant implications for biological treatments targeting B cell-related pathways in RA. 
 
In Chapter 5, I provide several lines of evidence with carefully controlled experiments to 
support the conclusion that the capacity of resting and TLR3-activated RASFs to directly 
contribute to AID expression and Ig class-switching in B cells can be regulated via the 
endogenous production of SLPI. In particular I showed that i) RASFs, but not RADFs, 
constitutively release high levels of SLPI mRNA and protein; ii)  TLR3 stimulation of 
RASFs further increases SLPI expression, iii) the ability of class-switching in BAFF/IL-4 
stimulated B cells is strongly restrained by SLPI; iv) the induction of BAFF expression 
via TLR3-stimuated RASFs is restrained by SLPI; v) the ability of TLR3-induced effects 
on B cells co-cultured with RASFs are partially blocked by SLPI treatment.  
 
The logical conclusion of this set of experiments is that the effect of TLR3 on class-
switching is dependent on BAFF/APRIL released by RASFs via a SLPI-regulated 
signaling programme. Overall, this work contributes to elucidate the mechanisms 
regulating the crosstalk between stromal cells and B cells in the synovial 
microenvironment and highlights the importance of the BAFF/APRIL/SLPI system 
in sustaining the functionality of synovial niches of autoreactive B cells. This 
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enhances the current understanding of the disease pathogenesis and identifies a 
novel promising strategy for therapeutic targeting in RA.   
 
 
 - 260 -  
CHAPTER 7 
Future Plans 
 
In my PhD thesis I highlighted an important role for TLR3 signaling in RASFs in 
mediating the release of B cell survival/proliferation factors resulting in the enhanced 
capacity of RASFs to promote AID expression and ongoing class-switching in 
unswitched IgD
+
 mature naïve B cells. Although these effects could be effectively 
blocked by inhibition of BAFF/APRIL signaling through their receptors on the B cell 
membrane, an alternative possibility that I am pursuing is to alter the TLR3 signaling 
pathway in order to directly regulate BAFF/APRIL expression by RASFs. In particular, 
one pivotal aspect of my future research efforts will focus on the identification of 
signaling molecules that participate in TLR3-mediated RASFs activation upstream of 
BAFF/APRIL production.  
 
Previous reports showed that TRIF-deficient mice defective in both TLR3- and TLR4-
mediated expression of IFN-β and activation of IRF3. Importantly, whereas TRIF-
deficient mice revealed a complete loss of TLR3-mediated NF-kB activation, TLR4-
mediated NF-kB activation was only completely abolished in mice with disrupted genes 
encoding both MyD88 and TRIF [476]. The finding that both PIC induced NF-kB and 
IRF3 activation are completely abolished in TRIF-deficient mice, demonstrating that 
TLR3 mediates its signaling only via TRIF-dependent pathways. In support of this 
conclusion, Jiang et al reported that mutation of the TRAF6-binding site of TRIF only 
abolished its ability to activate NF-κB but not IRF3 [477], suggesting that TLR3-
mediated the activation of NF-κB and IRF3 might bifurcate at TRIF. I therefore 
hypothesise that selective disruption of the signaling via the TRAM/TRIF pathway (the 
sole adaptor used by TLR3), may be crucial to limit the release of B cell survival factors 
by RASFs in resting conditions and upon TLR3 and TLR4 activation. In turn, I postulate 
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that this inhibition will impairs the downstream B cell activation in co-culture with 
RASFs.  
 
The future experimental plan is to employ a lentiviral delivery system for knocking down 
the TRIF-dependent pathway by using a construct encoding for a dominant negative 
TRIF that acts as a negative regulator of TRIF signaling. A preliminary experiment has 
been performed by Dr. Taher Taher, a post-doctoral fellow who has successfully 
generated a lentiviral vector encoding a dominant negative TRIF. The next immediate 
steps that I plan to perform include the stable transfection of RASFs with the TRIF 
lentivirus in order to investigate three specific aims:  
 
1) To dissect in vitro the modulation of basal/post-TLR3/4-induced BAFF 
mRNA/protein (and other TLR3-activated cytokines) in TRIF-lentivirus-
transfected RASFs;  
2) To investigate in vitro whether the TRIF-lentivirus transfected-RASFs have 
reduced ability to modulate class-switching and activation of AID in IgD
+
 
unswitched B cells in the co-culture system; 
3) To examine in vivo in the human RA/SCID chimeric model, whereby SCID mice 
are transplanted with rheumatoid synovium, what the effect of TRIF down-
modulation on the release of B cell survival factors and downstream B cell 
activation/autoantibody production in the in the presence or absence of TLR3 
stimulants.  
 
Such combination of in vitro and in vivo experiments should be able to provide further 
information on the mechanisms regulating the fine tuning of BAFF/APRIL release from 
RASFs, and provide proof of concept in support of the rationale for blocking the TRIF 
signaling pathways (specifically within the rheumatoid synovial tissue) as a tool to 
control critical pro-inflammatory pathways that are aberrantly activated in the RA joints. 
 
In parallel with this work, I plan to capitalise on the results described in Chapter 5, in 
which I highlighted a novel endogenous pro-resolving route mediated by an SLPI-
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dependent pathway in RASFs. In my work so far I demonstrated that the addition of 
recombinant SLPI reduced the production of BAFF at both the mRNA and protein level 
in TLR3-stimulated RASFs and that blockade of endogenous SLPI with antagonistic anti-
SLPI antibodies exerts opposite effects, suggesting that SLPI is an important regulator of 
BAFF expression in RASFs. Moreover, I showed that SLPI could directly attenuate the 
expression of AID and inhibit the machinery responsible for Ig class-switching in human 
B cells either alone or in co-culture with RASFs.  
 
Thus, critical questions that remain to be elucidated include: 
i) Which are the mechanisms through which SLPI exerts its immunoregulatory 
properties in RASFs/B cell interactions and, 
ii) Whether modulation of SLPI in gain/loss of function experiments results in 
profound alteration of critical pro-inflammatory pathways, which are active in RA 
synovitis. 
 
Regarding the first aspect, I will primarily focus on the capacity of SLPI to impair NF-kB 
activation in resting and activated RASFs and B cells, alone and in co-culture 
experiments; I will employ the electrophoretic mobility-shift assay and supershift assay 
(EMSA) in order to detect NF-kB nuclear translocation in response to exogenous SLPI 
and anti-SLPI antibodies. The prediction is that exogenous SLPI will result in attenuated 
nuclear translocation of NF-kB in response to inflammatory stimuli, such as TLR ligands. 
In addition, I will investigate whether the capacity of SLPI to inhibit the release of 
soluble BAFF is also related to its anti-protease properties and in particular whether SLPI 
can affect the enzymatic activity of the furin convertase resulting in accumulation of 
membrane bound BAFF.  
 
Regarding the second aspect, I plan to dissect the functional role of SLPI in modulating 
RA synovitis and its potential as a therapeutic adjuvant in controlling inflammatory 
arthritis. As previously mentioned, Song et al demonstrated that SLPI ameliorates 
arthritis in the streptococcal-cell wall induced rat model by inhibiting proteolytic tissue 
destruction as well as in suppressing the production of the inflammatory mediator TNF-α 
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[343]. Therefore, here I plan to use two in vivo models in order to dissect the effect of 
SLPI gain/loss of function experiments and the possible therapeutic role of SLPI in RA 
disease.  In the first in vivo model, of which I present preliminary data in Chapter 8 
(Supplementary Results), where I demonstrate that exogenous SLPI is able to modulate 
collagen-induced arthritis (CIA) in DBA/1 mice by delaying the onset of arthritis and 
reducing clinical severity of synovitis.  Based on such promising data, in the near future I 
plan to better characterise the effect of SLPI in the CIA model by: 
 
1) Performing histological analysis for inflammatory cell infiltration, cartilage 
destruction and osteoclast activation/bone erosion; 
2) Investigating the downstream effect on the production of inflammatory cytokines 
within the inflamed synovium and; 
3) Assessing the effect of SLPI in modulating autoantibody production in the CIA 
model, in particular the production of anti-type II collagen antibodies. 
 
In the second in vivo model, I plan to translate these observations in the human SCID-RA 
chimeric model. Here the plan is to engraft SCID mice with RA synovium with/without 
ectopic B cell follicles and investigate whether recombinant SLPI (loss of function) or 
anti-SLPI antibodies (gain of function) are able to: i) modulate basal or TLR3 stimulated 
production of proinflammatory cytokines and B cell survival factors; ii) affect B cell 
survival/proliferation and modulate AID activation and ongoing CSR; iii) regulate the 
production of ACPA antibodies within the synovial tissue.   
 
Overall, these data should provide novel and relevant observations on the functional 
capacity of SLPI to influence the microstructural organisation of RA synovial tissues, 
which modulate autoreactive B cell activation in the ectopic microenvironment and affect 
in situ autoantibody production. If successful, this set of experiments could be highly 
relevant in paving the way to exploit the anti-inflammatory, pro-resolving and 
immunomodulatory properties of SLPI for therapeutic purposes in RA synovitis. 
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CHAPTER 8 
Supplementary Data: An anti-
inflammatory role for SLPI in collagen-
induced arthritis 
 
In this final part of my PhD thesis, I will briefly present and discuss preliminary data 
obtained in vivo in the collagen-induced arthritis (CIA) model focusing on the therapeutic 
potential of SLPI in ameliorating inflammatory arthritis.  I will briefly introduce the CIA 
model and the experimental setting used for this in vivo work. 
8.1 Background: Animal models of RA 
RA is a complex multifactorial inflammatory disease. Experimental models of arthritis 
therefore serve as valuable tools for investigating the underlying mechanisms of disease 
pathogenesis and provide the possibility to investigate novel potential treatments of 
arthritis with the possibility of translation into humans. Nowadays, no particular model of 
arthritis mirrors all the pathogenic and clinical aspects of the human disease, but various 
animal models have been used to delineate several different pathways, all leading to 
arthritis onset. Overall, this approach has allowed a rapid and greater understanding of 
the cellular and immunological aspects underlying the development of synovitis and 
breach of tolerance, which would not have been possible to evaluate in humans due to 
obvious ethical reasons. 
 
In principle, there are three main basic factors to consider in experimental models of 
arthritis in rodents: (1) animal strains, (2) antigen used for immunisation, and (3) the use 
of adjuvants. Adjuvants are immunostimulatory agents that are applied together with an 
antigen in order to enhance the transportation and presentation of Ags to the local lymph 
node, primarily via the induction of a local inflammatory reaction at the site of 
immunisation, leading to the release of chemokines and up-regulation of adhesion 
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molecules. Subsequently, the local and/or systemic cytokines increase the infiltrating 
population of immune cells and stimulate the innate response through accessory cell 
PRRs. In a very schematic and non-comprehensive way, animal models of inflammatory 
arthritis can be subdivided into: (1) induced models whose development is based on 
immunisation with antigen that contains peptides or protein in the presence/absence of an 
adjuvant; (2) induced models whose development is based on chemical agents (non-
immunogenic adjuvants) which lacks bacterial cell wall components or any other 
components that contain peptides; (3) spontaneous models whose development is based 
on genetic manipulations. While each of these models has advantages and disadvantages, 
collagen-induced arthritis (CIA) has been the most widely studied model of RA.  
8.1.1 Collagen-induced arthritis  
CIA was first described in rats, but was subsequently found also to develop also in 
susceptible strains of mice and non-human primates following immunization with type II 
collagen (CII), the major constituent protein of articular cartilage, emulsified in either 
complete form, Freund's Complete Adjuvant (CFA), composes of inactivated and dried 
mycobacteria (usually Mycobacterium tuberculosis [MTB] suspended in mineral oil) or 
incomplete form (IFA), which lacks the mycobacterial components (hence consist of just 
the water in oil emulsion). The ‘‘gold standard’’ CIA disease model has been described 
in genetically susceptible DBA/1 mice that carry the MHC Class II I-Aq haplotype (H-
2q) [478]. Following immunisation, this CIA mouse model shares many similarities with 
RA and has been used in preclinical evaluation of RA drugs currently used in the clinic 
(e.g. etanercept) 
 
The immune response to CII is characterised by both the stimulation of collagen-specific 
T cells and the production of antibody specific for both the immunogen (heterologous 
CII) and the autoantigen (mouse CII) by B cells. Accordingly, immunoglobulin 
concentrates of sera from CIA mice are able to transfer the disease even to resistant 
mouse strains, demonstrating an active role of antibodies in mediating the pathology in 
this model [479]. Similar protocols are now used to induce arthritis and are collectively 
termed collagen antibody-induced arthritis (CAIA). The chief pathological features of 
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CIA include synovial hyperplasia, mononuclear cell infiltration, pannus formation, 
cartilage degradation, erosion of bone, and fibrosis. As in RA, pro-inflammatory 
cytokines, such as TNF-α and IL-1β are abundantly expressed in the arthritic joints of 
CIA mice and blockade of these molecules results in a reduction of disease severity [480]. 
This provides some hope that the results with CIA can be transferred to humans to treat 
and perhaps cure RA. 
 
8.2 Methods: Induction of CIA 
8.2.1 Immunisation 
A classic protocol for the development of CIA model was employed. The DBA/1JLacJ 
mouse strain was obtained from Jackson Labs. The colony was housed in a purpose-built 
area and maintained strictly according to the international and United Kingdom 
guidelines for animal care. All mice were maintained under germ-free conditions using 
specially adapted laminar flow cabinets and filter-top cages. Breeding and procedures 
were carried out according to Home office Guidelines on the Operation of the Animal 
(Scientific Procedure) Act 1986 (PPL 70/6109). A total of 26 male DBA/1 mice were 
used at 12-13 weeks of age and were randomly assigned to four groups as follows: 
control untreated animals (n=5); control CIA-injected animals, which received PBS on 
day 17 (n=7); CIA-injected animals treated with recombinant human SLPI (R&D) on day 
17 (n=7) at a lower dosage of 30μg (in 100μl); and CIA-injected animals treated with 
recombinant human SLPI on day 17 (n=7) at a higher dosage of 100μg (in 100μl). PBS 
and drugs were injected to CIA mice model intraperitoneally (i.p). From day 10 post-
collagen injection, all mice were monitored for clinical signs of arthritis. The severity of 
arthritis was determined by blind scoring of each ankle, digit and wrist joint, based on the 
degree of swelling/oedema (examined by plethysomometry) and disfigurement 
(Supplementary Figure 1). The overall clinical score was calculated by adding up the 
scores from all limbs during the course of the study (generally, clinical scoring was 
performed every other day from day 10 to day 35). 
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8.2.2 Type II collagen preparation 
Collagen is a fibrous protein and therefore it is insoluble in normal physiological 
conditions. Consequently, in order to keep CII in solution for the use in the CIA model, it 
should be solubilised and stored in diluted acetic acid. Briefly, 6mg of bovine native CII 
(home made by the Bone and Joint Department at the William Harvey Research Institute, 
QMUL) was reconstituted overnight on a stirrer in 1.5ml of 0.01M acetic acid in the cold 
room. This process should be carried out at 4
o
C using pre-chilled reagent and glassware 
to avoid denaturing CII. 
 
8.2.3 Complete Freund’s adjuvant (CFA) preparation 
The best arthritis incidence is obtained if an emulsion is made with proper adjuvant. 
Freund's adjuvant is a solution of Ag emulsified in mineral oil and utilised as an 
immunopotentiator (booster). Most mouse strains require immunization with CFA to 
elicit a high incidence of full-blown arthritis. It has been suggested that the stimulatory 
capacity of heat-killed Mycobacteria in the adjuvant promotes an inflammatory response 
that initiates an immune response to CII [481]. In short, CFA was prepared by grinding 
and mixing 6mg heat-killed MTB (strain H37RA, Difco Laboratories, 231141), in a 
mortar and pestle with 1.5ml of IFA (Sigma F5506). CII (6mg in 1.5ml of acetic acid) 
was then added to the CFA, and therefore the CII/CFA emulsion contained collagen and 
MTB at a final concentration of 2mg/ml. The CII/CFA emulsion was then homogenised 
on ice with various pulses. A satisfactory emulsification could be observed if the 
emulsion did not dissipate on water where it floated as a discrete circle.   
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8.2.4 Induction of collagen-induced arthritis in DBA/1 mice 
CIA was induced in DBA/1 mice by intradermal immunization at the base of the tail with 
200 µg (100µl) of bovine CII/CFA emulsion using a syringe and a 25-G needle, followed 
by a boost with bovine CII/IFA on day 21. From day 10 after immunization, mice were 
examined daily for the onset of disease (Supplementary Figure 1). Paw thickness and 
clinical score were measured every other day until day 35 post-arthritis. At the end of the 
35 day period of monitoring, mice were sacrificed and processed as follows: (1) arthritic 
paws were collected and placed in 20ml sterile universal tubes containing RNA later for 
at least 24h at 4
o
C before transferring to -80
o
C for long term storage; (2) draining 
inguinal, axillary and popliteal lymph nodes, were collected and placed in cryotubes 
containing RNA later as mentioned above; (3) blood was collected and placed into an 
1.5ml eppendorf tube followed by gently mixing with pipette tips in order to prevent 
blood clots and was centrifuged at 1,500 rpm for 10min. The centrifuged blood samples 
were separated into two distinct layers, with red blood cells (RBCs) pelleted to the 
bottom of the centrifuge tube and the liquid supernatant (serum) formed at the top portion, 
which was carefully collected by sterile Pasteur pipettes into a cryotube and stored at -
80
o
C.  
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Supplementary Figure 8.1. Collagen-induced arthritis (CIA) in DBA/1 mice with 
maximal arthritis.  
Each numeral represents one clinical score.  
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8.3 Preliminary result 
8.3.1 Recombinant SLPI delays the onset and reduces the severity on joint 
inflammation in the CIA model of RA 
As shown in Supplementary Figure 2, the hallmarks of chronic arthritis (joint swelling, 
erythema, and disfigurement) appeared after the re-boost of type II collagen at day 21. As 
compared to the control (CIA-mice injected with PBS), a single i.p. administration of 
SLPI at 100ng/ml was shown to delay the onset and reduce the severity of arthritis at day 
26. A subtle suppressive effect was observed with the lower dosage of 30ng/ml SLPI. 
Finally, SLPI did not appear to completely resolve synovial inflammation as some 
clinical progression still appeared during the course of the CIA and the clinical 
inflammatory score the clinical symptoms reappeared during the late chronic disease 
stage even after a second injection of SLPI. Of particular interest in this context is how 
exogenously delivered recombinant SLPI exerts its therapeutic effect (reduces disease 
severity) within the joint. One explanation may be the fact that such low-molecular-mass 
molecule has advantages of size, diffusibility (negatively charge), and possible anchorage 
to the synovium, which is where the action is. Moreover, the pharmacodynamic activity 
of SLPI may be accounted for, in part, by its half-life within the joint. In asthma, where 
the SLPI has a short half-life value of 6.5h in the epithelial lining fluid [482], little is 
known within the synovial fluid. However, it should not rule out the fact that the period 
between the first dosage of SLPI (day 17) and the initiation of arthritis (day 21) may 
provide sufficient time for tissue distribution to maximise its inhibitory activity. As a 
result of intracellular compartmentalization of SLPI or distribution to the surface in the 
synovium, the half-life value determined from synovial fluid may fail to fully quantify 
SLPI in the synovium. 
 
In our experiments, the two treatment groups, i.e. mice which received recombinant SLPI 
(100ng/ml) and PBS (control), demonstrated a trend of increased disease severity after 
day 26, probably due to the limited half-life of SLPI. The lost of ability in inhibiting 
responses when administered after the initiation of arthritis responses (day 21), 
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suggesting a potential utility of SLPI as a delay agent rather than a rescue therapy. 
Moroever, my current data has only demonstrated an overall effect of SLPI against 
pathophysiologic responses associated with arthritis, additional works are required to 
fully determine the extent of the ability of SLPI to prevent joint pathology in association 
with B cells/the stromal cells (SCID model, see Chapter 7). Another important 
observation is that the concentration of SLPI within RA patients is around 80ng/ml 
(Supplementary Figure 3), suggesting the selected dosage of 100ng/ml of recombinant 
SLPI is closely mimics physiological conditions. Although preliminary, my data provides 
initial preclinical evidence for a promising role for SLPI in delaying the onset and/or 
slow down the progression of arthritis in CIA mice. In addition, this platform provides 
the basis for a large series of experiments to further elucidate the role of SLPI in 
modulating synovial inflammation and B cell autoreactivity (see Chapter 7, future plans), 
thus providing a stronger rationale for further pursuing SLPI as a critical regulator of 
synovial inflammation and exploit its anti-inflammatory properties for therapeutic 
purposes. 
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Supplementary Figure 8.2. Suppression of experimental arthritis by recombinant 
SLPI.  
 
Arthritis was initiated by a single intradermally injection of type II collagen on day 0 and 
the clinical score measured as described above for the course of the study. An 
intraperitoneal injection of 30ng and 100ng of recombinant human SLPI was 
administered at day 17 and again at day 30 after re-boost of type II collagen on day 21. 
Each point represents the mean clinical score ± SEM for each group of animals. 
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Appendix 
 
MEDIA AND MEDIA SOLUTIONS 
Cell culture medium 
DMEM/F12 500ml 
10% FBS (50ml) 
50IU/ml Pen/strep (5ml) 
10mM Hepes (5ml of 1M Hepes) 
 
Freezing medium 
10% DMSO 
90% FBS 
Add 1ml per vial of cell 
 
BUFFERS 
20μl Master Mix (PCR x 1 reaction) 
12.3μl Baxter water 
0.4 μl 10mM dNTP 
2μl 10X buffer 
1.2μl 25mM MgCl2 
1μl sense primer   
1μl anti-sense primer   
0.1μl Taq polyermerase 
2μl template (cDNA) 
 
Wash buffer (Western blot) 
4.84g Tris-base 
17.52g NaCl 
Make up to 2L with deionised water, pH 7.5 
Add 1ml Tween-20 
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5X Tris-glycine eletrophoresis buffer, pH 8.3 
25mM Tris (15.1425g of 1M Tris in 1L) 
250mM Glycine (93.84g of Glycine in 1L) 
0.1% SDS (100ml of 10% SDS in 1L) 
Dilute 1:5 with deionised water before use and adjust pH if necessary. 
 
Stripping buffer (80ml, pH6.7) 
62.6mM Tris (5ml of 1M Tris)  
100mM of beta-mercaptoethanol (559μl of 14.3M beta-mercaptoethanol) 16ml of 10% 
20% SDS (16ml of 10% SDS) 
Make up the solution with 58.4ml of deionised water* 
*Large amount of 10M HCL (around 10ml) was required for adjusting the buffer to 
pH6.7 
 
2ml Disruption buffer (Western blot cell lysate preparation) 
      Dilution factor 2ml 
1M Tris (pH8)     1:20   100μl 
5M NaCl     1:33   60μl 
10% NP40     1:10   200μl 
100mM NaF     1:20   100μl 
500mM EDTA    1:250   8μl 
500mM phosphatase inhibitor  1:250   8μl 
1X Protease inhibitor    1:100   20μl 
Bring up to 2ml with deionised water  
 
Laemmli 5X lysis buffer 
2.5 SDS 
1.93g Dithiothreiotol (DTT) 
2.5ml Glycerol *** 
11ml 1M Tris pH6.8 
5ml 0.2% Bromophenol Blue in methanol * 
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6.5ml deionised water ** 
* Bromophenol Blue will turn to orange in methanol, once dilute in water, the colour 
should change to blue 
** add just before glycerol 
*** last step for the recipe 
 
1.5M Tris pH 8.8 
Dissolve 18.17g of Tris-base with 100ml of deionised water 
Stored the solution at 4
o
C 
 
1X Transfer buffer 
2.9g glycine 
5.8g Tris-base 
800ml deionised water 
pH should be adjust to around 8.3 
Add 200ml methanol 
Note: All solution prepared for Western Blot were required to be diluted in deionised  
water rather than distilled water 
 
POLYACRYLAMIDE AND AGAROSE GEL SOLUTIONS 
 
20ml Tris-glycine SDS polyacrylamide gel (always 13%) 
5.9ml deionised water 
8.7ml of  30% acrylamide mix  
5ml 1.5M Tris (pH8.8) 
0.2ml 10% SDS 
0.2ml 1% ammoniun sulphate* 
0.008ml TEMED* 
*Lastly add fresh ammonium sulphate and TEMED as these agents cause polymerization 
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10ml Stacking gel (always 5%) 
6.8ml deionised water 
1.7ml of 30% acrylamide mix  
1.25ml of 1M Tris (pH6.8) 
100μl of 10% SDS 
100μl of 10% ammoniun sulphate* 
10μl of 1 TEMED* 
*Add Last 
  
Transfer 
 Soak 4 pieces of Whatman filter paper, 2 sponge pads and 1 piece of PVDF membrane* (cut 
to size of gel to ensure current running through the cassette is directed through correctly) in 
chilled transfer buffer.  
 
Assemble transfer cassette as follows:  
*******************  (-) NEGATIVE ELECTRODE. BLACK 
IIIIIIIIIIIIIIIIIIIIIIIIIIIII Sponge pad  
¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬ 2 Sheets Whatman 
---------------------------- Nitrocellulose membrane  
---------------------------- Polyacrylamide gel 
¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬¬ 2 Sheets Whatman 
IIIIIIIIIIIIIIIIIIIIIIIIIIIII Sponge pad 
*******************  (+) POSITIVE ELECTRODE. RED 
  
When assembling cassette sandwich ensure there are no air bubbles between any of the layers 
otherwise transfer will be impaired.Use a universal to roll over the membrane in order to 
push air bubbles out. 
Proteins run from (-) negative to (+) positive (i.e. Assemble black plate to black electrode). 
* Place the PVDF membrane in methanol for few sec to soak before transferring it to a 
containers with the chilled transfer buffer 
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IMMUNOHISTROCHEMISTRY 
10X Tris (hydroxymethyl)methylamine-buffered saline (TBS) 
60.6g Triza HCL 
13.9g Triza base 
90g NaCl Mix to dissolve to adjust pH to 7.6 using concentrated HCl. Storage at room 
temperature. Dilute 1:10 with distilled water before use and adjust pH if necessary. 
 
100mM glycine in PBS 
Add 1.5g glycine to 300ml of PBS 
Adjust pH to 7.2 
Filter to sterilise and store at 4oC 
 
4% paraformaldehyde (PFA) 
8g of (PFA) into 100ml deionised water (performed under the fume hood). The mixture 
was allowed to dissolve by heating at 65oC with frequent stirring. 100μl of 10M NaOH 
was then added to fully dissolve the mixture into solution, which was then neutrolise with 
1ml of 1M HCl. 20ml of 10X PBS was added with 80ml deionised water added to make 
up the final solution of 100ml of 4% PFA. The solution was finally filtered and keeps at 
4oC 
 
Mowiol 488 mounting medium 
2.4g of Mowiol was added into a conical flask containing 6 g of glycerol. 6 ml of distilled 
water then added and allow to mixture at room temperature for at least 2h with a small 
magnetic stir bar. Thereafter, 12ml of 0.2M Tris (pH8.5) was added and heated at 50oC 
for 10min with occasional mixing in order to dissolve the Mowiol. Mowiol was then 
clarify by centrifugation at 5000g for 15min for the removal any undissolved solids. The 
supernatant was aliquot and sotre in 1ml eppendorf tubes at -20oC. Mowiol was warm to 
room temperature before use and opened tubes can be stored at 4oC for 1month. 
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ELISA 
Coating buffer (pH 9.6) 
3.7g sodium Bicarbonate 
0.63g sodium carboniate 
1L distilled water 
 
Wash solution 
1L 1X TBS (pH 8, see below) 
0.5ml Tween-20 
 
Blocking solution 
1X TBS 
0.5g BSA (Sigma, A7030)* 
*best blockage effect for the specific albumin from bovine serum 
 
Sample/Conjugate diluent 
50ml wash buffer (see above) 
0.5g BSA (Sigma, A7030) 
 
Stop solution 
1.11ml of sulphuric acid (sp. gravity 1.84) in 10ml of deionised water 
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DYES, STAINS, AND COLORANTS 
 
Loading dye (Bromophenol-blue dye 6X) 
300ml of 30% glycerol and 400ml of EDTA 0.5M (pH8) were added to 300ml of 
deionised water and mixed well. 2mg of bromophenol-blue were added to the solution 
and dissolved by inversion. Solution was stored at -20oC and diluted to working at the 
time of use. 
 
10X Ponceau S 
2% Ponceau S  
30% trichloroacetic acid (TCA)   
Diluted to 1X before use (can be re-used many times) 
 
OTHER SOLUTIONS AND REAGENTS 
 
1M Tris pH 7.5 
Dissolve 12.14g of Tris-base with 100ml of deionised water 
 
0.5M Ethylenediaminetetra-acetate (EDTA, pH 8.0) 
Add 16.81g of EDTA to around 50ml deionised water.  
While stirring with a magnietic stirrer, adjust to pH8.0 with pellets of NaOH (as EDTA 
only dissolved at pH8, large amount ~20g of NaOh might be required) 
The solution was stored at room temperature 
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